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THESIS ABSTRACT 
This thesis focuses on the role of gastric emptying and gastrointestinal hormones 
in the regulation of glycaemia and appetite in health and patients with type 2 
diabetes. The key issues relate to: 1) dietary strategies to improve postprandial 
glycaemia  and  appetite  by  modulation  of  gastric  emptying  and  gut  hormone 
release,  2)  comparative  patterns  of  incretin  hormone  secretion  in  response  to 
known rates of small intestinal glucose delivery in healthy subjects and type 2 
patients, and 3) whether non-nutrient substances impact on gastric emptying and 
hormone secretion. 
 
The  rate  of  gastric  emptying  and  secretion  of  the  incretin  hormones, 
glucagon-like  peptide-1  (GLP-1)  and  glucose-dependent  insulinotropic 
polypeptide  (GIP),  are  major  determinants  of  glucose  homeostasis.  Dietary 
strategies  that  aim  to  increase  endogenous  GLP-1  secretion  and  slow  gastric 
emptying are therapeutically appealing in type 2 diabetes. The study reported in 
Chapter 5 evaluated the acute effects of whey protein, when given as a „preload‟, 
on gastric emptying, incretin hormones and postprandial glycaemia in patients 
with type 2 diabetes. Different doses of whey preload were evaluated for their 
effects on glycaemia, fullness and energy intake in Chapter 6. The study reported 
in Chapter 7 addressed the question of whether the acute effects of whey are 
sustained with „chronic‟ administration.     ix 
The  study  reported  in  Chapter  8  evaluated  plasma  GLP-1  and  glycaemic 
responses to a small load of enterically coated lauric acid, designed to be released 
over  a  long  length  of  terminal  ileum,  after  both  breakfast  (with  which  the 
formulation was given), and a subsequent lunch, in patients with type 2 diabetes.   
 
Patients with type 2 diabetes have been reported to have impaired postprandial 
secretion of GLP-1, but gastric emptying was not quantified in these studies. It 
has been established that the rate of gastric emptying is an important determinant 
of  incretin  hormone  secretion,  and  gastric  emptying  is  frequently  abnormally 
slow  in  patients  with  diabetes.  In  Chapter  9,  glycaemia,  insulinaemia,  and 
incretin hormone release were evaluated in response to duodenal glucose loads in 
patients with type 2 diabetes, and were compared to healthy controls. 
 
Sucralose, a noncaloric sweetener, has been reported to stimulate GLP-1 release 
from  L-cells  in  vitro.  The  study  described  in  Chapter  10  evaluated  whether 
sucralose  stimulated  GLP-1  release  or  affected  gastric  emptying  in  healthy 
subjects. In rodents, sucralose stimulates glucose absorption by enhancing apical 
availability of the GLUT2 transporter. In the study reported in Chapter 11, the 
effects  of  exposure  of  the  proximal  small  intestine  to  sucralose  on  glucose 
absorption and the glycaemic response were evaluated. Cephalosporin antibiotics 
mimic peptones and stimulate release of cholecystokinin (CCK) in rodents. In   x 
Chapter 12, the acute effects of orally administered cefaclor on CCK release, 
gastric  emptying,  and  postprandial  blood  glucose  and  insulin  responses  in 
healthy subjects were assessed.     xi 
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CHAPTER 1: PHYSIOLOGY OF GASTROINTESTINAL MOTOR 
FUNCTION AND APPETITE 
1.1 Introduction 
The  gastrointestinal  tract,  where  nutrients  are  digested  and  absorbed,  plays  a 
central  role  in  energy  and  glucose  homeostasis.  This  chapter  reviews  the 
physiological control of gastrointestinal motor function and appetite in healthy 
individuals. The role of the gut in insulin secretion will be discussed in Chapter 
2. 
 
1.2 Physiology of gastrointestinal motor function 
1.2.1 Patterns of motility in the stomach and duodenum 
From the functional point of view, the stomach can be divided into proximal and 
distal regions (Figure 1.1). The proximal part of the stomach is mainly associated 
with storage of ingested food. It consists of the fundus and the proximal third of 
the corpus. The characteristic motor activity of the proximal stomach is that of 
slow and sustained tonic contraction, which modifies the intragastric pressure 
and, therefore, determines the pressure gradient between the stomach and the 
duodenum, an important driving force for the emptying of liquids (Cullen and 
Kelly  1993;  Indireshkumar  et  al.  2000).  Proximal  gastric  tone  transiently 
decreases  when  food  enters  the  stomach  from  the  oesophagus,  allowing  an   2 
increase in stomach volume, known as „receptive relaxation‟ (Cullen and Kelly 
1993). This is followed by a more prolonged „accommodative relaxation‟, which 
permits the stomach to store ingested volume without a substantial increase in 
pressure (Horowitz et al. 1994).   
 
The distal stomach consists of the distal two thirds of the corpus and the entire 
antrum. Contractions of the distal stomach, which are restricted to a maximal rate 
of 3/min, grind solids into small particles < 2mm in diameter, and pump the 
chyme across the pylorus to the duodenum, predominantly in a pulsatile manner. 
Postprandial gastric motility also involves an increase in tonic, and the frequency 
of phasic, pyloric pressures, acting as a „brake‟ to gastric outflow (Horowitz et al. 
1994). The temporal and spatial patterns of duodenal contractions are complex, 
and  contribute  to  the  regulation  of  gastric  emptying  by  either  facilitating,  or 
resisting the flow of contents in the lumen (Andrews et al. 2001).   
 
Gastric emptying depends on the integration of motor activity in the proximal 
stomach, antrum and pylorus with the proximal small intestine, and is under the 
control of electrical signals („slow waves‟) originating from the interstitial cells 
of Cajal (ICCs) in the circular and longitudinal muscle layers (see section 1.2.4). 
This pattern of gastric motility differs between the fasting and postprandial states. 
During fasting, gastric and small intestinal motility undergoes a cyclical pattern,   3 
termed  the  „migrating  motor  complex‟  (MMC),  consisting  of  phase  I  (~  40 
minutes; motor quiescence), phase II (~ 50 minutes; irregular contractions) and 
phase III (~ 5 - 10 minutes; regular contractions at 3/min in the stomach and 
10-12/min in the small intestine) (Horowitz et al. 2004). Indigestible solids are 
emptied  from  the  stomach  mainly  during  phase  III.  Postprandial  motility  is 
characterized  by  irregular  contractions  of  variable  amplitude,  which  permit 
mixing and digestion of food (Camilleri 2006). Return of phase III marks the end 
of the postprandial period and the resumption of the interdigestive state. 
 
The overall rate of gastric emptying is regulated within the relatively broad range 
of 1-4 kcal/min, varying with the viscosity, texture, particle size, and fat, fibre 
and energy  content of  the  meal  (Camilleri 2007). Non-nutrient  liquids empty 
rapidly in an overall monoexponential pattern (Camilleri 2007). High nutrient 
liquids are retained in the distal stomach, then empty in a linear fashion at the 
same caloric rate as homogenized solids (Collins et al. 1991). When liquid is 
consumed with solids, the liquid empties preferentially. Solids are stored in the 
proximal  stomach  (corresponding  to  an  initial  „lag  phase‟),  before  being 
redistributed  to  the  antrum  to  be  ground  into  small  particles,  prior  to  their 
emptying (Collins et al. 1991).   
 
Gastric motility in healthy subjects is modulated by a complex set of neural (both   4 
afferent  from  the  stomach  and  small  intestine,  and  efferent)  and  hormonal 
(predominantly  from  the  small  intestine)  signals.  Feedback  arising  from  the 
interaction of nutrients with the small intestine acts to regulate the rate of entry of 
chyme  from  the  stomach  to  the  small  intestine  by  relaxing  the  fundus, 
suppressing antral motility, and augmenting pyloric contractions (Heddle et al. 
1988a). Small intestinal regulation of gastric activity is dependent on a number 
of factors, including the length (Lin et al. 1989; Lin et al. 1990) and the region 
(Azpiroz and Malagelada 1985) of the small intestine exposed to nutrients, and 
the magnitude of the nutrient load (Pilichiewicz et al. 2007a; Pilichiewicz et al. 
2007b),  and  is  regulated  by  gut  hormones  including  glucagon-like  peptide-1 
(GLP-1), cholecystokinin (CCK) and peptide YY (PYY) (Horowitz et al. 2004).   
 
1.2.2 Neural regulation of gastrointestinal motility 
The  stomach  and  intestines  are  innervated  by  the  enteric  nervous  system, 
distributed within the wall of the gut, as well as extrinsic autonomic nerves, in 
parasympathetic (predominantly vagus nerve) and sympathetic divisions.   
 
Intrinsic innervation 
The gastrointestinal tract is capable of motor function without the input of the 
central  nervous  system,  by  virtue  of  the  enteric  nervous  system.  The  enteric 
nervous system is distributed along the gut, as the myenteric plexus between the   5 
longitudinal  and  circular  layers  of  muscle,  and  the  submucous  plexus  in  the 
submucosa between the circular muscle layer and the muscularis mucosae (Goyal 
and Hirano 1996). The myenteric plexus predominates in the stomach (Schemann 
et al. 2001), and the submucous plexus is more predominant in the small and 
large intestine (Furness 2000). Subclasses of neurons within the enteric nervous 
system include instrinsic primary afferent neurons, interneurons,  excitatory or 
inhibitory motor neurons,  vasomotorneurons,  and secretomotorneurons  (Goyal 
and Hirano 1996; Di Nardo et al. 2008). Instrinsic primary afferent neurons sense 
chemical  stimuli,  and  mechanical  changes  such  as  distension  (Furness  2000). 
Interneurons connect the instrinsic primary afferent neurons with motor neurons 
(excitatory  or  inhibitory).  The  excitatory  neurons  utilize  acetyl  choline, 
tachykinins  and  substance  P  for  neurotransmission,  whereas  the  inhibitory 
transmitters include vasoactive intestinal polypeptide and nitric oxide (Furness 
2000).     
 
Extrinsic innervation 
The gastrointestinal tract is innervated by the parasympathetic and sympathetic 
divisions  of  the  autonomic  nervous  system.  The  parasympathetic  innervation 
originates from the dorsal motor nucleus of the vagus (DMV) in the medulla 
(Travagli et al. 2006), while the sympathetic supply derives from the prevertebral 
ganglia (Furness 2006). Gastric motility is controlled mainly by the vagus nerve,   6 
a  mixed  motor  and  sensory  nerve.  The  sensory  axons  of  the  vagus  receive 
afferent inputs from gastrointestinal receptors and then project to the nucleus of 
the solitary tract (Chang et al. 2003). NTS neurons activate vagal motor neurons 
in the nucleus ambiguus (NA) and the dorsomedial nucleus (DMN) to regulate 
the smooth muscle contractions in the stomach and duodenum, with these neural 
loops being known as vagovagal reflexes (Broussard and Altschuler 2000).   
 
Role of interstitial cells of Cajal (ICCs) 
In  the  absence  of  any  neural  or  hormonal  stimulus,  most  parts  of  the 
gastrointestinal  tract  generate  electrical  and  mechanical  activity.  Electrical 
activity originates from a specialized population of cells, the ICCs, which are 
distributed within the submucosal, intra-muscular and inter-muscular layers of 
the gastrointestinal tract (Ordog 2008). They serve to generate electrical „slow 
waves‟ and coordinate input from the autonomic nervous system to the smooth 
muscle cells (Ordog 2008). ICCs located between the longitudinal and circular 
muscle layers of the myenteric plexus (ICC-MY) (Ward and Sanders 2006) are 
essential for determining the maximal frequency of phasic contractions (Ward et 
al. 1994). „ICC-IM‟, lying among the smooth muscles cells in the circular and 
longitudinal  muscles  layers  of  the  stomach,  are  responsible  for  direct 
communication  with  enteric  nerve  terminals  (Ward  and  Sanders  2006). 
„ICC-SEP‟, in septa between muscle bundles, transmit depolarization between   7 
muscle bundles (Horiguchi et al. 2001). In the human small intestine, ICCs are 
densely  located  inside  the  circular  layer,  forming  a  deep  muscular  plexus 
(„ICC-DMP‟) (Vanderwinden and Rumessen 1999). The ICC-DMP plays a same 
role in small intestinal motility as the ICC-IM does in the stomach (Ward and 
Sanders 2006).   
 
1.2.3 Hormonal regulation of gastrointestinal motility 
Secretion  of  hormones,  including  GLP-1,  CCK  and  PYY,  in  response  to 
intestinal nutrients, plays an important role in the regulation of gastric emptying; 
this inhibitory effect on gastric emptying is reduced by octreotide, an inhibitor of 
peptide hormone secretion (van Berge Henegouwen et al. 1997).   
 
Among the macronutrients, fat empties most slowly from the stomach, in part 
due to its high energy density. The effects of small intestinal fat on hormone 
release and gastric emptying are dependent on fat digestion (Feinle et al. 2003; 
Feinle-Bisset et al. 2005). Compared to isocaloric triacylglycerol, the effects of 
fatty acids on CCK and PYY release and gastric emptying are markedly greater 
(Little  et  al.  2007).  When  the  lipase  inhibitor, tetrahydrolipstatin  (orlistat),  is 
infused  with  fat  intraduodenally,  the  stimulation  of  tonic  and  phasic  pyloric 
pressure waves, the suppression of antral contractions and the release of satiety 
hormones  are  abolished  compared  to  fat  alone  (Pilichiewicz  et  al.  2003;   8 
O'Donovan et al. 2004a). It is not surprising that release of GLP-1, CCK, and 
PYY are diminished with orlistat, and that energy intake at the following meal 
compensates  for  the  malabsorbed  fat  (Feinle  et  al.  2003;  Feinle-Bisset  et  al. 
2005).  The  action  of  lipase  on  the  surface  of  fat  droplets  is  an  important 
determinant of fat digestion. Thus, emulsions of fat with small droplet size have 
greater effects on hormone release and appetite than those with larger droplets 
(Seimon et al. 2009). Stimulation of CCK by fatty acids also varies with chain 
length (McLaughlin et al. 1999). Both C10 and C12 increase plasma CCK with 
the  effect  of  C12  being  greater,  and  C12,  but  not  C10,  stimulates  GLP-1 
secretion (Feltrin et al. 2004).   
 
Similarly, for carbohydrate, absorption of monosaccharide has been suggested to 
be necessary to induce GLP-1 release (Sugiyama et al. 1994; Gribble et al. 2003) 
and to slow gastric emptying in response to intestinal carbohydrate.   
 
Determinants of hormone release by proteins remain less clear, but it has been 
shown that peptones and certain amino acids are potent stimuli for CCK (Hira et 
al. 2009a) and GLP-1 secretion (Layer et al. 1995). 
 
GLP-1 
GLP-1 is released from L-cells, most densely located in the ileum and colon,   9 
although  they  have  also  been  found  more  proximally  in  the  duodenum  and 
jejunum (Theodorakis et al. 2006). Fasting plasma concentrations of total and 
intact  GLP-1  are  low  (5-10  pmol/L);  in  response  to  a  meal  rich  in  fat  or 
carbohydrate, circulating levels of GLP-1 increase up to five fold within minutes 
(Deacon 2005). The peak concentration in the circulation (~ 20 pmol/L) usually 
occurs at 30-45 min, before a return to basal concentrations by 2-3 h (Vilsboll et 
al. 2001). GLP-1 is synthesized as an inactive 37-amino acid peptide, derived 
from a larger proglucagon precursor (Deacon 2005). The half-life of GLP-1 is 
short  (~  2  min),  due  largely  to  rapid  degradation  by  the  enzyme,  dipeptidyl 
peptidase-IV (DPP-IV) (Mentlein et al. 1993). DPP-IV, also known as CD26, 
cleaves  dipeptides  from  the  N-terminal  to  inactivate  GLP-1  (Mentlein  1999). 
DPP-IV is located in diverse organs, including the kidneys, lungs, adrenals, liver, 
spleen, pancreas and intestines (Baggio and Drucker 2007). A large proportion of 
GLP-1  is  degraded  before  entering  the  systemic  circulation,  by  DPP-IV 
expressed on blood vessels draining the intestinal mucosa (Hansen et al. 1999).   
 
GLP-1 is one of two known incretin hormones, together with glucose-dependent 
insulinotropic  polypeptide  (GIP).  The  insulinotropic  effect  of  GLP-1  is 
glucose-dependent, via interaction with a specific receptor expressed on the cell 
membrane of β-cells (Scrocchi et al. 1996). GLP-1 receptors are found on β- and 
D-cells of the pancreas, parietal cells of the stomach, pylorus, adipose tissue,   10 
lungs and the brain. In animal models, a targeted deletion of the GLP-1 receptor 
results in glucose intolerance and fasting hyperglycaemia (Scrocchi et al. 1996). 
GLP-1  has  been  shown  to  stimulate  β-cell  proliferation  and  induce  islet 
neogenesis, inhibit apoptosis, and enhance the differentiation of new β-cells from 
progenitors in the pancreatic duct epithelium (Perfetti et al. 2000). GLP-1 also 
promotes  β-cell  differentiation,  from  exocrine  ductal  cells  or  immature  islet 
progenitors, towards a more differentiated β-cell phenotype (Drucker 2003). 
 
In healthy subjects, endogenous GLP-1 reduces glucagon release from the α-cells 
of the pancreas (Schirra et al. 2006), and intravenous administration of GLP-1 
lowers glucagon secretion in patients with type 2 diabetes (Meier et al. 2003). 
Like  the  insulinotropic  action  of  GLP-1,  the  inhibition  of  glucagon  is 
glucose-dependent, ie, it does not occur during euglycaemia, and does not have 
an  impact  on  the  counter-regulation  of  hypoglycaemia  (Nauck  et  al.  2002). 
Exogenous GLP-1 lowers fasting glycaemia even in patients with type 1 diabetes 
(Creutzfeldt  et  al.  1996),  indicating  the  importance  of  the  glucagonostatic 
property of GLP-1 in addition to its insulinotropic effect (Baggio and Drucker 
2007).   
 
Among the multiple physiological effects of GLP-1 (Figure 1.2), its effect on 
gastric  emptying  may  outweigh  its  insulinotropic  effect  in  the  regulation  of   11 
postprandial glycaemia  (Nauck et al. 1997).  It  has been long established that 
GLP-1 exerts an inhibitory effect on gastrointestinal motility and secretion. As an 
enterogastrone, GLP-1 decreases gastrin-induced acid and pancreatic secretion 
(Schjoldager et al. 1989), as well as the rate of gastric emptying, and may be an 
important mediator of the „ileal brake‟ (by which the presence of nutrients in the 
ileum  inhibits  upper  gastrointestinal  transit)  (Wettergren  et  al.  1993).  Motor 
actions  of  GLP-1  include  relaxation  of  the  fundus,  inhibition  of  antral  and 
duodenal contractions and stimulation of tonic and phasic contractions  of the 
pylorus, in response to intraduodenal infusion of nutrient (Schirra et al. 2006). 
The mechanism underlying the action of GLP-1 on motility is complex and not 
well understood. In animal models, it has been shown to depend on intact vagal 
innervation of the stomach (Imeryuz et al. 1997), while in humans, cholinergic 
pathways regulate the effect of endogenous GLP-1 on fundic accommodation 
(Schirra  et  al.  2000),  but  alternative  mechanisms  seem  to  be  involved  in  its 
effects  on  antropyloric  motility  (Schirra  et  al.  2009).  In  rats,  the  action  of 
exogenous  GLP-1  on  fasting  motility  in  the  small  intestine  appears  to  be 
mediated by nitric oxide (Tolessa et al. 1998).   
 
The finding of  GLP-1 receptors in  the heart and vessels  in  both rodents  and 
humans has focused recent attention on the potential effects of GLP-1 on the 
cardiovascular system (Grieve et al. 2009). Administration of GLP-1 increases   12 
systolic and diastolic blood pressure and heart rate in a dose-dependent manner 
in rodents (Barragan et al. 1994; Bojanowska and Stempniak 2000). In animal 
models,  exogenous  GLP-1  protects  cardiac myocytes  from  ischaemic damage 
and  heart  failure  (Ban  et  al.  2008;  Poornima  et  al.  2008).  However,  the 
mechanism(s) underlying the cardioprotective effects of GLP-1 are not known, 
and their significance is not yet well understood. Furthermore, it appears that 
some actions of GLP-1 in the cardiovascular system may be mediated by the 
„inactive‟ metabolite, GLP-1-(9-36) (Nikolaidis et al. 2005). 
 
CCK 
CCK is secreted from the I-cells in the duodenum and upper jejunum, and is also 
found  in  the  brain.  There  are  a  number  of  bioactive  forms,  such  as  CCK-8, 
CCK-22, CCK-33 and CCK-58, of which CCK-33 is the major form in human 
plasma and intestine (Rehfeld et al. 2001). The half-life of CCK is ~1-2 min. In 
healthy volunteers, the fasting CCK concentration of 1 pmol/L increases to 5–10 
pmol/L in response to a mixed meal (Liddle et al. 1985), peaks at about 30 min, 
and returns to the fasting value after ~ 3-5 h (Moran and Kinzig 2004). Protein, 
and particularly fat, are strong stimuli for CCK secretion, whereas carbohydrate 
results in much less stimulation (Liddle 2000).     
 
Small intestinal fat exerts a potent action on slowing gastric emptying which, in   13 
humans,  is  regulated  predominantly  by  CCK,  via  CCK-1  receptors,  and 
abolished by the CCK-1 antagonist, loxiglumide (Feinle et al. 1996; Schwizer et 
al.  1997).  CCK  slows  gastric  emptying  by  relaxing  the  proximal  stomach, 
increasing  basal  and  phasic  pyloric  pressures  and  suppressing  antral  motility 
(Schwizer et al. 1997; Rayner et al. 2000a), mediated by a vago-vagal reflex 
pathway  (Glatzle  et  al.  2003).  In  contrast  to  its  actions  on  the  stomach, 
exogenous  CCK  increases  small  intestinal  motor  activity  and  shortens  the 
intestinal transit time (Gutierrez et al. 1974).   
 
PYY 
PYY is co-located with GLP-1 in the L-cells of the distal gut and is involved in 
the so-called „ileal brake‟ (Wen et al. 1995). Plasma concentrations of PYY are 
low in the fasting state, and increase about 30 min after exposure of the small 
intestine  to  nutrients  (Vincent  and  le  Roux  2008).  PYY  is  secreted  in  a 
load-dependent fashion, with fat being the most potent stimulus, followed by 
carbohydrate  and  then  protein  (Degen  et  al.  2005a;  Huda  et  al.  2006).  The 
secretion of PYY in response to small intestinal fat is mediated partly by CCK 
(Lin et al. 2000). Because of its capacity to slow gastric emptying, PYY is also 
likely to improve postprandial glycaemia, although there is no evidence for an 
insulinotropic effect.   14 
1.3 Gastrointestinal function and appetite control 
1.3.1 Peripheral (ie. gastrointestinal) versus central mechanisms 
Modulation of appetite and energy intake is essential to maintain energy balance 
and body weight. Short-term appetite and food intake can be regulated by the 
hypothalamus,  which  constitutes  a  central  control  mechanism,  and  by  a 
peripheral  mechanism,  constituted  by  signals  arising  from  the  gastrointestinal 
tract (Havel 2001).   
 
The  hypothalamus  plays  a  pivotal  role  in  appetite  control.  It  incorporates  a 
satiety  centre  in  the  ventromedial  nucleus  (VMN)  and  a  feeding,  or  hunger, 
centre  in  the  lateral  hypothalamic  nucleus  (LHA).  Stimulation  of  the  VMN 
induces  satiety,  while  destructive  lesions  in  this  region  lead  to  hyperphagia, 
whereas  stimulation  of  the  LHA  induces  hunger,  and  destruction  results  in 
anorexia.  The  arcuate  nucleus  (ARC)  integrates  peripheral  signals  from 
circulating gut peptides to influence appetite. Two important groups of neurons 
are  found  in  the  ARC:  one  group  expresses  proopiomelanocortin  (POMC), 
α-melanocyte-stimulating  hormone  (α-MSH),  and  cocaine  and 
amphetamine-regulated  transcript,  while  the  other  expresses  neuropeptide  Y 
(NPY)  and  agouti-related  peptide  (AgRP).  Hypothalamic  nuclei,  such  as  the 
paraventricular  nuclus  (PVN),  dorsomedial  hypothalamus  (DMH),  LHA  and 
perifornical  area,  receive  NPY/AGRP  and  POMC/CART  neuronal  projections   15 
from the ARC. POMC/CART neurons are activated by anorexigenic hormones 
(CCK,  GLP-1,  PYY,  leptin  and  others),  and  inhibit  food  intake.  Orexigenic 
hormones (ghrelin and orexins) activate NPY/AgRP neurons and stimulate food 
intake. The nucleus tractus solitarius and area postrema (AP) in the brain stem 
represent  a  link  between  signals  from  the  periphery  and  the  hypothalamus 
(Konturek et al. 2005). 
 
1.3.2 Gastrointestinal control of appetite 
The  capacity  for  intestinal  nutrient  infusions  to  suppress  food  intake  at  a 
subsequent  meal  indicates  a  role  for  the  gastrointestinal  tract  in  regulating 
satiation (Ritter 2004). The signals from the gastrointestinal tract arise from the 
stomach (gastric distension and ghrelin release), proximal small intestine (CCK 
release) and distal small intestine (GLP-1 and PYY) in response to food (Huda et 
al. 2006).   
 
Distension is the main „gastric‟ mechanism of appetite control. In cats (Anand 
and Pillai 1967), gastric distension activates the hypothalamic satiety centre and 
suppresses  the  feeding  centre,  when  the  vagus  is  intact.  In  humans,  volume 
appears to be a determinant of satiety and subsequent meal intake, independent 
of food content (de Graaf and Hulshof 1996; Rolls et al. 1998). For example, the 
volume  of  isocaloric  milk  drinks  consumed  before  lunch  is  related  to  the   16 
suppression of food intake and an increased sensation of fullness (Rolls et al. 
1998).  Similarly,  water-filled  gastric  balloons  reduce  food  intake  when  the 
balloon volume is ≥ 400 ml (Geliebter 1988; Geliebter et al. 1988). Furthermore, 
small intestinal nutrient stimulation acts synergistically with gastric distention, 
converting the resultant  sensation  to  one of  „meal-like‟  fullness  (Feinle et  al. 
1996).   
 
Antral area relates more closely to postprandial fullness than does the area of the 
proximal stomach (Benini et al. 1994; Jones et al. 1997). Ultrasound studies have 
yielded insights into the particular importance of antral distension (Hveem et al. 
1996);  after  ingestion  of  a  liquid  meal,  antral  area  is  related  to  satiety  and 
accounts for about a third of the variation in energy intake at a subsequent meal 
(Sturm  et  al.  2004).  The  maximum  antral  distension  and  the  onset  of  the 
perception  of  fullness  occur  at  the  same  time  (~  5  min),  and  the  correlation 
between satiation and antral area is much stronger than that between satiation and 
proximal gastric volume (Mundt et al. 2005).   
 
Ghrelin, a 28-amino acid peptide, is an orexigenic hormone, which is secreted 
mostly from the gastric mucosa; small quantities can be found in the duodenum 
and hypothalamus (Tschop et al. 2000). Plasma ghrelin concentrations are high in 
the  fasting  state  and  decrease  with  nutrient  ingestion  (Gomez  et  al.  2004).   17 
Ghrelin  declines  equally  after  gastric,  intraduodenal  and  intrajejunal  nutrient 
infusions  in  rodents  and  humans,  suggesting  that  gastric  distension  does  not 
regulate  its  suppression  (Overduin  et  al.  2005;  Parker  et  al.  2005).  Rather, 
exposure of the small intestine to nutrients is required to suppress ghrelin (Parker 
et al. 2005). Fasting and postprandial fluctuations of ghrelin are also related to 
insulin concentrations and sensitivity (Blom et  al. 2005). For example, obese 
individuals  with  insulin  resistance  have  a  blunted  suppression  of  ghrelin  in 
response to nutrients (Greenman et al. 2004).   
 
In both rodents (Tschop et al. 2000) and humans (Wren et al. 2001), exogenous 
ghrelin administration increases energy intake, while patients with Prader-Willi 
syndrome,  characterized  by  excessive  feeding  behaviour,  have  high  levels  of 
circulating ghrelin (Cummings et al. 2002a). Proximal Roux-en-Y gastric bypass 
decreases  ghrelin  secretion,  which  may  contribute  to  weight  loss  after  this 
procedure (Cummings et al. 2002b). Ghrelin modulates appetite via the ARC of 
the  hypothalamus  (Currie  et  al.  2005);  it  enhances  NPY  and  AgRY  gene 
expression and release in the LHA, and inhibits the anorexigenic POMC neurons 
in the ARC (Nakazato et al. 2001). In contrast to ghrelin, leptin, an anorexigenic 
hormone,  inhibits  orexigenic  neurons  containing  NPY  and  AgRY,  while 
stimulating POMC neurons in the ARC (Cowley et al. 2001). Leptin attenuates 
the activity of ghrelin in the ARC and suppresses food intake. Thus, ghrelin and   18 
leptin interact with each other in the appetite centre, in a so-called „ghrelin-leptin 
tango‟ (Cummings and Foster 2003). 
 
CCK was the first gut hormone found to be related to appetite (Gibbs et al. 1973). 
CCK exerts its effects via two receptors, CCK-1 and CCK-2. The suppressive 
effect of CCK on energy intake in rats and humans is predominantly mediated by 
CCK-1 receptors (Moran et al. 1992). CCK-1 receptor antagonists increase meal 
size,  while  CCK-1  receptor  deficient  rats  develop  hyperphagia  and  obesity 
(Moran  and  Bi  2006).  In  rats,  it  has  been  demonstrated  that  chronic 
administration of a CCK antagonist results in weight gain out of proportion to 
increased feeding (Meereis-Schwanke et al. 1998), but this probably reflects a 
synergistic  effect  between  CCK  and  leptin  on  energy  intake  and  long-term 
balance  of  body  weight  (Wang  et  al.  2000).  In  humans,  exogenous  CCK 
dose-dependently reduces energy intake at a buffet style meal (Brennan et al. 
2008) and the CCK-1 antagonist, loxiglumide, increases energy intake modestly 
in healthy adults (Beglinger et al. 2001). However, the long term effects of CCK 
administration in humans and its role in obesity therapy are not clear. 
 
Gastric distension augments the suppressive effect of exogenous CCK on food 
intake (Kissileff et al. 2003), and CCK-induced satiation is related to the effect 
on  gastric  emptying,  which  favours  gastric  distension  (Moran  and  McHugh   19 
1982). Suppression of energy intake and slowing of gastric emptying by CCK are 
both regulated by vagal afferents, mainly capsaicin-sensitive C-type fibres and 
A-type  afferent  neurons  (van  de  Wall  et  al.  2005).  CCK  increases  c-fos 
expression in the PVN and NTS, which suppresses NPT/AgRP activity in the 
ARC, also contributing to its anorexigenic actions (Kobelt et al. 2005). 
 
Intracerebroventricular injection of GLP-1 inhibits feeding in rats (Hwa et al. 
1998),  as  does  peripheral  infusion  of  GLP-1  and  its  agonist,  exendin-4 
(Rodriquez  de  Fonseca  et  al.  2000).  Peripheral  administration  of  GLP-1  is 
associated with enhanced satiety and reduction of food intake in healthy humans 
(Gutzwiller et al. 1999b), the obese (Naslund et al. 1998), and patients with type 
2 diabetes  (Gutzwiller et  al.  1999a). Obese subjects  may  have slightly  lower 
plasma  GLP-1  concentrations  than  lean  individuals  (Ranganath  et  al.  1996). 
Postprandial  GLP-1  secretion  increases  substantially  after  Roux-en-Y  gastric 
bypass for morbid obesity, suggesting that enhanced GLP-1 secretion contributes 
to satiation and weight loss (Morinigo et al. 2006). The mechanism of increased 
GLP-1 secretion is likely to relate to exposure of more distal small intestinal 
regions (with a larger density of L-cells) to ingested nutrients. In type 2 diabetic 
patients, the GLP-1 analogue, exenatide (Byetta, Amylin Pharmaceuticals, San 
Diego), leads to modest weight loss in prolonged studies (Blonde et al. 2006). 
GLP-1  analogues,  such  as  exenatide,  are  approved  for  the  management  of   20 
glycaemia control in type 2 diabetic patients, and their utility as an antiobesity 
therapy is currently under investigation (Chaudhri et al. 2008).   
 
PYY circulates  as two main forms, PYY3-36 and PYY1-36, with the former 
being active in suppressing appetite (Eberlein et al. 1989). In addition to delaying 
gastric and gall-bladder emptying, inhibiting gastric and pancreatic secretion, and 
slowing  colonic  transit  (Conter  et  al.  1987),  peripheral  administration  of 
PYY3-36 reduces food intake in rats, monkeys and humans (Moran et al. 2005; 
Neary  et  al.  2005;  Vrang  et  al.  2006).  In  humans,  both  pharmacological  and 
„physiological‟ intravenous PYY3-36 infusions elicit fullness and suppression of 
food  intake,  the  latter  lasting  over  12  hours,  despite  the  plasma  PYY 
concentration falling to baseline (Batterham et al. 2002). In addition, there is a 
synergistic effect of exogenous PYY3-36 with GLP-17-36 on reduction of energy 
intake (Neary et al. 2005), whereas exogenous PYY reduces circulating ghrelin 
concentrations  (Batterham  et  al.  2003).  It  remains  contentious  whether  the 
suppressive  effect  of  PYY3-36  on  energy  intake  in  humans  represents  an 
aversive effect; there are no specific antagonists of PYY which are available for 
use in humans. 
 
Injection  of  PYY3-36  into  the  ARC  in  rats  decreases  NPY  expression  while 
stimulating expression of POMC, which would account for reduced food intake   21 
(Batterham et al. 2002). The putative pre-synaptic NPY Y2 receptor (Y2R) in the 
ARC of the hypothalamus appears to mediate these effects (Abbott et al. 2005). 
Like GLP-1, plasma concentrations of PYY are slightly lower in the fasting and 
postprandial states and hunger is greater, in obese compared to lean individuals 
(le Roux et al. 2006b). Low PYY levels predict a trend to overweight, but in 
obese  children,  PYY  is  normalized  following  weight  loss  (Roth  et  al.  2005). 
However, the obese are as sensitive as lean subjects to suppression of food intake 
by  exogenous  PYY3-36  (Batterham  et  al.  2003).  Again,  like  GLP-1,  obese 
patients have elevated PYY levels after jejunoileal bypass surgery, which may 
contribute to loss of appetite (Naslund et al. 1997).   
 
1.4 Summary 
The  crucial  roles  of  gastric  emptying/distention  and  the  release  of  peptide 
hormones  such  as  CCK,  GLP-1  and  PYY  in  response  to  nutrient  intake  are 
increasingly being recognized as important physiological regulators of appetite. 
A better understanding of the mechanisms of appetite regulation is required to 
enable the development of effective anti-obesity therapies. Current therapy for 
obesity is less than ideal, and bariatric surgery is limited to severe cases. After 
Roux-en-Y gastric bypass, important gut signals such as GLP-1 and PYY are 
potentiated,  which  suggests  a  role  for  gut  hormones  in  the  manipulation  of 
energy homeostasis and diabetes management in the long term (Pournaras et al.   22 
2009), particularly as obese subjects appear to maintain their sensitivity to the 
actions  of  gut  hormones  (Wren  2008).  Dietary,  or  pharmacological  strategies 
based on regulation of gut hormones and motility are likely to be of fundamental 
importance in the management of obesity.   
 
Studies that address the manipulation of physiological nutrient-gut interactions in 
health and disease reported in this thesis include: 
(i)  Effects of a protein „preload‟ on gastric emptying,  glycaemia, and  gut 
hormones after a carbohydrate meal in diet-controlled type 2 diabetes, 
both  acutely  (Chapters  5  and  6)  and  with  more  sustained  exposure 
(Chapter 7). 
(ii)  Effects  of  enterically  coated, nutrient-containing  pellets  („CTM#3‟)  on 
the release of gastrointestinal peptides, and glycaemic control in patients 
with type 2 diabetes (Chapter 8). 
(iii)  Effects of variations in duodenal glucose load on glycaemic, insulin, and 
incretin responses in type 2 diabetes (Chapter 9). 
(iv)  Effect  of  the  artificial  sweetener,  sucralose,  on  gastric  emptying  and 
incretin  hormone  release  (Chapter  10)  and  on  small  intestinal  glucose 
absorption (Chapter 11) in healthy humans. 
(v)  Effects of the antibiotic, cefaclor on gastric emptying and cholecystokinin 
release in healthy humans (Chapter 12).   23 
 
 
Figure 1.1 Schematic representation of gastrointestinal motility. Adapted from 
Koch 1999.   24 
 
 
Figure  1.2  Schematic  representation  of  biological  effects  of  GLP-1.  Adapted 
from Drucker 2007.   25 
CHAPTER 2: INSULIN SECRETION IN HEALTHY SUBJECTS AND 
PATIENTS WITH TYPE 2 DIABETES - ROLE OF THE 
GASTROINTESTINAL TRACT 
Adapted from Ma J et al. Best Pract Res Clin Endocrinol Metab. 23:413-424, 
2009. 
2.1 Introduction     
The gastrointestinal tract stores ingested nutrients in the stomach and empties 
them,  in  a  closely  regulated  fashion,  into  the  small  intestine,  where  they  are 
digested,  stimulate  the  release  of  gut  peptides  that  influence  appetite,  insulin 
secretion,  and  the  rate  of  subsequent  gastric  emptying,  and  are  ultimately 
absorbed,  resulting  in  a  postprandial  excursion  in  the  blood  glucose 
concentration. It is, therefore, logical that the gut plays a central role in glucose 
homeostasis. 
 
There is increasing recognition that postprandial hyperglycaemia is the major 
contributor to overall glycaemic control, as measured by glycated haemoglobin 
(Del Prato 2002; Ceriello et al. 2004), and is therefore pivotal to the development 
and progression of the micro-, and probably macro-vascular, complications of 
diabetes (The Diabetes Control and Complications Trial Research Group 1993;   26 
UK Prospective Diabetes Study (UKPDS) Group 1998; Nathan et al. 2005). The 
peak value of plasma glucose in patients with diabetes (estimated by a 2 hour 
postprandial measurement), more so than the incremental area under the blood 
glucose  curve,  correlates  strongly  with  glycated  haemoglobin  (American 
Diabetes Association 2001). This dictates that an understanding of the impact of 
the  gastrointestinal  tract  on  glycaemic  control  and  insulin  secretion  is  of 
fundamental importance to the development of effective strategies for diabetes 
management.   
 
This chapter focuses on the factors that regulate emptying of a meal from the 
stomach, and the mechanisms by which nutrients then interact with the small 
intestine to determine both blood glucose and insulin concentrations in healthy 
individuals and those with diabetes.   
 
2.2 The incretin effect 
Following a meal, carbohydrate is absorbed and enters the circulation, elevating 
the  blood  glucose  concentration  and  stimulating  insulin  release  from  the 
pancreatic beta cells. It has been long established that the insulin response to an 
oral  glucose  load  is  three-  to  four-fold  greater  than  that  observed  after  an 
„isoglycaemic‟ intravenous infusion of glucose (Perley and Kipnis 1967). This 
phenomenon, known as the „incretin effect‟, led to the discovery of hormones,   27 
secreted from the gastrointestinal tract in response to nutrients, that stimulate 
insulin  secretion  in  a  glucose-dependent  manner.  The  two  known  incretin 
hormones  are  glucose-dependent  insulinotropic  polypeptide  (GIP),  originating 
predominantly from the proximal small intestine, and  glucagon-like peptide-1 
(GLP-1), found predominantly in the distal small intestine and colon. GLP-1 and 
GIP appear to be responsible for over 50 % of the postprandial insulin response 
in  healthy  humans  (Horowitz  and  Nauck  2006).  Circulating  GIP  and  GLP-1 
concentrations are low in the fasting state, but rise within 15 minutes of nutrient 
ingestion, typically peaking by 30-45 minutes, and returning to basal levels over 
2-3 hours (Deacon 2005). The circulating molecular forms of active GLP-1 are 
GLP-1 (7-36) amide, representing the majority of active GLP-1 found in plasma, 
and glycine-extended GLP-1 (7-37) (Drucker 2006). These are rapidly degraded 
by the enzyme dipeptidyl peptidase-IV (DPP-IV) to GLP-1 (9-36) amide and 
GLP-1 (9-37) (Drucker 2006). Similarly, circulating active GIP (1-42) is rapidly 
degraded to inactive GIP (3-42). 
 
2.3 Gastric emptying and its influence on blood glucose and insulin secretion 
Nutrients  empty  from  the  stomach  at  an  overall  rate  of  about  2-3  kcal/min 
(Brener et al. 1983), regulated predominantly by neural and hormonal feedback 
from  the  small  intestine  that  slows  further  emptying  by  relaxing  the  fundus, 
suppressing antral and duodenal contractility, and stimulating tonic and phasic   28 
contractions that are localized to the pylorus (Schirra et al. 2000; Schirra et al. 
2006).  GLP-1  is  one  of  the  peptides  involved  in  this  feedback  loop;  others 
include  cholecystokinin  (CCK)  and  peptide  YY  (PYY),  though  not  GIP 
(MacIntosh et al. 1999).   
 
Although the rate of gastric emptying does not affect insulin secretion directly, it 
regulates  the  delivery  of  carbohydrate  and  other  macronutrients  to  the  small 
intestine, and, therefore, has a major impact on both the timing and magnitude of 
the blood glucose excursion, and the secretion of the incretin peptides, thereby 
modulating  insulin  release  indirectly.  Indeed,  it  has  been  established  that 
variations in the rate of gastric emptying account for some 35 % of the variance 
in the peak blood glucose concentration after 75 g oral glucose, in both healthy 
subjects and patients with type 2 diabetes (Figure 2.1) (Horowitz et al. 1993; 
Jones et al. 1996). Interventions that modify gastric emptying, therefore, have the 
potential  to  affect  glycaemic  control  in  patients  with  diabetes.  For  example, 
accelerating nutrient entry from the stomach to the small intestine with the potent 
prokinetic  drug,  erythromycin,  increases  the  postprandial  glycaemic  response, 
whereas  slowing  gastric  emptying  with  morphine  reduces  postprandial  blood 
glucose concentrations in patients with type 2 diabetes (Gonlachanvit et al. 2003). 
The impact of gastric emptying on both the peak and initial rise in blood glucose 
appears more direct than that on overall glycaemia (Gonlachanvit et al. 2003).   29 
Similarly, the  insulin  requirement  to  sustain  normoglycaemia  after  a  standard 
meal  is  significantly  lower  in  type  1  patients  with  gastroparesis  than  those 
without, with  the difference being  apparent  during the first  two hours  of the 
postprandial  period  (Ishii  et  al.  1994).  Conversely,  when  gastric  emptying  is 
accelerated by giving a meal with smaller particle size in type 1 patients with 
gastroparesis- a group at risk for postprandial hypoglycaemia- the postprandial 
blood glucose dip is diminished (Olausson et al. 2008). 
 
The effects of different rates of gastric emptying on glucose homeostasis can be 
mimicked in the laboratory by infusing glucose through a transnasal catheter, 
directly into the duodenum (Figure 2.2) (Pilichiewicz et al. 2007a). Using this 
technique,  variations  in  the  rate  of  delivery  of  glucose  to  the  small  intestine 
within the physiological range are seen to have differential effects on glycaemia, 
insulin  and  incretin  hormone  release  in  healthy  subjects  (Pilichiewicz  et  al. 
2007a). For example, glucose infusion at 2 kcal/min increases the blood glucose 
concentration more than infusion at 1 kcal/min, but infusion at rates of 2 and 4 
kcal/min  result  in  comparable  blood  glucose  responses,  reflecting  the 
substantially greater insulin response to the 4 kcal/min load. Under low caloric 
exposure  (1  kcal/min),  there  is  minimal,  transient  stimulation  of  GLP-1, 
compared with sustained elevation in GIP, suggesting a much lesser contribution 
of GLP-1 towards the „incretin effect‟ in this circumstance. When intraduodenal   30 
glucose delivery is increased to 2 or 4 kcal/min, progressively increasing GLP-1 
secretion,  in  contrast  to  apparently  capped  levels  of  GIP,  appears  to  be 
responsible for the marked increase in insulin. Similar studies are required to 
address the pathophysiology of insulin secretion in type 2 diabetic patients.   
 
Given that the rate of gastric emptying plays such a major role in determining 
postprandial blood glucose, one could speculate that the initial rate of glucose 
entry into the small intestine may be particularly important in establishing the 
response to ongoing glucose exposure over the next hour or two. This may be the 
case, particularly in type 2 diabetes, where the first phrase of insulin release is 
delayed, whereas the overall insulin response to a meal may be relatively intact 
(Bruce et al. 1988; Gerich 1996). Indeed, in both healthy subjects and type 2 
patients, initially more rapid delivery of glucose to the small intestine does boost 
both the incretin and insulin responses when compared to constant delivery of an 
identical  glucose  load  (O'Donovan  et  al.  2004b;  Chaikomin  et  al.  2005). 
Nevertheless,  this  early  increase in  insulin  cannot  compensate for the  greater 
initial rise in absorbed glucose, so that overall glycaemic control is not improved 
(Figure 2.3) (O'Donovan et al. 2004b; Chaikomin et al. 2005). 
 
2.4 Role of the small intestine 
The  small  intestine,  being  the  site  of  glucose  absorption  from  the  external   31 
environment  and  the  source  of  numerous  regulatory  peptides,  including  the 
incretins, is central to glucose homeosatasis and postprandial insulin secretion. It 
is,  therefore,  remarkable  that  knowledge  regarding  many  aspects  of  small 
intestinal function is rudimentary. 
 
The maximal capacity of glucose absorption from the small intestine is about 0.5 
g per minute (or 2 kcal/min) per 30 cm (Duchman et al. 1997). Therefore, it 
would be expected that changes in small intestinal motor function that act to 
spread  glucose  over  a  larger  surface  area  would  increase  the  rate  of  glucose 
absorption, and indeed, absorption of the glucose analogue, 3-O-methylglucose 
(3-OMG), increases in proportion to the frequency of small intestinal pressure 
waves  and  propagated  pressure  wave  sequences  in  both  healthy  subjects  and 
patients with type 1 diabetes (Rayner et al. 2002; Schwartz et al. 2002). Recently, 
the measurement of electrical impedance at multiple sequential sites within the 
small intestine has yielded information about flow events in the lumen (Nguyen 
et al. 1995). This technique has been validated against fluoroscopy (Imam et al. 
2004) and can be used  in studies which are several hours in duration. When 
duodenal  flow  events  (evaluated  by  impedance)  were  suppressed  by  the 
anticholinergic drug, hyoscine butylbromide, there was marked attenuation of the 
rise in blood glucose and 3-OMG, together with a delay in secretion of both the 
incretins  and insulin  (Chaikomin  et  al.  2007).  Further studies  are  required  to   32 
examine  the  relationship  between  small  intestinal  flow  patterns  and  glucose 
absorption  in  patients  with  diabetes,  many  of  whom  have  disturbed  small 
intestinal motility (Camilleri and Malagelada 1984), with slow small intestinal 
transit in some, but rapid transit in others (Samsom and Verhagen 2004).   
 
It is also unclear to what degree variations in glucose absorption at the level of 
the mucosa are relevant to postprandial glycaemic control in diabetes. Rodent 
models of diabetes are associated with increased absorption of glucose across the 
small intestinal mucosa (Fujita et al. 1998), while acute hyperglycaemia itself 
appears  to  enhance  glucose  absorption  (Csaky  and  Fischer  1977;  Csaky  and 
Fischer 1981; Fischer and Lauterbach 1984; Cheeseman and Maenz 1989). While 
the rate of small intestinal glucose absorption has not been consistently reported 
to be increased in humans with diabetes (Costrini et al. 1977; Gulliford et al. 
1989), expression of monosaccharide transporters SGLT1, GLUT5, and GLUT2 
is increased in type 1 and type 2 diabetic humans (Dyer et al. 2002), and a direct 
relationship has been reported between the rate of intestinal glucose absorption 
and  the  ambient  blood  glucose  concentration  in  type  1  patients  and  healthy 
volunteers (Rayner et al. 2002). Further studies are required to clarify the clinical 
significance of these observations.   
 
Similarly, knowledge about the precise mechanisms and determinants of incretin   33 
hormone release is limited. The size of the nutrient load is clearly important; GIP 
secretion  increases  with  increasing  small  intestinal  glucose  loads  within  the 
physiological range of gastric emptying (up to about 4 kcal/min) (Pilichiewicz et 
al. 2007a). On the other hand, it has been suggested that a threshold of small 
intestinal glucose delivery of about 1.8 kcal/min needs to be exceeded in order to 
stimulate GLP-1 release (Schirra et al. 1996), although studies in our laboratory 
have documented a small, early but transient peak in GLP-1 with a glucose load 
as low as 1 kcal/min (Kuo et al. 2008). The early rise in GLP-1 after nutrient 
exposure  appears  inconsistent  with  the  notion  that  this  hormone  is  secreted 
predominantly  from  the  distal  intestine,  and  raises  the  possibility  of  a 
neuroendocrine loop to the distal small intestine that allows simulation of the 
distal L-cells indirectly (Rocca and Brubaker 1999). GIP appears to mediate such 
a loop in rodents, but not in humans (Nauck et al. 1993a; Nauck et al. 1993c). 
Alternatively, the early rise in GLP-1 could reflect direct stimulation of duodenal 
or jejunal L-cells by luminal glucose (Theodorakis et al. 2006). Moreover, we 
have  shown  that  distal  small  intestinal  exposure  to  glucose  is  required  to 
stimulate GLP-1 release in humans; when exposure was limited to the proximal 
60 cm of small intestine by an occluding balloon, there was no rise in GLP-1 
(Little et al. 2006a). Macronutrient composition also determines GLP-1 release; 
in  addition  to  carbohydrate,  fat  and  protein  induce  GLP-1  and  GIP  secretion 
(Elliott et al. 1993; Herrmann et al. 1995), and the GLP-1 response is greater and   34 
more prolonged with the latter two macronutrients (Elliott et al. 1993; Bowen et 
al. 2006b). Fructose tends to stimulate a similar GLP-1 response to glucose, but 
does not induce GIP release (Rayner et al. 2000b).   
   
2.5 Gastrointestinal function and the incretin response in type 2 diabetes 
Gastric emptying of solids and/or nutrient liquids is abnormally slow in 30-50 % 
of patients with long standing type 1 and type 2 diabetes, although the magnitude 
of the delay in emptying is often modest (Horowitz et al. 1996b). Some groups 
have reported that gastric emptying is abnormally rapid in „early‟ type 2 diabetes 
(Phillips et al. 1992; Frank et al. 1995; Schwartz et al. 1996), although this has 
not been uniformly observed (Jones et al. 1996). The only study to evaluate the 
natural history of gastric emptying in diabetes has demonstrated that there were 
no marked changes in the rate of emptying during follow up of about 12 years 
(Jones et al. 2002). In the absence of symptoms such as nausea, vomiting, or 
bloating,  delayed  gastric  emptying  may  actually  be  beneficial  for  glycaemic 
control  in  type  2  diabetes  managed  by  oral  hypoglycaemic  drugs  or  diet,  by 
slowing  the  absorption  of  carbohydrate,  as  discussed  earlier.  Conversely,  in 
patients treated with insulin, delayed emptying can present a problem if it results 
in a mismatch between the absorption of nutrients and the action of exogenous 
insulin.   
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2.5.1 The incretin effect in type 2 diabetes 
Comparisons of the incretin effect in type 2 patients with that in healthy subjects 
have, to  date, all  been  assessed  after  oral  administration of  nutrients,  so that 
potential differences in the rate of gastric emptying have not been accounted for 
as a confounding factor. A comparison of the incretin response to intraduodenally 
delivered glucose in type 2 diabetes compared to healthy controls is lacking, and 
represents a significant gap in current knowledge. 
 
GIP 
It has been reported that secretion of GIP is increased, decreased or normal in 
patients with type 2 diabetes (Krarup 1988). However, it appears clear that the 
insulinotropic action of GIP is markedly attenuated in these patients (Elahi et al. 
1994), particularly during the „late phase‟  of insulin secretion  (Vilsboll  et  al. 
2002).  The  mechanism  of  this  attenuated  response  remains  uncertain,  but 
defective expression of the GIP receptor has been observed in Zucker diabetic 
fatty rats (Lynn et al. 2001). About 50 % of glucose-tolerant first-degree relatives 
of  type  2  diabetic  patients  demonstrate  a  reduced  insulin  response  to  GIP 
compared with healthy controls, suggesting that the defect might be genetically 
determined, and could represent a primary abnormality leading to the subsequent 
development of diabetes (Meier et al. 2001). However, it has also been reported 
that patients with different aetiologies from typical type 2 diabetes, including   36 
newly diagnosed type 1 diabetes, diabetes secondary to pancreatitis, monogenic 
diabetes  (MODY3),  lean  type  2  diabetes,  and  latent  autoimmune  diabetes  in 
adults, also have diminished insulin responses to GIP when compared to GLP-1, 
implying that the defect in responsiveness to GIP may be a consequence of the 
diabetic state (Vilsboll et al. 2003a).   
 
GLP-1 
Both total and active concentrations of GLP-1 following a standardized meal are 
lower  in  patients  with  type  2  diabetes  when  compared  to  matched  controls 
(Toft-Nielsen  et  al.  2001).  This  phenomenon  might  contribute  to  impaired 
postprandial insulin secretion because, in contrast to GIP, the insulin response to 
exogenous GLP-1 is essentially intact in type 2 diabetes (Nauck et al. 1993c).   
 
2.6 Therapeutic strategies to optimize glycaemia involving modulation of gut 
function 
Potential strategies to optimize postprandial glycaemia in patients with type 2 
diabetes that involve dietary or pharmacological modulation of gastrointestinal 
function include i) slowing gastric emptying to minimize postprandial glucose 
excursions,  ii)  inhibiting  carbohydrate  absorption  in  the  small  intestine,  iii) 
augmenting  incretin  hormone  release,  and  iv)  modifying  macronutrient 
composition.  It  should  be  recognized  that  in  practice,  many  of  these  goals   37 
overlap (Table 2.1). As discussed earlier, the peak blood glucose concentration 
should be particularly targeted by these interventions. Nevertheless, reduction of 
the incremental area under the blood glucose curve is also a goal of therapy.   
 
2.6.1 Slowing gastric emptying 
As  discussed,  in  patients  with  type  2  diabetes  who  are  treated  with  insulin, 
slowing the absorption of nutrients should be beneficial, as the first phase of 
insulin secretion is diminished. An increase in  soluble fibre (Chandalia et al. 
2000), adding the non-absorbable polysaccharide, guar gum (Russo et al. 2003), 
or combining fat with a carbohydrate-containing meal (Cunningham and Read 
1989), all improve blood glucose while lowering insulin responses. Fat is the 
most potent among the macronutrients to slow gastric emptying, a process that is 
mediated by the stimulation of a number of gut hormones, including CCK and 
PYY, as well as GLP-1, and is dependent on lipolysis of triglycerides to fatty 
acids in the small intestine (Feinle et al. 2003). Therefore, the effect of fat on 
slowing gastric emptying and releasing gut peptides is attenuated by the lipase 
inhibitor,  tetrahydrolipstatin  (orlistat),  in  healthy  subjects  and  type  2  patients 
(O'Donovan  et  al.  2004a).  The  requirement  that  triglyceride  digestion  occurs 
before gastric emptying can be slowed suggests the concept of giving fat at an 
interval (eg. 30 min) before the meal. Indeed, this concept of a „preload‟ does 
appear more efficacious than incorporation of fat into the meal (Gentilcore et al.   38 
2006a).  Furthermore,  the  „preload‟  concept  could  also  have  the  advantage  of 
suppressing appetite and reducing energy intake at the subsequent meal.     
 
Pharmacological  agents  which  slow  gastric  emptying  are  also  effective  at 
improving postprandial glycaemic control in patients with diabetes. For example, 
the human amylin analogue, pramlintide, acts predominantly by slowing gastric 
emptying  in  patients  with  type  1  and  2  diabetes  (Thompson  et  al.  1997; 
Thompson et al. 1998; Singh-Franco et al. 2007), while also suppressing both 
postprandial glucagon secretion and appetite (Aronne et al. 2007). Analogues of 
GLP-1, such as exenatide or liraglutide, have been developed primarily with the 
rationale of stimulating insulin secretion, but in practice, inhibition of gastric 
emptying  by  exogenous  GLP-1  appears  to  outweigh  its  direct  insulinotropic 
effects. Thus, when GLP-1 is administered with a meal in healthy subjects, there 
is a dose-dependent reduction of, rather than an increase in, postprandial insulin 
(Nauck  et  al.  1997;  Little  et  al.  2006b).  It  has  recently  been  confirmed  that 
slowing of gastric emptying makes a major contribution to the effect of exenatide 
in  reducing  postprandial  hyperglycaemia  in  patients  with  type  2  diabetes 
(Cervera et al. 2008). 
 
2.6.2 Inhibiting absorption of carboydrate 
The alpha-glucosidase inhibitor, acarbose, is routinely used in the treatment of   39 
diabetes, and reduces postprandial plasma glucose excursions by delaying the 
absorption of carbohydrate (other than monosaccharides) from the small intestine 
(Bischoff 1994). In healthy volunteers, when sucrose is consumed with acarbose, 
the delay in absorption allows exposure of the more distal gut to carbohydrate, 
resulting in greater and more prolonged GLP-1 release than with sucrose alone, 
which  probably  accounts  for  the  observed  slowing  of  gastric  emptying, 
representing an additional mechanism contributing to the therapeutic effect of 
acarbose (Qualmann et  al. 1995; Ranganath et  al. 1998). However, in  type 2 
diabetic  patients,  ingestion  of  acarbose  with  a  mixed  meal  failed  to  enhance 
GLP-1 release or slow gastric emptying (Hucking et al. 2005). Slowing of small 
intestinal carbohydrate absorption can also be achieved by diets high in fibre, 
particularly  soluble  fibre,  and  by  low  glycaemic  index  diets,  which  may,  for 
example, contain carbohydrate as starch in the form of amylose, or within kernels 
that are resistant to digestion (Mourot et al. 1988; Ou et al. 2001; Bjorck and 
Elmstahl 2003).   
 
2.6.3 Augmenting the incretin response 
GLP-1 is rapidly degraded in vivo by the enzyme DPP-IV, as discussed earlier. 
Analogues of GLP-1 that are resistant to DPP-IV degradation, such as exenatide, 
have therefore been developed for therapeutic use (Drucker 2007), and appear to   40 
retain all the anti-hyperglycaemic effects of GLP-1 (Fineman et al. 2003). An 
alternative approach to enhance circulating concentrations of endogenous active 
GLP-1  is  to  inhibit  DPP-IV.  DPP-IV  inhibitors,  such  as  vildagliptin  and 
sitagliptin,  are  available  as  oral  formulations  that  are  effective  in  improving 
glycaemic  control  either  as  initial  monotherapy  or  in  combination  with 
sulfonylureas or metformin (Charbonnel et al. 2006; Ahren 2007), by increasing 
the insulin to glucose ratio and suppressing glucagon (Ahren 2007). Some data 
suggest that DPP-IV inhibitors slow gastric emptying (Woerle et al. 2007), while 
other investigators have not observed a significant effect (Vella et al. 2007). The 
apparent  discrepancy  might  be  accounted  for  by  more  modest  stimulation  of 
GLP-1 with the meal used in the latter study. 
 
2.6.4 Modifying macronutrient composition 
Low carbohydrate and low glycaemic index diets 
Lowering  the  carbohydrate  load  improves  both  fasting  and  postprandial 
glycaemia in type 2 patients who have failed treatment with conventional diets or 
sulfonylureas. Conversely, maintaining high carbohydrate ingestion, even with 
caloric restriction, is associated with poor glycaemic control, and higher levels of 
glycated haemoglobin (Gutierrez et al. 1998). Low carbohydrate intake improves 
hyperglycaemia  and  hyperlipidaemia  over  follow  up  of  at  least  12  months, 
compared to a conventional diet (Stern et al. 2004).   41 
The  glycaemic  index  ranks  the  effect  of  carbohydrate  in  various  foods  on 
postprandial  blood  glucose,  in  comparison  to  a  standard  of  glucose  or  white 
bread. While many low glycaemic index foods have a high fibre content, the 
benefits  of  which  are  discussed  above,  they  have  beneficial  effects  on  blood 
glucose control independent of their fibre content (Wolever 1990). In addition to 
slower  rates  of  gastric  emptying,  and  lower  glucose  absorption  in  the  small 
intestine (Bjorck and Elmstahl 2003), low glycaemic index carbohydrates have 
the potential to increase the length and duration of exposure of the small intestine 
to  nutrients,  enhancing  the  release  of  distal  gut  hormones,  including  GLP-1 
(Little et al. 2006a).   
 
Protein supplementation 
High protein diets have attracted recent attention in the management of type 2 
diabetes; for example, increasing the percentage of dietary protein from 15 % to 
30 % for 5 weeks in type 2 patients reduced postprandial glycaemia and achieved 
a modest (0.4 %) decrease in glycated haemoglobin (Gannon et al. 2003). It has 
been established for some time that the addition of protein to an oral glucose load 
lowers the subsequent glycaemic excursion, and, in type 2 patients, stimulates 
increased secretion of insulin over that of glucose alone (Gannon et al. 1988). 
Addition of protein to a glucose drink slows gastric emptying of the carbohydrate 
and stimulates the release of incretin hormones (Karamanlis et al. 2007), while   42 
an additional effect of whey protein, noted in rodents, is the inhibition of small 
intestinal  DPP-IV  by  digested  protein  fragments  (Gunnarsson  et  al.  2006).  A 
recent study, adopting the „preload‟ concept discussed above, demonstrated that 
whey protein, given 30 minutes before a carbohydrate meal in subjects with type 
2 diabetes, profoundly lowered the blood glucose profile when compared to a 
preload without protein; not only was emptying of the meal slowed, but insulin 
release  was  markedly  stimulated  (Ma  et  al.  2009c).  This  approach  requires 
further investigation to develop a dietary strategy that is applicable for long term 
use.   
 
2.7 Summary and implications 
The gastrointestinal tract, which regulates the absorption of carbohydrate and 
releases  the  „incretin‟  peptides  that  stimulate  insulin  secretion,  is  of  central 
importance  to  glucose  homeostasis.  Interventions  that  slow  gastric  emptying 
and/or  stimulate  the  incretin  effect  appear  to  be  effective  strategies  for  the 
treatment of non-insulin treated type 2 diabetes.   
 
Further  information  is  required  to  understand  the  determinants  of  incretin 
hormone  release  in  humans,  and  dietary  or  pharmacological  modulation  of 
gastrointestinal function needs to be evaluated in medium- or long-term clinical 
trials to establish its benefits for controlling postprandial glycaemia.   43 
Table 2.1 Adapted from Chaikomin et al. 2006. 
Therapeutic strategies directed at minimising postprandial glycaemia 
 
Mechanism  Strategy 
Slow gastric emptying    High fibre diets 
  Adding  guar  gum,  a non-absorbable 
polysaccharide   
  Fat „preloads‟ 
  Protein „preloads‟ 
  Low glycaemic index carbohydrates 
  Acarbose   
  GLP-1 analogues   
  DPP-IV inhibitors 
  Pramlintide 
Inhibit  small  intestinal 
carbohydrate absorption 
  Acarbose 
  High fibre diet 
  Low glycaemic index carbohydrates 
Augment the incretin response    GLP-1 analogues   
  DPP-IV inhibitors   
  Acarbose   
  Fat „preloads‟ 
  Protein „preloads‟   44 
  Low glycaemic index carbohydrates 
Modify  macronutrient 
composition   
  Low carbohydrate diets   
  Low glycaemic index carbohydrate 
  Protein supplementation 
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Figure 2.1 Relationship between the blood glucose concentration at 10 minutes 
and the gastric half-emptying time (T50) of a drink containing 75 g glucose in 
300 mL water, in healthy subjects (open circles, r = -0.56, P < 0.05) and patients 
with type 2 diabetes (filled circles, r = -0.67, P < 0.005). Adapted from Jones et al. 
1996.   46 
                                                             
 
 
Figure 2.2 Blood glucose (A), plasma insulin (B), GLP-1 (C) and GIP (D) in 
response to  intraduodenal  glucose  (25 %, 1390 mOsmol/L)  infused over 120 
minutes at rates of 1 (“G1”), 2 (“G2”), or 4 (“G4”) kcal/min, or saline (4.2 %, 
1390 mOsmol/L) control (“C”), in 10 healthy males. (A) * vs. control: P < 0.05, 
# vs. G1: P < 0.05, § vs. G2: P < 0.05. (B) * vs. control: P < 0.05, # vs. G1: P < 
0.05, § vs. G2: P < 0.05. (C) * vs. control: P < 0.05, # vs. G1: P < 0.05, § vs. G2: 
P < 0.05. (D) * vs. control: P < 0.01, # vs. G1: P < 0.05. (E) * vs. control: P <   47 
0.05, # vs. G1: P < 0.01, § vs. G2: P < 0.01. Data are means ± SEM. Adapted 
from Pilichiewicz et al. 2007a.     48 
   
 
Figure  2.3  Effect  of  initially  more  rapid  intraduodenal  glucose  infusion  (3 
kcal/min between t = 0 and 15 min and 0.71 kcal/min between t = 15 and 120 
min) (closed symbols) compared to constant infusion (1 kcal/min between t = 0 
and 120 min) (open symbols) in healthy subjects (squares) and patients with type 
2 diabetes (circles) on blood glucose, plasma insulin, plasma GLP-1, and plasma 
GIP. Each pair of curves differs between 0 and 30 min for variable vs. constant 
intraduodenal infusion (P < 0.05). Adapted from O'Donovan et al. 2004b.     49 
CHAPTER 3: GASTRIC MOTILITY IN PATIENTS WITH TYPE 2 
DIABETES- DIAGNOSIS AND MANAGEMENT 
Adapted from Ma J et al. Drugs. 69:971-986, 2009. 
3.1 Introduction 
Gastroparesis refers to the presence of delayed gastric emptying occurring in the 
absence of mechanical obstruction (Parkman et al. 2004). In the United States, 
gastroparesis-related hospitalizations doubled from 1995 to 2004 (Wang et al. 
2008c).  The  most  common  disease  complicated  by  gastroparesis  is  diabetes 
mellitus  (Abell  et  al.  2006),  accounting  for  about  one  third  of  patients  with 
gastroparesis in a large study from a tertiary referral centre (Parkman et al. 2004). 
Gastroparesis  often  occurs  in  patients  with  longstanding  diabetes  and 
concomitant microvascular complications such as retinopathy, neuropathy, and 
nephropathy  (Camilleri  2007).  Most  patients  with  gastroparesis  present  with 
upper  gastrointestinal  symptoms,  such  as  nausea,  early  satiation,  postprandial 
fullness, vomiting and bloating (Schvarcz et al. 1996; Ricci et al. 2000), although 
the correlation of symptoms with delayed gastric emptying is relatively weak, 
and  some  patients  are  asymptomatic  (Jones  et  al.  1995).  Furthermore,  the 
contribution  of  disordered  gastric  emptying  to  impaired  glycaemic  control  in 
insulin-treated  diabetic  patients  (type  1  and  type  2)  has  been  generally 
underestimated.     50 
3.2 Prevalence of impaired gastric emptying in diabetes 
Gastric motor dysfunction in diabetes was first reported in 1937, when on X-ray 
examination, stomach contractions were observed to be „slow, lack vigor and die 
out quickly‟ compared to those in healthy subjects (Ferroir 1937). More recently, 
it  has  been  demonstrated  that  gastric  emptying  is  delayed  in  30-50%  of 
long-standing  type  1  and  type  2  patients  (Figure  3.1)  (Horowitz  et  al.  1991; 
Horowitz et al. 1996b; Horowitz et al. 2001), with the prevalence about equal in 
both types of diabetes (Moldovan et al. 2005). Gastric emptying of nutrient liquid 
has been reported to be abnormally rapid in „early‟ type 2 diabetes (Phillips et al. 
1992), although this has not been observed consistently (Jones et al. 1996), and 
rapid emptying is uncommon in type 1 diabetes (Nowak et al. 1995). 
 
3.2.1 Physiology of gastric emptying 
3.2.2 Gastric motor and sensory dysfunction in diabetes 
Delayed gastric emptying can potentially result from disordered function of the 
proximal stomach, antrum, pylorus, and duodenum, or from incoordination of 
motor activity between different parts of the stomach. Impaired function of the 
proximal  stomach  has  been  found  in  type  1  patients,  with  a  reduced  fasting 
fundic tone and impaired accommodation to nutrient ingestion (Samsom et al. 
1995; Samsom et al. 1998). In the distal stomach, infrequent or low amplitude   51 
contractions of the antrum have been observed (Samsom et al. 1996), as well as 
incoordination  between  the  antrum  and  duodenum  (Wehrmann  et  al.  1991; 
Kawagishi et al. 1994). Prolonged and excessive tonic and phasic contractions of 
the pylorus have been documented in some patients (Mearin et al. 1986). There is 
also an increased prevalence of dysrhythmias of the gastric slow wave in diabetes, 
either  abnormally  fast  (tachygastria)  or  slow  (bradygastria)  (Koch  2001), 
although the association with delayed gastric emptying is imprecise (Nohara et al. 
2006). In summary, the motor dysfunctions observed in diabetic gastropathy are 
heterogeneous, which could explain the mixed success of existing treatments, 
and may have implications for the need to tailor therapy to individual patients. 
Furthermore, most studies evaluating disordered gastric function in diabetes have 
not been done during euglycaemia, so the contribution of a potentially reversible 
component  of  motor  dysfunction  attributable  to  acute  hyperglycaemia,  as 
discussed below, cannot be determined.   
 
The presence of delayed gastric emptying does not appear fully to explain upper 
gastrointestinal  symptoms,  as  discussed  earlier  (Jones  et  al.  1995).  Several 
studies  have  evaluated  perceptions  of  proximal  gastric  distension  in  diabetic 
patients, and have reported these to be increased when compared with healthy 
controls (Samsom et al. 1995; Rayner et al. 2000c; Kumar et al. 2008), implying 
that  visceral  hypersensitivity  potentially  contributes  to  the  aetiology  of   52 
gastrointestinal symptoms in patients with diabetes. 
 
3.3 Pathogenesis of diabetic gastroparesis 
The  pathogenesis  of  gastroparesis  is  poorly  understood  but  appears  to  be 
multi-factorial.  Many  recent  insights  have  been  gained  from  examination  of 
gastric  tissue  in  animal  models  and  humans  with  diabetes,  while  potentially 
reversible alterations in gastric motor function can occur with acute variations in 
the blood glucose concentration.   
 
3.3.1 Anatomical and functional observations 
While  irreversible  autonomic  neuropathy  has  been  regarded  widely  as  the 
underlying  cause  of  gastroparesis,  recent  evidence  indicates  a  heterogeneous 
picture,  with  a  range  of  fixed  pathology  and  potentially  reversible  functional 
abnormalities. Animal models of diabetes have shown deficiencies of inhibitory 
neurotransmission,  reduced  numbers  of  ICCs,  decreased  extrinsic  autonomic 
neuron numbers and apoptosis of enteric neurons (Rayner and Horowitz 2006). 
Diabetic rodents exhibit pathologically distinctive dystrophic axons and dendrites 
in  sympathetic  ganglia  without  neuronal  loss  (Schmidt  2002),  and  these 
abnormalities  can  be  reversed  by  exogenous  insulin  or  pancreatic  islet 
transplantation  (Schmidt  et  al.  1983).
 In  the  NOD  mouse  model  of  diabetes,   53 
gastric ICCs are dependent on both insulin and IGF-1 (Horvath et al. 2005), and 
deficiency  of  these  results  in  ICC  depletion  (Horvath  et  al.  2006).  Loss  of 
neuronal nitric oxide synthase (nNOS) expression within myenteric neurons is 
associated with dysfunction of the antrum and pylorus in diabetic mice (Watkins 
et al. 2000; Gangula et al. 2007).   
 
Evaluation of gastrointestinal autonomic function in humans is difficult, and tests 
of  cardiovascular  autonomic  function  are  widely  used  as  a  surrogate  marker. 
However,  the  correlation  between  disordered  motility  and  abnormal 
cardiovascular autonomic function in diabetic patients is weak (Horowitz et al. 
2002b; Asakawa et al. 2005), suggesting that autonomic neuropathy is unlikely 
to be the sole explanation for diabetic gastropathy. Recent studies of tissue from 
humans with gastroparesis undergoing surgical procedures have provided useful 
information  about  the  pathogenesis  of  this  condition.  Documented  changes 
include loss of neurons in the myenteric plexus of the stomach (Yoshida et al. 
1988),  while  absent  or  decreased  ICCs  have  been  found  in  about  a  third  of 
patients with diabetic or idiopathic gastroparesis, correlating with abnormalities 
of gastric slow waves (Forster et al. 2005). There may be a preferential loss of 
inhibitory  neurotransmission  (Pasricha  et  al.  2008),  although  changes  are 
heterogeneous when different patients with gastroparesis are compared.  Some 
patients also have abnormalities of gastric smooth muscle, with fibrosis of the 
muscle  layer  (Pasricha  et  al.  2008)  and  inclusion  bodies  within  myocytes   54 
(Ejskjaer et al. 1999) evident in some reports. 
 
3.3.2 Effects of hyperglycaemia   
Regardless  of  the  presence  of  fixed  pathological  changes  in  diabetes,  acute 
variations in blood glucose levels have a major impact on gastric motor function 
in both healthy subjects and diabetic patients (Rayner et al. 2001). In patients 
with diabetes, marked hyperglycaemia (16-20 mmol/l) leads to prolongation of 
the  lag  phase  and  half  emptying  time  of  solids  and  liquids,  increasing  the 
proportion  of  patients  in  the  „gastroparetic‟  range  when  compared  with 
euglycaemia  (5-8  mmol/l)  (Fraser  et  al.  1990).  Even  in  the  physiological 
postprandial glycaemic range, the rate of gastric emptying is slower at a blood 
glucose of 8 mmol/l than 4 mmol/l in both healthy subjects and patients with 
uncomplicated type 1 diabetes (Schvarcz et al. 1997). In contrast, insulin-induced 
hypoglycaemia  accelerates  gastric  emptying,  even  in  type  1  patients  with 
gastroparesis (Schvarcz et al. 1993; Schvarcz et al. 1995; Russo et al. 2005). 
Acute hyperglycaemia is associated with reduction of fundic tone, suppression of 
antral waves, increased pyloric contraction (Rayner et al. 2001), and induction of 
abnormal  gastric electrical  rhythms  (Jebbink  et al.  1994;  Hasler  et  al. 1995). 
Hyperglycaemia also increases the perception of gastrointestinal symptoms in 
patients with diabetes (Barnett and Owyang 1988; Russo et al. 2005). However, 
the chronic effects of high blood glucose concentrations on gastric motor and   55 
sensory function are not known. The effects of variations in glycaemia on gastric 
emptying in type 2 diabetes are less well-documented than for type 1, although 
cross-sectional data imply similar effects in this group (Horowitz et al. 1989). 
 
3.4 Clinical presentation 
Disordered gastric motility in diabetes is associated with upper gastrointestinal 
symptoms, poor drug absorption, impaired glycaemic control, malnutrition, poor 
quality of life and a high rate of hospitalization (Gallar et al. 1993; Bell et al. 
2002).  Gastric  bezoar  formulation  is  a  rare  complication  of  delayed  gastric 
emptying in diabetic gastroparesis (Whitson et al. 2008), probably reflecting the 
reduction in gastric phase 3 activity (Horowitz et al. 2002b). 
 
The  prevalence  of  gastrointestinal  symptoms,  such  as  fullness,  postprandial 
nausea, vomiting, abdominal pain and bloating (Schvarcz et al. 1996; Ricci et al. 
2000),  is  greater  in  patients  with  diabetes  compared  with  nondiabetic  groups 
(Bytzer et al. 2001), although the presence of symptoms correlates poorly with 
the rate of gastric emptying; only postprandial fullness appears to be a significant 
predictor  of  delayed  gastric  emptying  of  solids  (Jones  et  al.  2001). 
Gastrointestinal symptoms seem to be more common in those with worse chronic 
glycaemic control as assessed by glycated hemoglobin (Bytzer et al. 2001; Quan   56 
et al. 2008) and occur more frequently in patients with markers of psychological 
disorders (Talley et al. 2001). 
 
The rate of gastric emptying regulates the delivery of carbohydrate and other 
macronutrients to the small intestine, and therefore has a major impact on the 
postprandial blood glucose excursion. It has been established that variations in 
the rate of gastric emptying account for 35 % of the variance in the initial rise of 
blood glucose after a 75 g oral glucose load, in both healthy subjects and patients 
with  type  2  diabetes  (Horowitz  et  al.  1993;  Jones  et  al.  1996).  Even  minor 
changes of initial rate of carbohydrate delivery to the small intestine can have a 
substantial  impact  on  glycaemia  (O'Donovan  et  al.  2004b;  Chaikomin  et  al. 
2005).  Thus,  dietary  and  pharmaceutical  interventions  that  modify  gastric 
emptying  have the potential  to  affect  postprandial glycaemia  in  patients  with 
diabetes.  Accelerating  gastric  emptying  with  erythromycin,  increases  the 
postprandial  blood  glucose  concentrations,  whereas  slowing  emptying  with 
morphine  reduces  postprandial  glycaemic  response  in  patients  with  type  2 
diabetes (Gonlachanvit et al. 2003). Similarly, after a standard meal, the insulin 
dosage to sustain normoglycaemia is substantially less during the first two hours 
of the postprandial period in type 1 patients with gastroparesis than those without 
(Ishii  et  al.  1994).  Indeed,  delayed  gastric  emptying  has  recently  been 
documented as an important cause of otherwise unexplained hypoglycaemia in   57 
insulin-treated patients (of which an increasing proportion have type 2 diabetes) - 
a phenomenon that has  been termed  „gastric hypoglycaemia‟ (Horowitz et al. 
2006;  Ohlsson  et  al.  2006).  Therefore,  it  is  important  to  match  the  rate  of 
carbohydrate  delivery  into  the  small  intestine  with  the  action  of  exogenous 
insulin; this may potentially entail accelerating gastric emptying so that nutrient 
delivery occurs in a more predictable fashion. In contrast, in patients with type 2 
diabetes not  treated  with  insulin,  slowing the  absorption  of nutrients  is often 
beneficial for glycaemic control so long as symptoms do not arise. An increase in 
soluble fibre (Chandalia et al. 2000), adding the non-absorbable polysaccharide, 
guar gum (Russo et al. 2003), or fat given before (Gentilcore et al. 2006b), or 
with, a carbohydrate-containing meal (Cunningham and Read 1989) all improve 
blood  glucose  acutely  by  slowing  gastric  emptying  of  carbohydrate.  Indeed, 
slowing of gastric emptying is the predominant mechanism by which GLP-1 and 
its analogues, such as exenatide, reduce postprandial hyperglycaemia in patients 
with type 2 diabetes managed by diet and/or oral hypoglycaemic drugs (Cervera 
et al. 2008; Linnebjerg et al. 2008).   
 
Delayed gastric emptying also influences the delivery and absorption of orally 
administered  drugs  in  the  small  intestine,  generally  resulting  in  later,  or 
fluctuating,  maximal  serum  concentrations  (Hebbard  et  al.  1995).  This  is 
particularly important when a rapid onset of drug action is required and has been   58 
documented  with  oral  hypoglycaemic  drugs  (Groop  et  al.  1989).  Drugs  with 
longer half-lives are less likely to be affected (Horowitz et al. 2002b). 
 
3.5 Diagnosis 
Diabetic  patients  with  upper  gastrointestinal  symptoms  suggestive  of 
gastroparesis should be investigated to exclude other  causes, and to ascertain 
whether  gastric  emptying  is  indeed  delayed.  Acute,  reversible  disorders  of 
gastrointestinal function due to drugs, infection, or electrolyte disorders must be 
excluded (Horowitz et al. 2001) (Table 3.1). Other disorders that result in similar 
symptoms,  including  peptic  ulcer  disease,  gastroesophageal  reflux  disease, 
gastric  cancer,  pancreatic  or  biliary  disease,  and  gastric  outlet  or  mechanical 
small  bowel  obstruction  (Parkman  et  al.  2004),  need  to  be  excluded  with 
appropriate  investigations,  such  as  endoscopy  and  contrast  radiology  studies. 
Diabetic gastroparesis also needs to be differentiated from chronic gastric stasis 
due to previous surgery, metabolic and endocrine disease (liver or renal disease, 
thyroid  dysfunction),  central  nervous  system  disease  (brain  tumour,  stroke  or 
trauma), malignancy and HIV infection (Horowitz et al. 2002b). 
 
3.5.1 Methods for measuring gastric emptying   
Evaluation of solid emptying is more sensitive than that of low-nutrient liquid or   59 
semi-solid meals in the diagnosis of gastroparesis (Wright et al. 1985), and there 
is debate as to whether liquid emptying should also be studied; some patients will 
only exhibit delay of the latter. Gastric emptying can be affected acutely by many 
factors  including  medications,  smoking,  and  the  blood  glucose  concentration 
(Camilleri  et  al.  1998;  Maurer  and  Parkman  2006).  Medications  which  may 
influence  gastric  emptying  should  be  withdrawn  for  48-72  hours,  or  for  the 
half-life of the drug, prior to the test (Camilleri et al. 1998), smoking should be 
avoided on the test day (Abell et al. 2008), and the blood glucose concentration 
should be monitored, and should ideally be below 10 mmol/L at the beginning of 
the test (Abell et al. 2008). Failure to demonstrate delayed gastric emptying need 
not imply that symptoms are not attributable to „diabetic gastropathy‟, of which 
abnormal visceral sensation may be a component, as discussed earlier, but does 
help guide the choice of drug therapy.   
 
Scintigraphy   
Scintigraphy  is  regarded  as  the  „gold  standard‟  for  measurement  of  gastric 
emptying of solid and nutrient liquid meals. After meal consumption, a gamma 
camera is used to monitor scintigraphic counts in various „regions of interest‟. 
The parameters that may be derived include the half-emptying time of solids and 
liquids, lag phase for solids, and intragastric distribution of a meal (proximal 
versus distal retention). The percentage of meal retention at the end of each hour   60 
may be more accurate than the half emptying time (Abell et al. 2008). It has been 
suggested that extending the study time up to four hours increases the sensitivity 
for diagnosis of delayed gastric emptying compared with the retention at two 
hours (Guo et al. 2001), although meal retention at three hours correlates well 
with the four hour value (Ziessman et al. 2007). Intragastric distribution of the 
meal is frequently abnormal in diabetes (Jones et al. 1995), but meal retention in 
the whole stomach is used as the diagnostic measure. The standardization of the 
meal between centres has been a major limitation, rectified to some extent by 
recent  „consensus‟  guidelines,  which  recommend  a  low  fat  egg  white  meal 
labelled  with 
99mTc  sulfur  colloid,  and  consumed  with  jam  and  toast  as  a 
sandwich, with a glass of water (Abell et al. 2008). Despite these guidelines, 
some issues are unresolved, including whether gastric emptying of nutrient liquid 
should also be measured. Although criteria of „severity‟ based on the degree of 
retention at four hours were suggested in the „consensus‟ guidelines, these do not 
include any measure of symptoms and therefore may not be the most appropriate 
guide.   
 
Other measurement techniques 
The limitations of scintigraphy are that patients are exposed to a modest dose of 
radiation, and the test is relatively expensive and confined to specialist centres. 
This has made the use of breath tests an appealing option, at least as a screening   61 
tool  for  delayed  gastric  emptying.  Breath  tests  employ  non-radioactive 
13C-acetate  or  -octanoic  acid  as  a  label  and  are  safe,  easy  to  administer  and 
inexpensive (Chew et al. 2003; Bures et al. 2005; Sanaka et al. 2006). After 
ingestion, the labelled meal passes through the stomach to the small intestine, 
where the 
13C-acetate or -octanoate is absorbed, metabolized into
 13CO2 in the 
liver and exhaled via the breath,  with  the rate  of  gastric  emptying being the 
rate-limiting step. Breath samples are collected and analyzed for 
13CO2 by mass 
spectrometry (Sanaka et al. 2007). Breath tests correlate well with scintigraphy in 
healthy subjects and patients with diabetes (Pfaffenbach et al. 1995; Zahn et al. 
2003), with a sensitivity and specificity  ≥  80 % for detecting delayed gastric 
emptying (Viramontes et al. 2001). This method does assume normal intestinal 
absorption and pulmonary excretion; therefore, further validation is required in 
various patient groups. It is not valid in those patients with markedly delayed 
gastric emptying. 
 
Ultrasonography  is  noninvasive,  and  2-dimensional  ultrasound  has  been 
validated for measuring the emptying of liquids or semi-solids, as well as antral 
motility and transpyloric flow (Haruma et al. 2008). 3-dimensional ultrasound 
offers more comprehensive imaging of the whole stomach (Hveem et al. 1996; 
Gilja et al. 1997; Gentilcore et al. 2006c; Stevens et al. 2008a). However, obesity 
and abdominal gas, together with the need for an experienced operator, limit the   62 
wide use of ultrasonography.   
 
Electrogastrography  noninvasively  measures  gastric  myoelectrical  activity  by 
placing  surface  electrodes  on  the  epigastric  skin  (Koch  2001).  The  normal 
frequency of the gastric slow wave is about 3 cycles per minute. As discussed, 
gastric  dysrhythmia  is  often  associated  with  disordered  gastric  emptying  and 
symptoms  (Kara  et  al.  2006),  but  the  relationship  between  symptoms  and 
dysrhythmia is variable, and electrogastrography should be viewed as a research 
tool at present. 
 
A barium meal has a place in excluding mucosal lesions or obstruction, but has 
no role in quantifying gastric emptying. 
 
3.6 Treatment   
Treatment of patients with diabetic gastroparesis aims to relieve gastrointestinal 
symptoms,  improve  nutritional  status,  enhance  quality  of  life,  and  optimize 
glycaemic  control.  The  latter  represents  a  major  goal  in  the  management  of 
diabetes, in order to reduce the risk of micro- and macrovascular complications 
(UK  Prospective  Diabetes  Study  (UKPDS)  Group  1998).  Careful  attention 
should be paid to improving glycaemic control, which has the capacity to affect 
gastric motility, as discussed above. Type 2 patients might need insulin therapy   63 
rather than oral medication, while patients with type 1 diabetes might benefit 
from an insulin pump to optimize blood glucose control (O'Donovan et al. 2003). 
Patients with unexplained hyperglycaemia or hypoglycaemia should be screened 
for  delayed  gastric  emptying,  in  addition  to  those  with  upper  gastrointestinal 
symptoms.  Patients  with  severe  symptoms  may  require  hospitalization  to 
stabilize their fluid and electrolyte status and provide nutritional support. Many 
aspects of treatment for gastroparesis have not been evaluated in well–designed 
controlled trials, and this represents a major limitation. 
 
3.6.1 Dietary management 
There  have  been  no  published  studies  evaluating  the  effects  of  dietary 
modification in diabetic gastroparesis. Since fibre and fat in particular have the 
potential  to  slow  gastric  emptying,  a  low-fat,  low-fibre  diet  is  generally 
recommended. Frequent (4-6 per day), small-volume meals are also advocated 
(Olausson et al. 2008), with an increased percentage of nutrients in liquid form, 
as gastric emptying of liquids is often less affected than that of solids (Wright et 
al. 1985). 
 
3.6.2 Pharmacological interventions 
Most  patients  with  gastroparesis  require  pharmacological  therapy  to  relieve   64 
symptoms  and/or  accelerate  gastric  emptying.  Given  the  weak  correlation 
between the presence of symptoms and the degree of impairment of emptying, it 
is not surprising that the improvement of gastric emptying is not closely related 
to  the  relief  of  gastrointestinal  symptoms  during  treatment  (Talley  2003). 
Prokinetic agents including erythromycin, metoclopramide and domperidone are 
most  commonly  used  in  the  treatment  of  diabetic  gastroparesis  (Table  3.2). 
Prokinetic  drugs  tend  to  improve  gastric  emptying  and/or  symptoms  in  a 
dose-dependent fashion, although their mechanisms of action are diverse. The 
acceleration  of  gastric  emptying  is  typically  greater  when  emptying  is  more 
delayed at baseline, and can be attenuated during acute hyperglycaemia, at least 
for  erythromycin  and  cisapride  (Petrakis  et  al.  1999;  Horowitz  et  al.  2002a). 
Some  prokinetic  drugs  have  additional  effects  such  as  central  antiemetic 
properties  or  suppression  of  visceral  sensation.  The  choice  of  medication  is 
dependent on potential side effects, the nature of the symptoms and concomitant 
diseases,  drug  availability,  and  personal  preference  of  the  clinician.  In  a 
systematic analysis of clinical trials of prokinetic agents, erythromycin seemed to 
have the strongest effect on gastric emptying when compared with domperidone, 
cisapride  or  metoclopramide  (Sturm  et  al.  1999),  while  erythromycin  and 
domperidone appeared to be most effective in relieving symptoms (Sturm et al. 
1999). Nevertheless, there are few head-to-head comparisons of drugs, and little 
information  about  combinations  of agents.  Furthermore, well-designed double   65 
blind controlled trials generally report more modest effects than open label or 
single-blind studies (Sturm et al. 1999).   
 
Erythromycin 
Erythromycin, a motilin receptor agonist, is one of the most potent gastrokinetic 
drugs when given by the intravenous route (Janssens et al. 1990; Ehrenpreis et al. 
1998); therefore, it has been used as first-line therapy for hospitalized patients 
with  severe  gastroparesis  (Rayner  and  Horowitz  2005).  Administration  of 
erythromycin  is  associated  with  increased  antral  contractions  and  accelerated 
emptying of solids and liquids (Janssens et al. 1990; Richards et al. 1993). Oral 
erythromycin suspension results in an improvement of gastric symptoms (Dhir 
and Richter 2004), although in the long term, tolerance frequently develops due 
to the downregulation of motilin receptors (Richards et al. 1993).   
 
Gastrointestinal symptoms, such as abdominal cramps, nausea and vomiting are 
common side effects of erythromycin, while the drug can prolong the QT interval, 
with a consequent risk of sudden death (Ray et al. 2004), especially with given 
concurrently with CYP3A inhibitors (Ray et al. 2004). Alteration of intestinal 
flora  and  fungal  infections  are  further  concerns  with  long-term  use.  Other 
macrolide  antibiotics,  such  as  clarithromycin  and  azithromycin,  have  been 
reported to have prokinetic properties, but their potential has not been evaluated   66 
sufficiently in clinical trials (Sengupta et al. 2006; Sutera et al. 2008). 
 
Metoclopramide   
Metoclopramide  acts  peripherally  and  centrally  as  a  dopamine  D2  receptor 
antagonist and stimulates smooth muscle contraction by release of acetylcholine 
from enteric cholinergic neurons (5-HT4 agonist) (Rabine and Barnett 2001). The 
former is associated with an antiemetic effect, but also entails a risk of adverse 
effects,  including  extrapyramidal  reactions  and  hyperprolactinaemia. 
Metoclopramide in pill or liquid suspension forms, and as a suppository in some 
countries,  is  suitable  for  outpatients  with  gastroparesis.  Subcutaneous 
administration  provides  comparable  plasma  concentrations  to  the  intravenous 
route and is a useful alternative in patients who cannot tolerate oral medications 
(McCallum et al. 1991). Metoclopramide appears less effective than cisapride in 
improving  the  rate  of  gastric  emptying,  but  its  antiemetic  effects  provide 
significant symptom relief (McHugh et al. 1992). Tardive dyskinesia can occur in 
about  1  %  of  patients  with  long  term  use  (Tonini  et  al.  2004),  and  may  be 
irreversible.   
 
Domperidone 
Domperidone,  acting  on  peripheral  D2  receptors,  possesses  similar  antiemetic 
and  prokinetic  effects  to  metoclopramide.  However,  domperidone  is  not   67 
associated with central nervous system side effects due to its poor penetration of 
the blood-brain barrier (Rayner and Horowitz 2005). It is, therefore, safe for use 
in  Parkinson‟s  disease,  but  like  metoclopramide,  can  be  complicated  by 
hyperprolactinaemia  (Rabine  and  Barnett  2001).  Domperidone  may  be  more 
effective than cisapride in children with diabetic gastroparesis (Franzese et al. 
2002),  while  the  combination  of  domperidone  and  cisapride  was  superior  to 
cisapride alone in accelerating gastric emptying and improving gastrointestinal 
symptoms  in  patients  with  functional  dyspepsia  (Tatsuta  et  al.  1992). 
Domperidone  is  available  in  the  US  through  the  investigational  new  drug 
program.   
 
Cisapride 
Cisapride  used  to  be  the  first  line  oral  prokinetic  agent  in  the  treatment  of 
gastroparesis,  providing  long-term  symptomatic  relief  and  improvement  of 
gastrointestinal motility (Abell et al. 1991; Veysey et al. 2001). It mainly acts on 
the  5-HT4  receptors  of  the  myenteric  plexus  to  stimulate  smooth  muscle 
contraction,  and  accelerates  solid  and  liquid  emptying  from  the  stomach 
(Horowitz et al. 1987). It also acts as a 5-HT3 antagonist, providing an antiemetic 
action. The effects on gastric emptying and improvement in symptoms appear to 
be sustained with long term use (Kendall et al. 1997; Braden et al. 2002). 
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Cisapride has been withdrawn from most markets due to its potential to prolong 
the QT interval, which has been associated with lethal ventricular arrhythmias 
(Tonini et al. 1999). Predisposing factors include high doses (80 mg/day) and 
combination with CYP3A inhibitors (O'Donovan et al. 2003). Cisapride is still 
available in many countries under restricted access arrangements, requiring close 
patient monitoring for ECG abnormalities and other risk factors. The maximum 
daily dose of cisapride should be limited to 40mg, and medications which delay 
cisapride metabolism such as azole antifungals (e.g. ketoconazole) and macrolide 
antibacterials (e.g. erythromycin), or which prolong the QT interval, should be 
avoided (Tonini et al. 1999). 
 
Antiemetics 
Antiemetic  medications  may  be  beneficial  in  relief  of  symptoms,  particularly 
when nausea and vomiting are predominant, even though most do not accelerate 
emptying  and  some  can  delay  it.  The  most  common  antiemetic  medications 
include 5-HT3 receptors antagonists (eg. ondansetron), dopamine antagonists (eg. 
prochlorperazine),  tricylic  antidepressants  (eg.  amitriptyline  or  nortriptyline), 
cannabinoids  (dronabinol)  and  antihistamines  (cyclizine,  dimenhydrinate  and 
meclizine),  while  there  are  anecdotal  reports  regarding  the  neurokinin  NK1 
antagonist, aprepitant (Hasler 2007).   
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Other motilin agonists 
Motilin is an endogenous hormone that accelerates gastric emptying by induction 
of phase III-like contractions (Itoh 1997), but its therapeutic use is limited by the 
need  for  intravenous  administration  and  its  short  half  life.  Orally  available 
motilin analogues have therefore been developed. These include ABT-229, which 
accelerated gastric emptying acutely (Verhagen et al. 1997), but failed to relieve 
symptoms in diabetic patients with gastroparesis, possibly due to tachyphylaxis 
(Tack and Peeters 2001; Thielemans et al. 2005). Unlike ABT–229, mitemcinal 
induces  sustained  acceleration  of  gastric  emptying  over  4  weeks  in  diabetic 
gastroparesis  (McCallum  and  Cynshi  2007a),  and  shows  modest  benefit 
compared to placebo in terms of symptom relief (McCallum and Cynshi 2007b).   
 
Itopride   
Itopride acts as a dopamine D2 receptor antagonist and an acetylcholinesterase 
inhibitor, and does not cross the blood-brain barrier (Iwanaga et al. 1994). One 
trial  reported  symptomatic  benefit  in  patients  with  functional  dyspepsia 
(Holtmann et al. 2006), but this was not confirmed in a larger study (Talley et al. 
2008). Furthermore, itopride (200 mg t.i.d. for 7 days), had minimal effect on the 
gastric  emptying  of  solids  and  liquids  in  patients  with  longstanding  diabetes 
mellitus; only in those with delayed emptying at baseline did the improvement in 
liquid emptying reach statistical significance (Stevens et al. 2008b). In this latter   70 
study, symptoms were not improved, but patients were not selected on the basis 
of being symptomatic.   
 
Ghrelin   
Intravenous  infusion  of  ghrelin,  an  orexigenic  hormone,  accelerates  gastric 
emptying in both diabetic patients and those with functional dyspepsia (Murray 
et al. 2005; Tack et al. 2005). Ghrelin receptor agonists are in development, and 




Acute  and  chronic  administration  of  levosulpiride,  a  dopamine  D2  receptor 
antagonist, is associated with accelerated gastric emptying and improvement in 
upper gastrointestinal symptoms in patients with diabetic gastroparesis (Mansi et 
al.  1995;  Melga  et  al.  1997),  but  the  drug  is  not  available  outside  Europe. 
Although tegaserod, a 5-HT4  agonist,  improves  gastric  emptying, it has been 
withdrawn due to an excess of cardiac events (Morganroth et al. 2002; Degen et 
al. 2005b). Sildenafil has been reported to accelerate gastric emptying in rodent 
models  of  diabetes  (Watkins  et  al.  2000),  but  this  has  not  been  consistently 
reported in patients with diabetic gastroparesis (Bianco et al. 2002; Dishy et al. 
2004).  For  a  subset  of  patients,  where  abdominal  pain  is  a  major  symptom,   71 
gabapentin and pregabalin might be useful agents (Duby et al. 2004; Tolle et al. 
2008), but there are no controlled trials of these medications for this indication. 
The CCK-A receptor antagonist, dexloxiglumide, has been reported to reduce 
dyspeptic symptoms  induced by  nutrients  in  the  small  intestine  (Feinle  et  al. 
2001). 
 
3.6.3 Physical treatment 
Several non-pharmaceutical treatments have been the focus of recent attention in 
the  management  of  gastroparesis,  including  gastric  electrical  stimulation  and 
intrapyloric injection of botulinum toxin. 
   
Gastric electrical stimulation 
Gastric  electrical  stimulation  shows  promise  in  the  treatment  of  refractory 
gastroparesis. However, it should be noted that there are very limited controlled 
data regarding its efficacy (Abell et al. 2003; Jones 2008), and this will need to 
be addressed before this  therapy  can be recommended  outside  the  context  of 
clinical  trials.  Two  stimulation  parameters,  involving  long  pulses  (low 
frequency/high energy), or short pulses (high frequency/low energy) have been 
used. Stimulation with long pulses delivers current at about 3 cycles per minute, 
and in patients with refractory gastroparesis can entrain the gastric slow wave 
and  reverse  gastric  dysrhythmias,  accelerate  gastric  emptying,  and  improve   72 
symptoms (Lin et al. 1998; McCallum et al. 1998). However, an implantable 
device capable of delivering the required energy for this mode of stimulation is 
not currently available. In contrast, gastric electrical stimulation with short pulses, 
such as that approved by the US Food and Drug Administration, called „Enterra‟ 
Therapy, delivers pulses at about 12 cycles per minute, which do not entrain the 
slow wave, and probably do not accelerate gastric emptying (Abell et al. 2002; 
Lin et al. 2004; Lin et al. 2008). Electrical stimulation is performed by inserting a 
pair  of  electrodes  into  the  serosa  of  the  greater  curvature  via  laparoscopy  or 
laparotomy  (Zhang and Chen 2006); endoscopic placement of electrodes also 
appears to  be feasible  (Elfvin et  al.  2007;  Xu et  al.  2007;  Pinto  et  al. 2008; 
Sallam et al. 2008). 
 
In uncontrolled studies, gastric electrical stimulation has been reported to reduce 
the  severity  and  frequency  of  symptoms  such  as  nausea  and  vomiting 
significantly, and to enhance quality of life (Mason et al. 2005; McKenna et al. 
2008), with improvement maintained over three years (Lin et al. 2006). Patients 
with  diabetic  gastroparesis  apparently  respond  better  than  idiopathic  patients, 
while those with pain (as opposed to nausea and vomiting), or using narcotics at 
baseline, tend to respond poorly (Maranki et al. 2008). 
 
The mechanism by which gastric electric stimulation acts is unclear. Stimulation   73 
of vagal afferents with increased thalamic activity, increased perception threshold 
to gastric distention, and improvement in postprandial gastric accommodation 
have all been reported (McCallum et al. 2006).   
 
Intra-pyloric injection of botulinum toxin   
In a manometric study from Mearin et al. (Mearin et al. 1986), a majority of 
patients  with  diabetic  gastroparesis  were  found  to  have  prolonged,  excessive 
tonic  contractions  of  the  pylorus  („pylorospasm‟).  Botulinum  toxin  (Botox) 
blocks  the  release  of  neuromuscular  transmitter  at  cholinergic  terminals 
(Jankovic  and  Brin  1991)  and  is  used  widely  for  treatment  of  achalasia  by 
injection  into  the  lower  oesophageal  sphincter  (Pasricha  et  al.  1995).  In 
uncontrolled series, involving patients with diabetic and idiopathic gastroparesis, 
injection of Botox into the pylorus was associated with acceleration of gastric 
emptying and reduction in pyloric contractions, paralleled by relief of symptoms 
(Ezzeddine et al. 2002; Lacy et al. 2002; Miller et al. 2002; Lacy et al. 2004). 
However, two recent sham-controlled trails, one in patients with predominantly 
idiopathic gastroparesis (Arts et al. 2007), and the other with a large proportion 
of diabetic patients (Friedenberg et al. 2008), failed to show superiority of Botox 
over  saline  in  improving  gastric  emptying  or  symptoms  (Arts  et  al.  2007; 
Friedenberg et al. 2008). Unfortunately, pyloric manometry was not carried out 
before or after injection in either study. Further evaluation is required before the   74 
therapy should be used widely.   
 
Acupuncture 
Acupuncture has been used for gastrointestinal complaints for thousands of years 
in  China,  with  reported  efficacy  for  symptom  relief  (Wang  2004)  and 
acceleration of solid gastric emptying in patients with diabetic gastroparesis in a 
sham-controlled  study  (Wang  et  al.  2008a).  The  underlying  mechanisms  are 
unclear and cannot be attributed to differences in hormones such as motilin, CCK 
or vasoactive intestinal peptide (VIP) (Wang et al. 2007). Further investigations 
are required to evaluate the benefits of acupuncture in patients with symptomatic 
diabetic gastroparesis.   
 
3.6.4 Surgical therapy   
Most  trials  of  surgical  procedures  for  refractory  gastroparesis  are  small, 
uncontrolled,  or  retrospective,  with  very  limited  post-surgical  follow-up. 
Therefore,  these  procedures  should  be  regarded  as  a  last  resort,  and  should 
ideally be performed in centres with experience in managing such patients (Jones 
and Maganti 2003). Gastrostomy may be performed to relieve nausea, vomiting, 
pain  and  bloating,  whereas  jejunostomy  is  indicated  to  maintain  hydration, 
nutrition and glycaemic control (Jones and Maganti 2003). Subtotal or complete 
gastrectomy and reconstruction is used as the last resort for severe refractory   75 
gastroparesis and revision of postoperative gastroparesis (Rayner and Horowitz 
2005).  Pancreatic  transplantation  is  reported  to  benefit  diabetic  patients  with 
gastroparesis,  with  improvement  in  both  gastric  emptying  and  symptoms 
(Cashion et al. 2004).   
 
3.7 Summary and implications 
The prevalence of gastroparesis associated with diabetes is likely to increase in 
the  coming  years.  Patients  may  present  with  a  wide  spectrum  of  symptom 
severity,  or  may  be  asymptomatic,  but  have  disordered  glycaemic  control. 
Available therapeutic options are limited, while progress in the development of 
new  medications  is  suboptimal,  although  there  have  been  some  promising 
developments. The pathogenesis of gastroparesis is complex and incompletely 
understood, and will need further investigation in order to provide more specific 
and effective therapy.     76 
        
 
Figure 3.1 Gastric emptying, expressed as retention of a solid meal (minced beef) 
at 100 minutes, and 50 % emptying time of a nutrient liquid (10 % dextrose), in 
87 patients with diabetes and 25 healthy subjects. The range of gastric emptying 
rates in the healthy subjects is represented by the shaded area. Adapted from 
Horowitz et al. 1991.     77 
Table 3.1 Potential reversible causes of gastroparesis. Adapted from Horowitz et 
al. 2001.   
 
  Drugs  (eg.  anticholinergics,  calcium  channel  antagonists,  opiates, 
levodopa, octreotide, cannabis and alcohol) 
  Electrolyte  or  metabolic  disturbance  (hyperglycaemia,  hypokalaemia, 
hypomagnesaemia,  hyperthyroidism,  hypothyroidism,  hypopituitarism, 
Addison‟s disease) 
  Viral infection (gastroenteritis, herpes zoster) 
  Postoperative ileus 
  Critical illness 
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CHAPTER 4: METHODOLOGIES 
4.1 Introduction 
The techniques and methods used in the studies documented in this thesis were 
diverse  and  included  intubation  of  the  upper  gut  to  deliver  intraduodenal 
infusions,  measurement  of  gastric  emptying  by  scintigraphy  and  breath  tests, 
completion of diet diaries, evaluation of appetite by validated visual analogue 
scales, measurement of energy intake at a buffet meal, assays for gut hormones 
and  the  glucose  analogue,  3-O-methylglucose  (3-OMG),  and  assessment  of 
autonomic nerve function. 
 
4.2 Technique for positioning an intraduodenal catheter 
In  studies  involving  intraduodenal  nutrient  infusion  (Chapters  9  and  11),  a 
multilumen silicone manometry catheter (Dentsleeve International, Mui Scientic, 
Mississauga, Canada) incorporating multiple antral and duodenal sideholes and a 
pyloric sleeve sensor, was inserted through an anaesthetised nostril. The catheter 
was allowed to pass through the stomach into the duodenum by peristalsis, so 
that the sleeve sensor straddled the pylorus. The correct position of the catheter 
was monitored continuously by measuring the transmucosal potential difference 
(TMPD) at the most distal antral channel (~ -40 mV) and the most proximal 
duodenal channel (~ 0 mV), at either end of the sleeve sensor (Heddle et al.   80 
1988a). For this purpose the two channels were each connected to a calomel half 
cell (Ionode, Brisbane, Australia) by Dri-Ref
TM series reference electrodes filled 
with 3 M KCl and a small amount of hydrogel (World Precision Instruments, FL, 
USA)  (Heddle et  al.  1988a;  Heddle et  al.  1988b). A  reference electrode  was 
connected to a 21G cannula filled with 0.9 % saline, inserted subcutaneously in 
the forearm. The criteria for correct catheter position were (i) antral TMPD < -20 
mV, (ii) duodenal TMPD > -15 mV, and (iii) difference > 15 mV (Heddle et al. 
1988a).  The  catheter  included  a  large  diameter  channel  (0.9  mm  diameter), 
opening  ~  14.5  cm  distal  to  the  pylorus,  which  allowed  for  intraduodenal 
infusions via a volumetric infusion pump (Gemini PC-1; IMED Corp, San Diego, 
CA, USA). 
 
4.3 Techniques for measuring gastric emptying 
4.3.1 Scintigraphy 
Scintigraphy  was  used  to  quantify  the  rate  of  emptying  and  intragastric 
distribution of a semi-solid high carbohydrate meal (Chapters 5 and 7). In these 
studies,  it was  essential  to  detect even relatively  minor  differences  in  gastric 
emptying. Hence, the „gold standard‟ technique was used. The meal consisted of 
65  g  powdered  potato  (Deb,  Epping,  Australia)  and  20  g  glucose  (total 
carbohydrate  content:  61  g;  301  kcal),  reconstituted  with  250  ml  water  and   81 
labelled with 20 MBq 
99mTc-sulphur colloid (Gentilcore et al. 2006b). After meal 
consumption,  a  gamma  camera  was  used  to  monitor  the  amount  of 
intraabdominal radioactivity. Images were acquired as 60-sec frames for the first 
60 min and 3-min frames between 60 - 180 min. A „region of interest‟ was drawn 
around  the  whole  stomach,  and  was  subsequently  divided  into  proximal  and 
distal regions (Collins et al. 1991). Gastric emptying curves for each of these 
regions, expressed as percent retention over time, were derived. The retention of 
the meal in the total, proximal and distal stomach at 0, 15, 30, 45, 60, 75, 90, 105, 
120, 135, 150, 165, and 180 min was calculated. Data were adjusted for subject 
movement, radionuclide decay, and gamma-ray attenuation. The lag phase was 
defined visually as the time period before any radioactivity was present in the 
proximal small intestine. For the total stomach the half emptying time (T50) was 
also determined (Collins et al. 1983).   
 
4.3.2 Breath tests 
Breath tests are an indirect, but noninvasive and low-cost, measure of gastric 
emptying of liquid and solid meals. 
13C-acetate was used to label a liquid meal 
(Chapter 10) and 
13C-octanoic acid was incorporated into a solid meal (Chapter 
12).  In  these  studies,  a  less  precise  technique  than  scintigraphy  was  used  to 
quantify  gastric  emptying  for  logistical  reasons,  including  the  potential  to 
compromise  the  primary  endpoint,  if  the  studies  were  performed  in  a  busy   82 
Nuclear Medicine  Department.  With the breath test,  the labelled meal  passes 
through  the  stomach  to  the  small  intestine  where  the 
13C-octanoic  acid,  or 
13C-acetate, is absorbed. The rate of gastric emptying is the rate-limiting step in 
the absorption of the 
13C isotope and its metabolism to 
13CO2, which is then 
excreted in the breath. End-expiratory breath samples were collected at baseline 
and at pre-determined intervals after the meal and analyzed for 
13CO2 by isotope 
ratio mass spectrometry (Europa Scientific, ABCA model 20/20, Crewe, UK) 
(Sanaka et al. 2007). The ratio of 
13CO2 to 
12CO2 was calculated in each breath 
sample (Sun et al. 2003). Data were corrected for age, gender and body weight 
(Schofield 1985). T50 and gastric emptying coefficient (GEC) were calculated 
using the method of Ghoos et al which has been validated against scintigraphy 
(Ghoos et al. 1993). 
 
4.4 Measurement of appetite and energy intake 
4.4.1 Three-Factor Eating Questionnaire 
The Three-Factor Eating Questionnaire, a well developed psychometric test, was 
used to  evaluate eating  behaviour  (Chapters  6 and 7)  (Stunkard and Messick 
1985). It includes two parts, with 36 items in part 1 and 15 items in part 2. The 
questionnaire  allows  the  calculation  of  a  score  for  each  of  three  factors:  (i) 
„cognitive restraint of eating‟, (ii) „disinhibition‟ and (iii) „hunger‟ (Stunkard and   83 
Messick 1985). „Restrained eaters‟ are defined on those who limit their energy 
intake in order to control, or reduce, their body weight. In the studies presented 
in this thesis, volunteers with a score ≥ 11 were considered to be „restrained 
eaters‟ and were excluded, in order to evaluate the effects of different dietary 
inventions on energy intake optimally. 
 
4.4.2 Visual analogues scales (VAS) 
VAS questionnaires were used to assess appetite and gastrointestinal sensations 
in  the  study  reported  in  Chapter  6.  They  consisted  of  13  different  questions 
(Parker  et  al.  2004),  each  followed  by  a  100  mm  horizontal  line.  For  each 
question, the subject was asked to place a vertical mark at a point along the line 
to indicate the strength of that sensation eg. „How hungry do you feel?‟ or „How 
strong is your desire to eat‟ within the range from „weak‟ (to the left) to „strong‟ 
(to  the  right).  Scores  were  determined  by  measuring  the  distance  from  the 
starting point (on the left) to the mark. Other sensations evaluated in this way 
included fullness, nausea, bloating, and abdominal discomfort. VAS have been 
validated  as  being  predictive  of  food  intake  in  both  young  and  old  subjects 
(Parker et al. 2004). 
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4.4.3 Energy intake   
Food  consumption  from  an  ad  libitum  meal,  including  energy  intake  and  its 
macronutrient  distribution,  was  used  to  measure  energy  intake  in  the  study 
reported in Chapter 6 (Stubbs et al. 1998). Volunteers were offered a selection of 
foods in quantities greater than what they would be expected to eat, including 
whole meal bread, white bread, cheese, chicken, ham, cucumber, lettuce, tomato, 
yoghurt, custard, apple, banana, iced coffee, water, orange juice, margarine and 
mayonnaise, and were allowed to eat at will for up to 30 minutes (Lavin et al. 
1996). Energy intake was assessed by the difference in weight of each food item 
before and after consumption, to the nearest 0.1 g. FoodWorks software (version 
3.1, Xyris Software, Highgate Hill, Qld, Australia) was  used to  calculate the 
macronutrient content of the various foods.     
 
4.4.4 Three-day diet diary   
Food diaries were used to assess habitual food intake and eating patterns during 
various periods of intervention (Bingham et al. 1994). In Chapter 7, a 3-day diet 
diary was used to assess energy intake and macronutrient consumption of meals 
for  three  day  periods  at  baseline,  and  before  and  after  each  4-week  dietary 
treatment. During these three days, subjects were asked to weigh all food eaten in 
their main meals and snacks using digital scales, and measure volumes of fluids   85 
and alcoholic drinks using a „measuring‟ cup. The brand of bread and cereal, type 
of oil, and whether meat was fatty or lean, were also recorded. Energy intake 
(calculated  as  kcal)  and  macronutrient  intake  (calculated  as  g  or  %  of  total 
energy), were analyzed to the nearest 0.1 g or 0.1 kcal by FoodWorks software 
(version 3.1, Xyris Software, Highgate Hill, Qld, Australia).   
 
4.5 Ambulant glucose monitoring 
The  continuous  glucose  monitoring  system  (CGMS)  developed  by  MiniMed 
(Medtronic Minimed, CA, USA), incorporating a glucose oxidase based sensor, 
was  used  to  measure  the  extracellular  fluid  glucose  concentration  in  the 
subcutaneous tissue. In the study reported in Chapter 7, CGMS was performed 
concurrently with the assessment of energy intake by diet diary. CGMS has the 
capacity  to  measure  glucose  concentrations  from  2.2  mmol/L  to  22  mmol/L 
continuously and stores the „average‟ glucose measurement for every 5 min of 
sampling  for  up  to  14  days.  While  wearing  the  monitor,  there  are  some 
limitations to lifestyle, such as the inability to bathe or swim, but showering is 
possible.  The  CGMS  system  was  calibrated  using  fingerprick  blood  glucose 
levels, measured by a glucometer four times each day (20 min before each of 
three main meals and once before bedtime). After three days recording, stored 
data were downloaded via a Medtronic Minimed Com-station (MMT-7301) to a 
personal computer, for subsequent analysis (Pearce et al. 2008).   86 
4.6 Biochemical/hormone measurements 
Venous blood samples were collected in ice-chilled tubes containing EDTA and 
480KIU aprotinin (trasyol; Bayer Australia Ltd., Pymble, Australia) per litre of 
blood. Plasma was separated by centrifugation (3200 rpm, 15 min, 4 C) and 
stored at -70 C for later analysis (Wishart et al. 1998; MacIntosh et al. 1999).   
 
4.6.1 Blood glucose and gut hormones   
Blood glucose   
Blood  glucose  concentrations  were  measured  (glucose  oxidase  method)  by  a 
portable glucometer (Medisense Precision QID, Abbott Laboratories, Bedford, 
MA, USA). The accuracy of this method has been confirmed by the hexokinase 
technique (Horowitz et al. 1991). 
 
Insulin   
Plasma,  or  serum,  insulin  was  measured  by  solid-phase,  two-site 
chemiluminescent  immunometric  assay  (Immulite  2000  Insulin,  Siemens 
Medical Solutions Diagnostics, Los Angeles, CA, USA). The sensitivity was 2 
mU/L, intraassay CV was 3.9 % and interassay CV was 5.0 % (O'Donovan et al. 
2004b). 
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GLP-1 
Plasma total GLP-1 was measured by radioimmunoassay (RIA) (GLPIT-36HK, 
Linco Research, St. Charles, MO, USA). The sensitivity was 3 pmol/L, and the 
inter-assay coefficient of variation (CV) was 9.2 % (Ma et al. 2009c). 
 
GIP 
Total plasma GIP was measured by RIA. The standard curve was prepared in 
buffer  and  the  radioiodinated  label  was  provided  by  ProSearch  International 
(Victoria,  Australia).  The  sensitivity  was  2  pmol/L,  and  both  the  intra-  and 
inter-assay CVs were 15 % (O'Donovan et al. 2004b). 
 
CCK 
Plasma CCK-8 was measured by radioimmunoassay using an adaptation of the 
method of Santangelo et al. (15; 16). Standards were prepared using synthetic 
sulphated CCK-8 (Sigma Chemical, St Louis, MO, USA). Intra-assay CV was 




3-OMG, an analogue of glucose, was used to measure initial glucose absorption. 
It  is  transported  from  the  gut  lumen  in  the  same  way  as  glucose,  but  is  not   88 
metabolized  and  is  excreted  in  the  urine.  Accordingly,  plasma  3-OMG 
concentrations represent an index of enteral glucose absorption. Plasma 3-OMG 
concentrations  were  measured  by  liquid  chromatography/mass  spectrometry 
(Rayner et al. 2002).     
 
4.7 Autonomic nerve function 
Autonomic  nerve  function  was  evaluated  using  standardized  cardiovascular 
reflex tests (Ewing and Clarke 1982). Parasympathetic function was assessed by 
the change in heart rate (R-R interval) during deep breathing and in response to 
standing (30:15 ratio); sympathetic function was determined by the decrease in 
systolic blood pressure in response to standing (Ewing and Clarke 1982). Each 
test result was scored according to age-adjusted predefined criteria as: 0 = normal, 
1 = borderline, and 2 = abnormal, for a total maximum score of 6. A score of 3 or 




All methods used by the author in this thesis have been validated, and were well 
tolerated  by  subjects.  They  represent  the  optimal  techniques  to  address  the 
hypotheses underlying each study.   89 
CHAPTER 5: EFFECTS OF PROTEIN ON GASTRIC EMPTYING, 
GLYCAEMIA, AND GUT HORMONES AFTER A CARBOHYDRATE 
MEAL IN TYPE 2 DIABETIC PATIENTS 
Adapted from Ma J et al. Diabetes Care. 32:1600-1602, 2009. 
5.1 Summary 
Both the rate of gastric emptying and incretin hormone secretion are important 
determinants of the postprandial glycaemic excursion. We evaluated whether a 
whey protein „preload‟ could slow gastric emptying, stimulate incretin hormones, 
and thereby attenuate postprandial glycaemia in type 2 diabetes. 8 diet-controlled 
type  2  patients  were  studied  on  three  days  each  in  random  order.  Subjects 
ingested beef flavoured soup 30 min before a mashed potato meal; either 55g 
whey protein was added to the soup („whey preload‟), or to the potato („whey in 
meal‟),  or  no  whey  was  given.  Gastric  emptying  was  slowest  after  „whey 
preload‟ (half-emptying time 87.3  ±  5.4 min), and slower after „whey in meal‟ 
(53.0  ±  8.3 min) than „no whey‟ (39.0  ±  6.2 min; P < 0.0005 for each). The 
incremental area under the blood glucose curve was substantially less after „whey 
preload‟  (363.7  ±   64.5  mmol.min/l)  and  „whey  in  meal‟  (406.3  ± 
85.9mmol.min/l) than „no whey‟ (734.9  ±  98.9 mmol.min/l, P < 0.005), and the 
peak glucose concentration was lower after „whey preload‟ (11.3  ±  0.5 mmol/l)   90 
and „whey in meal‟ (11.7  ±  0.6 mmol/l) than „no whey‟ (14.3  ±  0.5 mmol/l, P 
=  0.0001).  Cholecystokinin  (CCK),  glucose-dependent  insulinotropic 
polypeptide (GIP) and insulin concentrations were higher on both whey days 
than after „no whey‟, whereas glucagon-like peptide-1 (GLP-1) was greatest after 
„whey preload‟ (P < 0.05). Whey protein consumed before a carbohydrate meal 
in type 2 diabetes acutely stimulates insulin and incretin hormone secretion, and 
slows  gastric  emptying,  leading  to  marked  attenuation  of  postprandial  blood 
glucose. This observation has substantial implications for dietary
 management of 
type 2 diabetes. 
 
5.2 Introduction 
Optimization  of  glycaemic  control,  as  evaluated  by  glycated  haemoglobin, 
represents a major aim in the management of diabetes, in order to reduce the 
development  and  progression  of  micro-,  and  probably,  macrovascular 
complications (The Diabetes Control and Complications Trial Research Group 
1993; UK Prospective Diabetes Study (UKPDS) Group 1998). For most patients 
with  type  2  diabetes,  postprandial  glycaemia  makes  a  greater  contribution  to 
glycated  haemoglobin  than  fasting  blood  glucose  (Monnier  et  al.  2003). 
Furthermore,  it  is  important  that  strategies  to  „normalize‟  glycaemia  do  so 
without increasing the risk of hypoglycaemia (Holman et al. 2008).   
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Both  gastric  emptying,  and  incretin  hormones  released  from  specialized 
entero-endocrine cells, are known to be major determinants of postprandial blood 
glucose concentrations (Chaikomin et al. 2006). It has been demonstrated that 
differences in the rate of gastric emptying account for about one third of the 
variation in the initial rise in blood glucose after an oral glucose load in healthy 
subjects and patients with type 2 diabetes (Horowitz et al. 1993; Jones et al. 
1996). Indeed, slowing the rate of entry of nutrients into the small intestine may 
well be the dominant mechanism by which exogenous GLP-1 analogs such as 
exenatide (Cervera et al. 2008), and the amylin agonist, pramlintide, improve 
glycaemic control (Edelman 2008). 
 
The  incretin  hormones,  GLP-1  and  GIP,  account  for  at  least  50  %  of  the 
postprandial insulin response in healthy humans (Horowitz and Nauck 2006). 
Some reports in patients with type 2 diabetes indicate that postprandial GLP-1 
concentrations are diminished in this group (Toft-Nielsen et al. 2001; Vilsboll et 
al.  2001), although  this  is  not  uniformly  the  case  (O'Donovan  et  al.  2004b). 
Nevertheless, GLP-1 has preserved incretin activity in type 2 diabetes (Nauck et 
al. 1993c). while the insulinotropic effect of GIP is said to be reduced (Nauck et 
al. 1993c). Other hormones such as CCK and peptide YY (PYY), secreted from 
gastrointestinal tract in response to nutrients, also delay gastric emptying (Wen et 
al. 1995; Schwizer et al. 1997; Rayner et al. 2000a) and are therefore likely to   92 
improve postprandial glycaemia, although there has not been consistent evidence 
that CCK and PYY enhance insulin secretion (Hasegawa et al. 1996; Hidalgo et 
al. 2002; Boey et al. 2007). 
 
One  strategy  to  minimize  postprandial  blood  glucose  excursions  could  be  to 
administer a small load of macronutrient at a fixed interval before a meal, so that 
the presence of nutrients in the small intestine would both induce the release of 
peptides such as GLP-1, GIP, and CCK, and slow gastric emptying in advance of 
the  main  nutrient  load  (Read  1992b).  We  previously  evaluated  this  „preload‟ 
concept by giving 30 ml olive oil 30 minutes before a carbohydrate-rich meal, 
which  resulted  in  markedly  slower  gastric  emptying,  stimulation  of  GLP-1 
secretion,  and  attenuation  in  the  postprandial  glucose,  insulin  and  GIP 
concentrations,  in  patients  with  type  2  diabetes  (Gentilcore  et  al.  2006b). 
However, despite a delay in peak blood glucose, the duration of measurements 
was  not  sufficient  to  determine  whether  the  overall  glycaemic  response  was 
lowered.   
 
It has  long been established that protein  ingestion is  not  accompanied  by  an 
increase in the blood glucose concentration (Conn and Newburgh 1936), and 
when given together with oral carbohydrate, protein enhances insulin release and 
slows  gastric  emptying,  compared  to  carbohydrate  alone,  in  type  2  diabetic   93 
patients (Nuttall et al. 1984). In addition to stimulating the release of GLP-1 and 
GIP, protein can potentially enhance insulin secretion by direct stimulation of the 
beta cell by amino acids (Fieseler et al. 1995; Karamanlis et al. 2007). In rodents, 
digested  fragments  of  whey  protein  also  inhibit  activity  of  dipeptidyl 
peptidase-IV  (DPP-IV),  the  enzyme  responsible  for  degrading  endogenous 
GLP-1 and GIP, in the upper small intestine (Gunnarsson et al. 2006).   
 
We therefore hypothesized that a protein „preload‟, in the form of a whey-based 
drink  ingested  before  a  carbohydrate-containing  meal,  would  reduce  both  the 
peak  blood  glucose  and  overall  postprandial  glycaemic  profile,  by  slowing 
gastric emptying and stimulating the release of GLP-1, GIP, CCK and insulin in 
patients with type 2 diabetes. 
 
5.3 Methods 
5.3.1 Subjects   
Subjects 
Eight patients with type 2 diabetes, diagnosed by World Health Organization 
criteria and managed by diet alone (7 male; age: 58 ±  3 yr; body mass index: 
28.6  ±  1.3  kg/m
2),  were  recruited  by  newspaper  advertisement.  None  had  a 
history  of  significant  comorbidities,  was  a  smoker,  or  was  taking  medication   94 
known  to  influence  gastrointestinal  function.  The  mean  duration  of  known 
diabetes was 5.4 ± 1.1 yr, glycated haemoglobin was 6.5 ± 0.2 %, and all had 
plasma creatinine ≤ 0.12 mmol/L. 
 
The study protocol was approved by the research ethics committee of the Royal 
Adelaide  Hospital,  and  each  subject  provided  written  informed  consent.  All 
experiments were carried out in accordance with the Declaration of Helsinki. 
 
5.3.2 Protocol 
The  study  followed  a  randomized,  single-blind,  cross-over  design.  All 
participants  attended  the  Department  of  Nuclear  Medicine,  PET  and  Bone 
Densitometry at the Royal Adelaide Hospital at approximately 0830 h after an 
overnight  fast  (14  h  for  solids,  12  h  for  liquids)  on  three  occasions,  each 
separated by at least 3 days. A cannula was placed in an antecubital vein for 
blood sampling, and each subject was seated with his/her back against a gamma 
camera. On one of three days, subjects consumed a whey-based „preload‟ (55 g 
whey protein (Murray Goulburn, Brunswick, VIC, Australia), 4 g non-caloric 
beef flavoring, and 350 ml water served at 40 C) within 1 min, 30 min before a 
mashed potato meal (t = -30). The meal consisted of 65 g powdered potato (Deb, 
Epping, Australia) and 20 g glucose (total carbohydrate content: 61 g; 1263 kJ),   95 
reconstituted with 250 ml water and labeled with 20 MBq 
99mTc-sulphur colloid, 
and was consumed within 5 minutes (Gentilcore et al. 2006b). On another day, 
the preload did not include whey and 55 g whey was mixed into the potato meal. 
On  a  third  day,  neither  the  preload  nor  the  meal  contained  whey.  Gastric 
emptying  was  assessed  from  the  time  of  ingestion  of  the  meal  for  180  min. 
Venous blood samples were taken immediately before the „preload‟ (t = -30 min), 
and  at  t  =  -15, 0, 15,  30, 60, 90, 120,  150, 180, 210, 240  and 300  min  for 
measurement  of  blood  glucose  and  plasma  insulin,  GLP-1,  GIP  and  CCK 
concentrations. Blood was also sampled at t = 45, 75, 105, 135, 165, 270 min for 
measurement of blood glucose only. Samples were placed into tubes containing 
EDTA and aprotinin on ice and centrifuged at 3200rpm for 15 minutes. Plasma 
was  separated  and  stored  at  -70  C  for  subsequent  hormone  analyses,  using 
established  assays.  On  one  of  the  study  days,  autonomic  nerve  function  was 
evaluated using standardized cardiovascular reflex tests (Ewing and Clarke 1982), 
after completion of the other measurements.   
 
5.3.3 Measurements 
Gastric emptying and intragastric meal distribution 
Radioisotopic data were acquired as 60-sec frames for the first 60 min and 3-min 
frames  between  60-180  min.  Data  were  adjusted  for  subject  movement, 
radionuclide decay, and gamma-ray attenuation. A „region of interest‟ was drawn   96 
along the total stomach, which was subsequently divided into proximal and distal 
regions, and gastric emptying curves (expressed as percent retention over time) 
were derived (Gentilcore et al. 2006b). The lag phase was defined visually as the 
period before any radioactivity was present in the proximal small intestine. The 
retention of the meal in the total, proximal, and distal stomach at 0, 15, 30, 45, 60, 
75, 90, 105, 120, 135, 150, 165, and 180 min was calculated; the 50 % emptying 
time (T50) was also determined.   
 
Blood glucose measurement 
Blood glucose concentrations were measured immediately using a glucometer 
(Medisense Precision QID, Abbott Laboratories, Bedford, MA, USA). 
 
Plasma Insulin, GLP-1, GIP and CCK assays 
Plasma  insulin  was  measured  by  solid-phase,  two-site  chemiluminescent 
immunometric  assay  (Immulite  2000  Insulin,  Siemens  Medical  Solutions 
Diagnostics,  Los  Angeles,  CA).  The  sensitivity  was  2  mU/L,  intraassay 
coefficient of variation (CV) was 3.9 % and interassay CV was 5.0 %. Total 
GLP-1  was  measured  by  radioimmunoassay  (RIA)  (GLPIT-36HK,  Linco 
Research,  St.  Charles,  Missouri).  The  sensitivity  was  3  pmol/L,  and  the 
inter-assay CV was 9.2 %. Plasma GIP was measured by RIA, with a sensitivity 
of  2 pmol/L, and both  intra-  and inter-assay CVs  of  15 %.  CCK-8 was  also   97 
measured by RIA with sensitivity of 1 pmol/L, intra-assay CV of 6.2 % and 
inter-assay CV of 14.2 % (Santangelo et al. 1998). 
 
Cardiovascular autonomic function 
Parasympathetic function was assessed by the variation in the heart rate (R-R 
interval) during deep breathing and the heart rate response to standing („30:15‟ 
ratio); sympathetic function was determined by the fall in systolic blood pressure 
in response to standing. Each test result was scored according to age-adjusted 
predefined criteria as: 0 = normal, 1 = borderline, and 2 = abnormal, for a total 
maximum score of 6. A score of 3 or higher was taken as evidence of autonomic 
dysfunction (Ewing and Clarke 1982). 
 
5.3.4 Statistical analysis 
Incremental  area  under  the  blood  glucose  and  plasma  hormone  concentration 
curves were calculated using the trapezoidal rule, ignoring any negative values 
(Wolever 2004). Data were evaluated using repeated measures ANOVA, with 
treatment and time as  factors.  In the event of a treatment  × time interaction, 
individual  time  points  were  compared  with  means  comparisons.  All  analyses 
were performed using StatView (version 5.0, Abacus Concepts, Inc., Berkeley, 
CA) and SuperANOVA (version 1.11, Abacus Concepts, Inc.). Data are shown 
as mean values ± standard error; P < 0.05 was considered significant.   98 
5.4 Results 
All  subjects  tolerated  the  study  well.  The  mean  score  for
  autonomic  nerve 
dysfunction  was  2.1  ±  0.8;  two
 of  the  eight  subjects  had  definite  autonomic 
dysfunction. 
 
5.4.1 Gastric emptying (Figure 1) 
Total stomach (Figure 1A) 
Gastric  emptying commenced after  a  short  lag  phase;  the  latter  tended  to  be 
longer when whey was consumed before the meal („whey preload‟, 7.1  ±  3.7 
min; „whey in meal‟, 1.8  ±  0.3 min; „no whey‟, 1.0  ±  0.0 min; P = 0.1). On 
the  „no  whey‟  and  „whey  in  meal‟  days,  emptying  was  rapid  initially,  and 
subsequently  slower.  In  contrast,  emptying  after  the  „whey  preload‟ 
approximated  a  linear  pattern.  Gastric  emptying  was  slowest  on  the  „whey 
preload‟ day than both the other days (P = 0.0001), and slower when whey was 
included in the meal compared to „no whey‟ (P < 0.0005). Accordingly, the T50 
was longer with the whey preload (87.3  ±  5.4 min) than both the „no whey‟ 
day (39.0  ±  6.2 min; P = 0.0001) and when whey was included in the meal 
(53.0  ±  8.3 min; P = 0.0001), and was longer with whey in the meal than „no 
whey‟ (P < 0.01). 
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Intragastric distribution (Figure 1B and 1C)   
There was a modest increase in meal retention in the proximal stomach with the 
whey preload compared to the other two days (P < 0.05), and when whey was in 
the meal compared with no whey (P < 0.05). In contrast, there was a marked 
increase in meal retention in the distal stomach after the whey preload compared 
with the other two days (P < 0.05), and distal meal retention was also greater 
when the whey was in the meal, compared to „no whey‟ (P < 0.05).   
 
5.4.2 Blood glucose concentrations (Figure 2A) 
There  were  no  differences  between  baseline  blood  glucose  concentrations,  or 
between -30  and 0 min on each day. There  was a postprandial rise in blood 
glucose, from 15 min with no whey (P < 0.001) or when whey was in the meal (P 
< 0.01), with a later rise at 30 min after the whey preload (P < 0.005). The blood 
glucose concentrations were lower after the whey preload and when whey was in 
the meal than with no whey (P < 0.005 and P < 0.05). In particular, the peak 
blood glucose concentration was markedly less after both the whey preload (11.3 
±  0.5  mmol/L)  and  when  whey  was  in  the  meal  (11.7  ±  0.6mmol/L), 
compared with no whey (14.3  ±  0.5 mmol/L; P = 0.0001). The incremental 
area under the curve (iAUC) was also less when whey was given as a preload 
(363.7  ±  64.5  mmol.min/l)  and  in  the  meal  (406.3  ±  85.9  mmol.min/l), 
compared to no whey (734.9  ±  98.9 mmol.min/l; P < 0.005). Blood glucose   100 
concentrations had returned to baseline at a mean of 210 min after the whey 
preload and when whey was in the meal, and at 240 min without whey. At t = 
300 min, blood  glucose concentrations  were lower than baseline on all  three 
days.   
 
5.4.3 Plasma insulin concentrations (Figure 2B) 
There  were  no  differences  in  baseline  insulin  concentrations.  Plasma  insulin 
increased on all 3 days (P = 0.0001) with an earlier response after whey preload 
(t = 15 min, P < 0.005) than when whey was in the meal (t = 30 min, P < 0.0005) 
or no whey was given (t = 30 min, P < 0.05). The plasma insulin response was 
markedly greater after both the whey preload (P < 0.05) and when whey was in 
the meal (P < 0.01), when compared to no whey. Plasma insulin was higher at 60 
min after whey preload than when whey was in the meal (P < 0.005), but less at 
120 150 and 180 min (P < 0.01). iAUC was greater when whey was given as a 
preload (32611.781  ±  9234.9 mU.min/l) or in the meal (37248.8  ±  10950.0 
mU.min/l), compared to no whey (12283.5  ±  3453.9 mU.min/l; P < 0.05 and P 
< 0.005). Despite an earlier response, the overall iAUC did not differ between the 
„whey preload‟ and „whey in meal‟ days. 
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5.4.4 Plasma GLP-1 concentrations (Figure 2C) 
There were no differences in GLP-1 concentrations at baseline. Plasma GLP-1 
markedly increased on all 3 days (P = 0.0001), and had already risen before the 
meal  after  the  whey  preload  (t  =  -15  min;  P  =  0.0001).  Plasma  GLP-1  was 
markedly  greater  when  whey  was  given  as  a  preload  or  in  the  meal,  when 
compared to no whey (P < 0.05 for each) and greater between -15 min and 90 
min with the whey preload when compared with whey in the meal (P = 0.0001). 
Accordingly,  iAUC  was  greater  after  whey  preload  (3965.2  ±   593.6 
pmol.min/l) and whey in the meal (3514.7  ±  675.6 pmol.min/l), compared to 
no whey (779.5  ±  169.2 pmol.min/l; P = 0.0001), but did not differ between 
the whey preload and whey in the meal.   
 
5.4.5 Plasma GIP concentrations (Figure 2D) 
There were no differences in baseline plasma GIP concentrations. There was a 
rise in plasma GIP on all 3 study days (P = 0.0001), with a rapid response from t 
= -15 min after the whey preload (P < 0.05). Plasma GIP concentrations were 
greater after the whey preload and when whey was in meal, compared with no 
whey (P < 0.05 and P < 0.05 respectively). GIP levels were also greater at t = -15, 
-5,  15  and  60  min,  and  lower  at  t  =  180  min,  after  the  whey  preload  when 
compared to whey in the meal (P < 0.05). Accordingly, iAUC was greater after   102 
the whey preload (9003.4  ±  701.2 pmol.min/l) and whey in the meal (8453.9 
±  1209.2 pmol.min/l), compared to no whey (4493.2  ±  609.6 pmol.min/l; P = 
0.0001), but did not differ between the whey preload and whey in the meal. At t 
= 300 min, plasma GIP was higher than baseline levels after the whey preload 
and when whey was in the meal, but lower than baseline on the day without 
whey.   
 
5.4.6 Plasma CCK concentrations (Figure 2E) 
There were no differences in baseline CCK concentrations. There was a rise in 
CCK on all 3 days (P = 0.0001), with a early increase after the whey preload (t = 
-15 min, P = 0.0001). The postprandial rise in plasma CCK was slightly greater 
after the whey preload and when whey was in the meal compared to no whey (P 
< 0.05 and P < 0.001 respectively). Plasma CCK was also greater at -15, -5 and 
15 min on the „whey preload‟ day than when whey was in the meal (P < 0.05). 
iAUC for CCK concentrations was greater after whey preload (856.8±  108.5 
pmol.min/l)  and  when  whey  was  in  the  meal  (898.7  ±  124.1  pmol.min/l), 
compared to no whey (444.1  ±  68.7 pmol.min/l; P = 0.0001), but did not differ 
between the whey preload and whey in the meal.   
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5.5 Discussion 
We demonstrated that whey protein, given either as a „preload‟ before a high 
carbohydrate  meal,  or  consumed  with  the  meal,  resulted  in  a  substantial 
reduction in both the peak and overall area of the postprandial blood glucose 
excursion  in  patients  with  diet-controlled  type  2  diabetes.  The  ingestion  of 
protein was associated with stimulation of GLP-1, GIP, and CCK, a markedly 
greater  insulin  response,  and  slower  emptying  of  the  potato  meal,  when 
compared to control. Whey given as a preload initiated a rise in insulin and gut 
peptides  in  advance  of  meal  ingestion,  so  that  the  feedback  mechanisms 
regulating gastric emptying and glycaemia were already active at the onset of the 
meal. Given that the magnitude of the reduction in postprandial glycaemia was at 
least  what  would  be  hoped  for  with  pharmacological  therapy  such  as  the 
sulphonylureas,  these  data  have  considerable  implications  for  the  further 
development of nutritional strategies in the treatment of type 2 diabetes. 
 
The role of the gastrointestinal tract in determining postprandial blood glucose 
has often been overlooked in the past, but is now rising to prominence, at least in 
part due to the development of gut peptide based therapies for diabetes, such as 
the GLP-1 analogue, exenatide (Cervera et al. 2008), and the amylin analogue, 
pramlintide (Thompson et al. 1998). Both the regulation of entry of carbohydrate 
from the stomach into the small intestine, and the release of peptide hormones   104 
from  the  small  intestine  that  stimulate  insulin  secretion,  make  the  upper 
gastrointestinal tract central to glycaemic control.   
 
Our  group  has  previously  demonstrated  that  olive  oil,  given  as  a  preload, 
modified  the  glycaemic  response  to  a  subsequent  high  carbohydrate  meal  in 
patients with type 2 diabetes (Gentilcore et al. 2006b). Like whey protein, oil had 
a profound effect in slowing the emptying of the meal from the stomach, which 
was associated with stimulation of GLP-1. After the oil preload, however, the 
GIP and insulin responses were diminished and delayed in contrast to the current 
study, and the effect on blood glucose was less marked. This implies that with oil, 
slowing  of  gastric  emptying  was  the  major  mechanism  for  attenuating 
postprandial glycaemia. Given that the whey preload had comparable effects on 
gastric emptying, but a much greater effect on blood glucose levels, it is likely 
that the stimulation of insulin by whey, in contrast to the delayed insulin response 
after oil, played the dominant role in improving glycaemia in the current study. 
 
Potential mediators of the stimulation of insulin by whey protein  include the 
incretin hormones, GIP and GLP-1, and direct stimulation of the beta cells by 
amino acids absorbed after digestion of whey (Fieseler et al. 1995). While there 
is no direct evidence that CCK enhances insulin secretion, this hormone was 
likely to have played a role in the slowing of gastric emptying induced by the   105 
preload (Liddle et al. 1988; Schwizer et al. 1997). Whey certainly stimulated the 
release of both GIP and GLP-1, and when given as a preload, plasma levels of 
these peptides had risen even before ingestion of the subsequent meal. The latter 
observation might account for the fact that the insulin profile showed an earlier 
increase after the whey preload than when whey was consumed with the meal. 
Subsequent to the meal, the magnitude of the GIP and insulin responses was 
otherwise similar on both whey days, in contrast to the greatly enhanced initial 
stimulation of GLP-1 when whey was given as a preload. The fact that insulin 
was not stimulated even more with the whey preload may be accounted for by 
the  action  of  GLP-1  to  retard  gastric  emptying,  and  thereby  limit  further 
carbohydrate  absorption,  since  the  insulinotropic  action  of  GLP-1  is 
glucose-dependent.  In  contrast  to  previous  reports  that  GLP-1  secretion  is 
deficient in type 2 diabetes (Toft-Nielsen et al. 2001; Vilsboll et al. 2001), we 
have observed both previously (O'Donovan et al. 2004b) and in the current study 
that diet-controlled type 2 patients can mount a strong GLP-1 response, and it is 
also  established  that  the  insulin  response  to  GLP-1  remains  intact  in  type  2 
diabetes (Nauck et al. 1993c). In contrast, type 2 patients become unresponsive 
to  GIP,  although  recent  evidence  suggests  that  this  can  be  reversed  by  tight 
glycaemic control  (Hojberg et  al.  2008).  In support of  the  importance  of  the 
incretin  hormones  in  stimulating  insulin  in  the  current  study  is  that  the  time 
course of insulin release seemed to follow that of GLP-1 and GIP. In addition to   106 
increasing  the  rate  of  glucose  disposal,  it  is  possible  that  the  stimulation  of 
insulin results in suppression of glucagon; however, we did not measure plasma 
glucagon concentrations. 
 
It appears that the choice of macronutrient is an important factor in the efficacy 
of the „preload‟ strategy. In addition to any benefit in glycaemic response, protein 
preloads  are  attractive,  as  they  may  promote  satiety  and  therefore  have  the 
potential to reduce total energy intake (Bowen et al. 2006b; Bowen et al. 2006c). 
The  type  of  protein  consumed  also  appears  to  be  important;  whey  results  in 
greater increases in GLP-1, GIP and CCK, more delayed gastric emptying, and 
lower energy intake when consumed as a preload, compared with casein (Hall et 
al. 2003). An additional advantage of whey is the capacity for digested protein 
fragments  to  inhibit DPP-IV in  the upper small intestine, resulting in  greater 
concentrations  of  the  active  forms  of  GIP  and  GLP-1,  at  least  in  rodents 
(Gunnarsson et al. 2006). Our assays for GIP and GLP-1 measured only total 
peptide concentrations; it would be of interest to evaluate the concentration of 
intact peptides to see whether this effect of whey is evident in humans. It would 
also be of interest to study the effects of a combination of whey protein with a 
DPP-IV inhibitor, in an effort to optimize the effects of incretin stimulation.   
 
Our  study  involved  a  relatively  small  number  of  subjects  who  had   107 
well-controlled, predominantly uncomplicated type 2 diabetes. Despite evidence 
of  autonomic  neuropathy  in  two  of  our  patients,  none  had  abnormally  slow 
gastric emptying on the control day, and therefore we cannot be certain that our 
results would apply to  patients with diabetic gastroparesis.  Further evaluation 
would also be required in order to generalise the outcome to patients with poorly 
controlled type 2 diabetes and those using pharmacological antidiabetic agents, 
and to determine whether the acute benefits that we observed are sustained in the 
longer term. The dose of whey protein was chosen on the basis of previous data 
that it was sufficient to stimulate gut hormones (Bowen et al. 2006c). It would be 
important  to  confirm  whether  the  effects  we  observed  are  maintained  with  a 
smaller  load  of  protein,  in  order  to  minimize  the  additional  energy  load. 
Nevertheless,  despite  the  small  sample  size,  the  improvement  in  postprandial 
glycaemia  was  marked,  and  consistent  between  subjects,  and  the  concept  of 
using dietary manipulations to treat type 2 diabetes, based on our knowledge of 
the contribution of gastric emptying and gut peptides to postprandial glycaemic 
responses, therefore holds much promise.   
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Figure 5.1 Meal retention in the total stomach (A), proximal stomach (B) and 
distal stomach (C) on three study days in 8 type 2 diabetic patients. On each day, 
subjects  ingested  350  ml  beef  flavoured  soup  30  min  before  a  radiolabeled 
mashed potato meal; either 55 g whey protein was added to the soup („whey 
preload‟), or the whey was added to the potato („whey in meal‟), or no whey was 
given („no whey‟). Data are mean ± standard error. * P < 0.05, whey preload vs. 
whey in meal; # P < 0.05, whey in meal vs. no whey; § P < 0.05, whey preload vs. 
no whey. 
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Figure  5.2  Concentrations  of  blood  glucose  (A),  plasma  insulin  (B),  plasma 
GLP-1 (C), plasma GIP (D) and plasma CCK (E) in response to a mashed potato   110 
meal in 8 diabetic patients. On each of study day, subjects ingested 350 ml beef 
flavored  soup  30 min before  a  radiolabeled  mashed potato meal;  either  55 g 
whey protein was added to the soup („whey preload‟), or the whey was added to 
the potato („whey in meal‟), or no whey was given („no whey‟). Data are mean ± 
standard error. * P < 0.05, whey preload vs. whey in meal; # P < 0.05, whey in 
meal vs. no whey; § P < 0.05, whey preload vs. no whey.   111 
CHAPTER 6: EFFECTS OF TWO PROTEIN ‘PRELOADS’ ON ENERGY 
INTAKE, GLYCAEMIA AND GASTROINTESTINAL HORMONES IN 
TYPE 2 DIABETES 
6.1 Summary 
A whey protein „preload‟ of 55 g was shown, in the study reported in Chapter 5, 
to reduce markedly the glycaemic response to a high carbohydrate meal in type 2 
diabetes,  associated  with  stimulation  of  glucose-dependent  insulinotropic 
polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and cholecystokinin (CCK), 
release, and slowing of gastric emptying. Both GLP-1 and CCK reduce appetite 
and  energy  intake.  The  primary  aim  of  the  current  study  was  to  determine 
whether whey, when ingested before a buffet-style meal, would dose-dependently 
suppress  hunger  and  increase  fullness,  and  reduce  energy  intake  in  type  2 
diabetes, while concurrently improving glycaemia by stimulating  gut peptides 
including  GIP,  GLP-1,  and  CCK.  Nine  patients  with  diet-controlled  type  2 
diabetes were studied on three separate days in randomized order. On each day, 
subjects consumed a chocolate-flavoured liquid „preload‟ (100 ml water mixed 
with either 25 g „diet‟ chocolate sauce (8 kcal), or with 25 g (89 kcal) or 55 g 
(195  kcal)  chocolate-flavoured  whey  protein  isolate.  30  minutes  later,  each 
subject was offered a cold buffet style meal from which they ate ad libitum for up   112 
to 30 minutes. The peak postprandial blood glucose was lower with 25 g and 55 
g whey protein than with placebo (12.0 ± 0.5 and 12.0 ± 0.6 vs. 12.7 ± 0.7 
mmol/L; P < 0.05). Both preloads also stimulated GIP and CCK before the meal 
(all P < 0.05); the stimulation of CCK was greater (P <0.05) with 55 g whey. 
Both  whey  preloads  increased  postprandial  fullness  slightly  (P  <  0.05),  but 
neither  effected  energy  intake.  In  conclusion,  a  whey  protein  „preload‟ 
dose-dependently  increased  fullness,  stimulated  CCK  and  GIP  and  reduced 
postprandial  glycaemia,  but  had  no  effect  on  energy  intake  in  patients  with 
diet-controlled type 2 diabetes.   
 
6.2 Introduction 
Excessive energy intake and obesity are strongly associated with diabetes (Wang 
et  al.  2008b);  the  majority  of  patients  with  type  2  diabetes  are  obese  or 
overweight, and the latter is associated with insulin resistance (Zeyda and Stulnig 
2009). Reduction of energy intake leading to weight loss, accordingly, represents 
an important goal in the management of diabetes. Therefore, there is substantial 
interest in dietary strategies to reduce energy intake and facilitate weight loss in 
this group.   
 
Exposure of the small intestine to nutrients plays a major role in the regulation of 
appetite and energy intake, mediated by slowing of gastric  emptying and the   113 
secretion of gastrointestinal hormones, including CCK, and GLP-1 (Read 1992a). 
The „preload‟ concept is a dietary strategy involving administration of a specific 
macronutrient  in  advance  of  a  subsequent  meal,  in  order  to  stimulate  gut 
hormone release prior to ingestion of the main meal. We have demonstrated that 
fat (Gentilcore et al. 2006b), and particularly whey protein (Ma et al. 2009c), 
preloads have the capacity to reduce markedly the glycaemic response to a high 
carbohydrate  meal  in  type  2  diabetes.  For  example,  ingestion  of  350  ml 
beef-flavoured  soup  with  55  g  whey  protein  before  a  carbohydrate  (mashed 
potato)  meal  markedly  potentates  the  secretion  of  GIP,  GLP-1  and  CCK, 
associated  with  slowing  of  gastric  emptying,  stimulation  of  insulin,  and 
attenuation of the peak and overall glycaemic response in patients with type 2 
diabetes (Ma et al. 2009c).     
 
Among the macronutrients, protein is probably the most satiating (Porrini et al. 
1995; Poppitt et al. 1998a; Latner and Schwartz 1999). Protein „preloads‟ have 
the capacity to reduce energy intake at a subsequent meal in lean and overweight 
subjects (Poppitt et al. 1998b; Bowen et al. 2006a), and may be associated with 
more sustained elevation of satiety hormones incuding CCK  and GLP-1, and 
suppression of ghrelin (which stimulates appetite), and slower gastric emptying, 
than with carbohydrate (Bowen et al. 2006d). We therefore aimed to determine 
whether the whey protein „preload‟ that we had demonstrated to be effective for   114 
lowering postprandial glycaemia would also increase fullness, suppress hunger 
and reduce energy intake when given in advance of an ad libitum meal. Since 55 
g  whey  represents  a  significant  caloric  burden,  we  also  aimed  to  investigate 
whether a smaller (25 g) whey protein preload would be effective in reducing 
appetite and energy intake, as well as for reducing glycaemia. Our hypothesis 
was that whey preloads, when ingested before a buffet-style meal, would result in 
a  dose-dependent  suppression  of  hunger  and  increase  in  fullness  as  well  as 
improving  glycaemia,  with  stimulation  of  GIP  and  CCK,  and  a  reduction  in 




Nine  patients  with  type  2  diabetes,  diagnosed  by  World  Health  Organization 
criteria and managed by diet alone (3 female; age: 61 ± 3 yr; body mass index: 
30.0  ±  1.7  kg/m
2),  were  recruited  by  newspaper  advertisement.  The  mean 
duration of known diabetes was 4 ± 1 yr, glycated haemoglobin was 6.7 ±  0.3 %, 
and  in  all  the  plasma  creatinine  was  ≤  0.12  mmol/L.  None  had  a  history  of 
significant  comorbidities,  was  a  smoker,  or  was  taking  medication  known  to 
influence  gastrointestinal  function.  The  study  protocol  was  approved  by  the 
Research  Ethics  Committee  of  the  Royal  Adelaide  Hospital,  and  all  subjects   115 
provided  written  informed  consent.  All  experiments  were  carried  out  in 
accordance with the Declaration of Helsinki. 
 
6.3.2 Protocol 
The  study  followed  a  randomized,  single-blind,  cross-over  design.  All 
participants attended the Discipline of Medicine at the Royal Adelaide Hospital 
at approximately 0830 h after an overnight fast (14 h for solids, 12 h for liquids) 
on  three  occasions,  each  separated  by  at  least  3  days,  when  an  intravenous 
cannula was inserted into an antecubital vein for blood sampling. On each of the 
study  days,  subjects  consumed,  within  60  sec,  a  chocolate-flavoured  liquid 
„preload‟ (100ml water mixed with either 25 g „diet‟ chocolate sauce (Cottee‟s, 
Southbank, VIC, Australia, 8 kcal), or with 25 g (Ascend, Murray Goulburn, 
Brunswick,  VIC,  Australia,  89  kcal)  or  55  g  (Ascend,  Murray  Goulburn, 
Brunswick, VIC, Australia, 195 kcal) chocolate-flavoured whey protein isolate) 
served at 40 C at t = -30 min (Pilichiewicz et al. 2007a). The order of the three 
days was randomized and subjects were asked whether they could distinguish 
between the preloads. Following the „preload‟ drink, subjects were offered a cold 
buffet style meal at t = 0 and were allowed to eat ad libitum for up to 30 minutes 
ie t = 0-30 min (Bowen et al. 2006a). The buffet meal comprised various food 
items, including bread, cheese, chicken, ham, yoghurt, fruit and juices (Sturm et 
al. 2004). Venous blood samples, for measurement of blood glucose and plasma   116 
hormones,  were  taken  immediately  before  the  preload  (t  =  -30  min),  and  at 
predetermined time points until t = 270 min. Blood glucose concentrations were 
measured immediately using a  glucometer (Medisense Precision QID,  Abbott 
Laboratories, Bedford, MA, USA). The remainder of each sample was placed in 
a prechilled EDTA tube containing aprotinin on ice and centrifuged at 3200rpm 
for  15  minutes.  Plasma  was  separated  and  samples  stored  at  -70  C  for 
subsequent  analysis  of  plasma  hormones  using  established  assays  (19;  20). 
Perceptions  of  appetite  were  assessed  by  visual  analogue  scales  (VAS) 




Blood glucose concentrations were measured at t = -30, -15, 0, 30, 45, 60, 90, 
120, 150, 180, 210, 240 and 270 min, using a glucometer (Medisense Precision 
QID, Abbott Laboratories, Bedford, MA, USA) (Horowitz et al. 1991). 
 
Plasma GIP and CCK 
These hormones were measured at t = -30, 0, 30, 45, 60, 90, 150, 210 and 270 
min. Plasma GIP was measured by radioimmunoassay (RIA), with a sensitivity 
of 2 pmol/L, and both intra- and inter-assay CVs of 15 % (Ma et al. 2009c). 
CCK-8 was also measured by RIA with sensitivity of 1 pmol/L, intra-assay CV   117 
of 6.2 % and inter-assay CV of 14.2 % (Santangelo et al. 1998). Plasma is stored 
awaiting GLP-1 and insulin assays; hence these data are not yet available.   
 
Appetite and energy intake     
Hunger  and fullness were assessed using validated VAS (Parker et al.  2004). 
Each of VAS consisted of a 100-mm horizontal line; the subject was asked to 
place  a  vertical  mark  to  indicate  the  strength  of  each  sensation.  Nausea  and 
bloating were also quantified in this way. 
 
Energy  intake  was  assessed  by  food  consumption  from  the  buffet  meal  and 
determined by weighing each item before and after consumption and calculating 
the    energy  intake  consumed  using  commercially  available  software 
(Foodworks 3.01; Xyris Software, Highgate Hill, QLD, Australia) (Brennan et al. 
2005).   
 
6.3.4 Statistical analysis 
Data were evaluated using repeated measures ANOVA, with treatment and time 
as factors. In the event of a treatment × time interaction, individual time points 
were  compared  with  means  comparisons.  Peak  blood  glucose  and  plasma 
hormones  levels  were  also  compared  using  ANOVA.  All  analyses  were 
performed using StatView (version 5.0, Abacus Concepts, Inc., Berkeley, CA,   118 
USA) and SuperANOVA (version 1.11, Abacus Concepts, Inc., Berkeley, CA, 




All subjects tolerated the study well and they were unable to distinguish between 
the preloads. 
 
6.4.1 Blood glucose concentrations (Figure 1A) 
Fasting blood glucose (t = -30 min) did not differ among the three study days, 
nor was there any change in blood glucose after the preload and before the meal 
(t = 0 min). Blood glucose concentrations increased after the meal (P < 0.001) 
with a significant treatment × time interaction (P = 0.0001). Blood glucose was 
lower at t = 30, 45, 60, 75, and 90 min, and higher at t = 180, 210 and 240 min, 
with the 55 g whey preload than placebo (P < 0.05). Blood glucose was also 
lower  at  t  =  60  and  75  min  (P  <  0.05)  with  the  25  g  whey  protein  preload 
compared to placebo. After the 55 g whey preload, blood glucose was lower at t 
= 45 min and higher at t = 150, 180, 210, 240 min than after the 25 g whey 
preload (P < 0.05). The peak blood glucose was lower with the 25 g and 55 g 
whey preload than with placebo (12.0 ± 0.5 and 12.0 ± 0.6 vs. 12.7 ± 0.7 mmol/L;   119 
P < 0.05), without any difference between the two whey preloads. At t = 270 min, 
blood glucose was less than baseline for placebo and the 25 g whey preload (P < 
0.05). 
 
6.4.2 Plasma GIP concentrations (Figure 1B) 
Baseline plasma GIP concentrations (t = - 30 min) did not differ. After both 
whey preloads there was a rise in GIP at t = 0 min (P < 0.0005 for 55g whey and 
P < 0.05 for 25 g whey, versus placebo), but without any difference between the 
two. After the meal, there was no difference in plasma GIP between placebo and 
either of the two whey preloads. At t = 270 min, plasma GIP was greater than 
baseline on all three days (P = 0.0001). 
 
6.4.3 Plasma CCK concentrations (Figure 1C) 
Baseline plasma CCK concentrations (t = -30 min) did not differ. After both 
whey preloads, there was a rise in CCK at t = 0 min (P < 0.0005 for each versus 
placebo), with a greater rise after 55 g than 25 g whey protein (P < 0.05). After 
the meal, there was a treatment × time interaction (P = 0.0001). Plasma CCK was 
greater at t = 60 min after the 25 g and 55 g whey protein preloads than placebo 
(P < 0.05 for both), and was also greater at t = 30, 150 and 270 min after the 55 g 
compared to the 25 g whey preload (P < 0.05 for all). At t = 270 min, plasma   120 
CCK was greater than baseline on all three days (P = 0.0001). 
 
6.4.4 Perceptions (Figure 2) 
Baseline scores (t = -30 min) for fullness were low and did not differ between the 
three days, nor did fullness change significantly after the preloads (t = 0 min). 
There was a significant treatment × time interaction for fullness scores after the 
meal (P < 0.0005). Fullness was slightly greater (P < 0.05) at t = 30, 45, 60, 75, 
150,  180,  210,  240,  270  min  after  the  55  g  whey  preload  than  placebo,  and 
greater (P < 0.05) after the 25 g whey preload at t = 150, 180, 210, and 270 min 
than placebo. Fullness was also greater after the 55 g whey protein compared to 
the 25g whey at t = 30, 45, 240 and 270 min (P < 0.05).   
 
There were no differences in hunger, desire to eat or nausea between the three 
days (data not shown).   
 
6.4.5 Energy intake (Figure 3) 
Energy intake was 1159 ± 170 kcal after placebo, 1095 ± 194 kcal after the 25 g 
whey preload and 1078 ± 186 kcal after the 55 g whey preload. These differences 
were not significant. Similarly, there was no difference in  total energy intake 
when calculated to include the preload (1168 ± 170 kcal after placebo, 1184 ±   121 
194 kcal after 25 g whey and 1273 ± 186 kcal after 55 g whey).   
 
6.5 Discussion 
This study has demonstrated that whey protein, when given as a preload before a 
buffet style meal, dose-dependently increased fullness and reduced postprandial 
blood  glucose  concentrations  in  patients  with  diet-controlled  type  2  diabetes, 
associated with stimulation of GIP and CCK, but had no significant effect on 
energy intake.   
 
Both gastric emptying and the incretin hormones are important determinants of 
postprandial blood glucose excursions. In our previous study, 55 g whey protein, 
when given as a preload, slowed gastric emptying of a high carbohydrate meal, 
which  probably  contributed  to  the  lowering  of  postprandial  blood  glucose 
concentrations (Ma et al. 2009c). Although we did not measure gastric emptying 
in the current study, slowing of emptying is likely to explain, at least in part, the 
lowering of postprandial blood glucose, particularly as the initial rise in blood 
glucose  was  diminished.  Another  important  effect  of  whey  protein  is  the 
stimulation of insulin secretion, both by the release of incretin hormones, GIP 
and  GLP-1,  in  a  glucose-  dependent  manner  (Drucker  2006),  and  by  direct 
stimulation  of  the  pancreas  by  amino  acids.  Furthermore,  in  rodents,  whey 
protein has been shown to inhibit dipeptidyl peptidase-IV (DPP-IV) activity in   122 
the proximal small intestine, which would potentially prolong the local action of 
GLP-1 and GIP (Gunnarsson et al. 2006). GLP-1 lowers postprandial glycaemia 
in patients with type 2 diabetes by stimulating insulin secretion, slowing gastric 
emptying and suppressing glucagon (Nauck and Meier 2005). GLP-1 receptor 
agonists, such as exenatide, and DPP-IV inhibitors, such as sitagliptin, are now 
used  in  the  clinical  management  of  diabetes  (Gilbert  and  Pratley  2009).  In 
contrast to GLP-1, the insulinotropic action of GIP is abolished in patients with 
type 2 diabetes (Nauck et al. 1993c). However, this resistance to the actions of 
GIP can be reversed by good glycaemic control (Hojberg et al. 2009), so the 
stimulation of GIP by whey preloads in the current study might have contributed 
to the improvement in the glycaemic response. At the time of writing this thesis, 
the  insulin  and  GLP-1  data  were  not  available,  so  conclusions  regarding  the 
mechanism of glucose-lowering by whey should be circumspect. An important 
implication from the current study, however, is that a smaller protein load than 
used in our initial acute whey preload study (ie 25 g versus 55 g) would be 
suitable for more prolonged studies in patients with type 2 diabetes if the primary 
aim is to improve glycaemic control.   
 
Potential mediators of the suppression of appetite and energy intake by protein 
include diet-related thermogenesis, the central effects of absorbed amino acids 
(Anderson 1979), the release of gut hormones such as CCK, GLP-1 (Hall et al.   123 
2003) and PYY (Batterham et al. 2006) and the suppression of ghrelin. The effect 
is dependent on the type of protein, with whey protein reducing energy intake 
more than protein from soya or egg (Anderson et al. 2004). Whey protein is 
rapidly digested to branched chain amino acids, including leucine, isoleucine and 
valine,  which  are  potent  in  suppressing  energy  intake  (Anderson  1979),  and 
administration of whey has been reported to result in prolonged stimulation of 
CCK and GLP-1, as well as GIP (Hall et al. 2003). In the current study, both 
whey protein preloads stimulated fullness, compared to placebo. The effect was 
modest, and evident soon after meal ingestion. 
 
We have previously observed that plasma GLP-1, GIP and CCK concentrations 
increased when 55 g whey was given as a „preload‟, and that these effects were 
evident before ingestion of a subsequent meal (Ma et al. 2009c). The importance 
of gut hormones in the regulation of appetite is highlighted by the observation 
following gastric bypass surgery (Pournaras et al. 2009), that increased satiety 
and weight loss are associated with enhanced PYY and GLP-1 secretion. Plasma 
GLP-1  data  for  the  current  study  are  not  yet  available,  and  PYY  was  not 
measured. 
 
A number of studies indicate that CCK is a physiological regulator of energy 
intake in humans. For example, exogenous CCK, infused at a rate designed to   124 
mimic „physiological‟ postprandial plasma concentrations, reduces energy intake 
(Ballinger et al. 1995; Lieverse et al. 1995), while the specific CCK-A receptor 
antagonist,  loxiglumide,  increases  hunger  and  energy  intake  (Beglinger  et  al. 
2001). It is, however, uncertain whether CCK plays an important role in protein 
induced-satiety.  We  observed  an  increase  in  CCK  concentrations  after  whey 
preloads  compared to  placebo,  but  no significant  difference in  energy  intake. 
This is in accordance with a previous study in which stimulation of CCK release 
by whey was associated with increased satiety, but no difference in food intake, 
although the meal was given later after the preload in that report (Bowen et al. 
2006b). It should be recognised, however, that the magnitude of CCK stimulation 
by whey was not marked, at least at the time the meal was ingested. Hence, both 
timing of the meal and the extent of CCK stimulation may be relevant to our 
observations.   
 
It has been suggested that plasma ghrelin levels are related to meal initiation 
(Cummings  et  al.  2001),  and  an  increase  in  satiety  after  whey  protein  could 
potentially be mediated by prolonged ghrelin suppression, with a delay in the 
subsequent timing of a meal and a sustained increase in fullness (Bowen et al. 
2006b). Plasma ghrelin has been reported to remain lower than the fasting value 
for 3-4 hours after consumption of whey protein (Bowen et al. 2006b). Plasma 
ghrelin was not measured in the current study.     125 
It is perhaps surprising that despite stimulation of CCK and increased fullness 
after whey preloads, there were no differences in energy intake. The number of 
subjects  we studied was  relatively  small  and it is  possible that the failure to 
demonstrate suppression of energy intake represented a type 2 error. It is likely 
that the variability of energy intake would be higher in type 2 diabetic patients 
than healthy controls, and there is little information about the effects of dietary or 
pharmacological interventions on energy intake in this group (Chapman et al. 
2005). The interval between the preload and the meal was selected to match our 
previous study, in which there was a marked effect of whey on glycaemia, and as 
discussed, this may have influenced the outcome. Of note, it has been reported 
that the suppression of energy intake by CCK is sustained for less than 30 min 
(Karhunen et al. 2008). Furthermore, since the interval between the preload and 
the meal was fixed, we were not able to evaluate whether consumption of the 
whey preload might delay the initiation of eating. It should also be recognised 
that breakfast may not be the ideal meal at which to detect differences in energy 
intake. In the current study, fullness was higher after whey preloads than with 
placebo for at least 4 hours and it would be of interest to evaluate the effects in 
energy intake at a second meal.     126 
 
Figure 6.1 Concentrations of blood glucose (A), plasma GIP (B) and CCK (C) 
before and after the meal. On each study day, subjects ingested 125 ml chocolate 
flavoured drink (100 ml water mixed with either diet chocolate-flavoured sauce, 
25 g or 55 g chocolate-flavoured whey protein isolate) 30 min before a buffet 
style meal. Data are mean ± SE. * P < 0.05, 25 g whey preload vs. 55g whey 
preload; # P < 0.05, 25 g whey preload vs. placebo; § P < 0.05, 55 g whey 
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Figure 6.2 Scores for fullness before and after the meal. On each study day, 
subjects ingested 125 ml chocolate flavoured drink (100 ml water mixed with 
either diet  chocolate-flavoured sauce, 25  g or 55 g chocolate-flavoured whey 
protein isolate) 30 min before a buffet style meal. Data are mean ± SE. * P < 0.05, 
25 g whey preload vs. 55 g whey preload; # P < 0.05, 25 g whey preload vs. 
placebo; § P < 0.05, 55 g whey preload vs. placebo. n = 9.   128 
      
Figure 6.3 Energy intake at the buffet style meal. On each study day, subjects 
ingested 125 ml chocolate flavoured drink (100 ml water mixed with either diet 
chocolate-flavoured sauce, 25 g or 55 g chocolate-flavoured whey protein isolate) 
30 min before the meal. Data are mean ± SE. n = 9 
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CHAPTER 7: ACUTE AND CHRONIC EFFECTS OF A PROTEIN 
‘PRELOAD’ ON GASTRIC EMPTYING, GLYCAEMIA, 
GASTROINTESTINAL HORMONE RELEASE AND ENERGY INTAKE 
IN TYPE 2 DIABETES 
7.1 Summary 
In Chapters 5 and 6, it was reported that whey protein, when given as a „preload‟, 
acutely reduced the glycaemic response to a subsequent meal in type 2 diabetes, 
associated  with  slowing  of  gastric  emptying  and  the  stimulation  of  incretin 
hormone  release.  However,  adaptive  changes  in  small  intestinal  feedback 
inhibition of gastric emptying and gut hormone release might reduce the efficacy 
of this therapy in the long term. The aim of the current study was to evaluate 
whether  the  effects  of  a  protein  preload  on  gastric  emptying,  glycaemia  and 
incretin hormone release are sustained with „chronic‟ (4 weeks) administration 
and impact on 72-hour glycaemic profiles and food intake. Seven patients with 
diet-controlled  type  2  diabetes  participated  in  the  study.  Each  consumed  a 
chocolate-flavoured „preload‟, (containing either 25 g whey protein or placebo), 
30 min before each of the three main meals for 4 weeks, followed by a „washout‟ 
period of 2 weeks, and then the alternative preload for 4 weeks, in a randomized 
crossover design. Gastric emptying (scintigraphy) and the glycaemic response   130 
after a standard meal 30 min after the preload, were measured at the beginning 
and  end  of  each  4  week  period.  Diet  diaries  and  glucose  monitoring  were 
undertaken concurrently for 3 day periods before and during the last week of 
each 4 week treatment period. The 25 g whey preload slowed gastric emptying 
and reduced postprandial blood glucose compared to the placebo, and the effects 
on glycaemia (P < 0.05) and gastric emptying (P < 0.05) were sustained after 4 
weeks administration. Fructosamine tended (P = 0.06) to be lower after 4 weeks 
whey than 4 weeks placebo, but there was no difference in energy intake. In 
conclusion, a whey preload remains effective in reducing postprandial glycaemia 
and slowing gastric emptying after sustained exposure.   
 
7.2 Introduction 
The risk of microvasular, and probably macrovascular, complications of diabetes 
is related to control of blood glucose concentrations, as assessed by glycated 
haemoglobin.  It  is  now  recognized  that  postprandial  glycaemia  is  a  key 
determinant  of  overall  glycaemic  control  (Heine  et  al.  2004).  Therapeutic 
strategies directed to minimizing postprandial blood glucose excursions therefore 
represent a major focus of the management of type 2 (as well as type 1) diabetes 
(Nauck and Meier 2005). 
 
Recent efforts to control postprandial blood glucose have been aimed at both   131 
slowing  the  rate  of  gastric  emptying  and  stimulating  the  incretin  response 
(Chaikomin et al. 2006). Indeed, glucagon-like peptide-1 (GLP-1) analogues and 
GLP-1  receptor  agonists  have  been  developed  for  the  treatment  of  diabetes. 
Slowing  the  rate  of  entry  of  nutrients  into  the  small  intestine  may  be  the 
dominant mechanism by which exogenous GLP-1 analogues such as exenatide 
(Cervera  et  al.  2008),  and  the  amylin  agonist,  pramlintide  (Edelman  2008), 
improve glycaemic control.   
 
One dietary strategy to stimulate incretin hormones and slow gastric emptying, as 
discussed  in  Chapter  5,  is  to  administer  a  small  load  of  macronutrient  as  a 
„preload‟ so that the presence of nutrients in the small intestine both induces the 
release  of  peptides  such  as  GLP-1  and  glucose-dependent  insulinotropic 
polypeptide (GIP), and slows gastric emptying, in advance of a meal (Gentilcore 
et al. 2006b; Ma et al. 2009c). In the study reported in Chapter 5, ingestion of 55 
g  whey  protein,  30  minutes  before  a  high  carbohydrate  meal,  slowed  gastric 
emptying, stimulated incretin hormone secretion, and markedly attenuated the 
postprandial rise in blood glucose in patients with type 2 diabetes  (Ma et al. 
2009c). In Chapter 6, a smaller load of protein (25 g whey) was shown also to 
lower the glycaemic response to a subsequent meal. However, adaptive changes 
in  gastric  emptying  might  occur  in  response  to  sustained  changes  in  dietary 
protein intake, presumably as a result of altered small intestinal feedback, as has   132 
been reported after a sustained increase in carbohydrate intake (Horowitz et al. 
1996a;  Beckoff  et  al.  2001).  Therefore,  the  aim  of  the  current  study  was  to 
determine whether the effects of a whey preload on gastric emptying, glycaemia 
and  incretin  hormone  release  are  sustained  with  „chronic‟  (4  weeks) 





Seven patients with type 2 diabetes, diagnosed by World Health Organization 
criteria and managed by diet alone (3 male; age: 60 ± 2 yr; body mass index: 31 
± 2 kg/m
2), were recruited by newspaper advertisement. None had a history of 
significant  comorbidities,  was  a  smoker,  or  was  taking  medication  known  to 
influence gastrointestinal function. The mean duration of known diabetes was 4 ± 
1 yr, glycated haemoglobin was 6.0 ± 0.2 %, and all had plasma creatinine ≤ 
0.12mmol/L. 
 
The study protocol was approved by the Research Ethics Committee of the Royal 
Adelaide  Hospital,  and  all  subjects  provided  written  informed  consent.  All 
experiments were carried out in accordance with the Declaration of Helsinki.   133 
7.3.2 Protocol 
The study followed a randomized, single-blind, cross-over design. Each subject 
consumed a chocolate flavoured preload (100 ml water with either 25 g chocolate 
flavoured „diet‟ sauce (Cottee‟s, Southbank, VIC, Australia, 8 kcal), or with 25 g 
whey protein isolate (Ascend, Murray Goulburn, Brunswick, VIC, Australia, 89 
kcal)),  30  min  before  each  of  three  main  meals  for  4  weeks  (weeks  1-4), 
immediately followed by a „washout‟ period of 2 weeks (weeks 5-6), and then 
the alternative preload for 4 weeks (weeks 7-10). The odour, taste, palatability, 
consistency  and  sweetness  of  the  preloads  were  similar  and  both  contained 
comparable, and relatively small, amounts of carbohydrate (3.1 g vs. 0.1 g), and 
fat (0.1 g vs. 0.4 g).   
 
All participants attended the Department of Nuclear Medicine, PET and Bone 
Densitometry at the Royal Adelaide Hospital at approximately 0830 h after an 
overnight fast (14 h for solids, 12 h for liquids) on four occasions, each separated 
by at least 3 days, at „baseline‟ and during weeks 4, 6, and 10. An intravenous 
cannula  was  inserted  into  an  antecubital  vein  for  blood  sampling  at  frequent 
intervals. Subjects were seated with their back against a gamma camera. On each 
of the four days, subjects consumed the preload corresponding to the treatment 
period  to  which  they  were  assigned.  The  preload  was  consumed  within  one 
minute, 30 min before a mashed potato meal, consisting of 65 g powdered potato   134 
(Deb,  Epping,  NSW,  Australia)  and  20  g  glucose,  reconstituted  with  250  ml 
water (total carbohydrate content: 62 g; 314 kcal (Gentilcore et al. 2006b)) and 
labelled  with  20  MBq 
99mTc-sulphur  colloid,  which  was  consumed  within  5 
minutes. Gastric emptying was assessed from the time of ingestion of the meal 
and  for  240  min  afterwards.  Blood  glucose  concentrations  were  measured 
immediately by glucometer. The remainder of each blood sample was placed in 
EDTA tubes containing aprotinin on ice, and was centrifuged at 3200rpm for 15 
minutes. Plasma was separated and stored at  -70 C for subsequent hormone 
analyses, using established assays. 
 
Food consumption (by diet diary) and blood glucose data (by continuous glucose 
monitoring) were collected concurrently for 3 day periods at baseline and in the 
second  half  of  weeks  4,  6  and  10.  Body  weight,  height,  fructosamine  and 
glycated haemoglobin were measured at baseline and at the end of weeks 4, 6, 
and 10. Compliance was monitored by assessing a checklist which the subject 




Radioisotopic data were acquired as 60-sec frames for the first 60 min and 3-min 
frames  between  60-240  min.  Data  were  adjusted  for  subject  movement,   135 
radionuclide decay, and gamma-ray attenuation. A „region of interest‟ was drawn 
around the total  stomach, which was  subsequently divided into proximal  and 
distal regions, and gastric emptying curves (expressed as percent retention over 
time) were derived (Gentilcore et al. 2006b). The lag phase was defined visually 
as the period before any radioactivity was present in the proximal small intestine. 
The retention of the meal in the total, proximal, and distal stomach at 0, 15, 30, 
45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210, 225 and 240 min was 
calculated; the 50% emptying time (T50) was  also determined (Collins et al. 
1983).   
 
Blood glucose measurement 
Blood glucose concentrations on the four study days were measured immediately 
using a  glucometer (Medisense Precision QID,  Abbott  Laboratories,  Bedford, 
MA, USA).   
 
Plasma insulin, GLP-1, GIP and CCK assays 
At the time of writing, the assays have not yet been completed. Plasma insulin 
will  be  measured  by  a  solid-phase,  two-site  chemiluminescent  immunometric 
assay  (Immulite  2000  Insulin,  Siemens  Medical  Solutions  Diagnostics,  Los 
Angeles, CA, USA). The sensitivity is 2 mU/L, intraassay coefficient of variation 
(CV) is 3.9 % and interassay CV is 5.0 %. Total GLP-1 will be measured by   136 
radioimmunoassay  (RIA)  (GLPIT-36HK,  Linco  Research,  St.  Charles,  MO, 
USA). The sensitivity is 3 pmol/L, and the inter-assay CV is 9.2 %. Plasma GIP 
will be measured by RIA, with a sensitivity of 2 pmol/L, and both intra- and 
inter-assay CVs of 15 %. CCK-8 will also be measured by RIA with sensitivity 
of 1 pmol/L, intra-assay CV of 6.2 % and inter-assay CV of 14.2 % (Santangelo 
et al. 1998).   
 
Energy intake 
A 3 day diet diary was used to assess energy intake for three day periods in the 
week before, and the last week of, each 4 week dietary treatment (Bingham et al. 
1994). During these three days, subjects were asked to weigh all food eaten in 
their main meals and snacks using digital scales, and measure volumes of fluids 
and alcoholic drinks using a „measuring‟ cup. The brand of bread and cereal, type 
of oil, and whether meat was fatty or lean, were also recorded. Energy intake 
(calculated as kcal) was analyzed to the nearest 0.1 kcal by FoodWorks software 
(version 3.1, Xyris Software, Highgate Hill, Qld, Australia).   
 
72-hour continuous glucose monitoring 
A  continuous  glucose  monitoring  system  (CGMS,  Medtronic  Minimed, 
Northridge, CA, USA) was used to monitor glucose levels over 72 hours, at the 
same time as the 3 day diet diary. Subjects were asked to input fingerprick blood   137 
glucose levels, measured by a glucometer four times each day (20 min before 
each of three main meals  and once before bedtime) in  order to calibrate the 
device (Pearce et al. 2008). 
 
7.3.4 Statistical analysis 
Blood glucose concentrations, gastric emptying data, fructosamine and glycated 
haemoglobin were analyzed by repeated measures ANOVA (StatView, version 
5.0, Abacus Concepts, Inc., Berkeley, CA, USA and SuperANOVA version 1.11, 
Abacus Concepts, Inc. Berkeley, CA, USA) with treatment and time as factors. 
In the event of a significant treatment × time interaction, individual time points 
were  compared  with  means  comparisons.  Data  are  shown  as  mean  values  ± 
standard error; P < 0.05 was considered significant. The number of subjects was 
based on power calculations derived from our previous work. 
 
7.4 Results 
All subjects completed the study and tolerated the protocol well. Analysis of the 
checklists  for  compliance  indicated  that  all  prelaods  were  taken,  with  the 
exception of two doses in one subject and three in another. 
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7.4.1 Blood glucose concentrations (Figure 1) 
At  baseline  and  week  6,  there  were  no  differences  in  blood  glucose 
concentrations, either fasting (t = -30 min), or before the meal (t = 0 min). There 
was a postprandial rise in blood glucose from 15min with both placebo (P < 
0.0005) and whey preloads (P < 0.05). Blood glucose concentrations were lower 
at t = 15, 30, 45, 60, 75, 90, and 105 min and greater at t = 165 min after the 
whey preload than with placebo (treatment × time interaction, P < 0.05). The 
peak blood glucose concentration was also reduced after the whey preload (12.5
±  0.8 mmol/L vs. 13.8  ±  0.5 mmol/L, P = 0.005).   
 
After 4 weeks administration of each preload, there was again no difference in 
blood glucose concentrations, either fasting (t = -30 min) or before the meal (t = 
0  min)  between  whey  preload  and  placebo.  There  was  a  postprandial  rise  in 
blood glucose from t = 15 min with placebo (P < 0.005) and from t = 5 min with 
whey (P < 0.05), and blood glucose concentrations were lower at t = 30, 45, 60, 
75, and 120 min and greater at t = 165 min after the whey preload than with 
placebo (treatment × time interaction, P < 0.05), although peak blood glucose did 
not differ between the placebo and whey preloads. There was no difference in 
blood glucose between the two whey days, nor between the two placebo days.   
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7.4.2 Gastric emptying (Figure 2) 
At baseline and week 6, gastric emptying commenced after a short lag phase; the 
latter tended to be longer after whey preload than placebo (7.7  ±  2.4 vs. 4.9  ± 
1.4  min;  P  =  0.10).  On  all  days,  emptying  was  more  rapid  initially,  and 
subsequently  slower.  Gastric  emptying  was  slower  after  the  whey  preload 
compared to placebo (treatment × time interaction, P < 0.0005). Meal retention 
was greater at t = 30, 45, 60, 75, 90 and 105 min after the whey preload than 
placebo (P < 0.05). Accordingly, the T50 was longer with the whey preload (81.3 
±  5.8 vs. 67.7  ±  8.4 min; P = 0.057).   
 
After 4 weeks exposure to each preload (weeks 4 and 10), the lag phase again 
tended to be longer after the whey preload than placebo (7.7  ±  3.0 vs. 3.9  ± 
2.0  min,  P  =  0.09).  Gastric  emptying  was  slower  after  the  whey  preload 
compared to placebo (treatment × time interaction, P < 0.0005), with  greater 
meal retention at t = 30, 45, 60, 75 and 90 min (P < 0.05). Again, the T50 was 
longer with the whey preload than placebo (76.5  ±  6.4 vs. 59.7  ±  7.5 min; P 
< 0.05). There was no difference in the rate of gastric emptying or T50 between 
the two whey days, nor between the two placebo days.   
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7.4.3 Fructosamine and glycated haemoglobin (Figure 3) 
At  baseline  and  week  6,  fructosamine  did  not  differ  between  the  whey  and 
placebo preloads (259.3 ± 16.4 vs. 257.3 ± 11.2 µmol/L). After 4 weeks exposure 
(week 4 and 10), fructosamine tended to be lower after the whey preload than 
placebo (252.9 ± 15.2 vs. 279.4 ± 9.6 µmol/L, P = 0.06). However, there was no 
significant difference between the values before and after whey, or before and 
after placebo.   
 
At  baseline  and  week  6,  glycated  haemoglobin  did  not  differ  significantly 
between the whey and placebo preloads (6.0 ± 0.3 vs. 6.0 ± 0.2 %).  After 4 
weeks  exposure  (week  4  and  10),  glycated  haemoglobin  again  did  not  differ 
between whey preload and placebo (5.9 ± 0.2 vs. 6.0 ± 0.2 %). There was no 
difference  between  the  values  before  and  after  either  the  whey  or  placebo 
treatment periods. 
 
7.4.4 Energy intake (Figure 4) 
Energy intake did not differ significantly between the whey and placebo preload, 
either before the intervention (baseline and week 6) (7818 ± 549 vs. 8535 ± 613 
kcal), or after 4 weeks exposure to preload (week 4 and 10) (7818 ± 354 vs. 7939 
± 673 kcal). There was no difference between energy intake before and after   141 
either whey or placebo treatment. 
 
7.4.5 Body weight   
Body weight did not differ significantly between the whey and placebo preload 
either before the intervention (baseline and week 6) (89.7 ± 6.8 vs. 89.4 ± 6.8 kg), 
or after 4 weeks exposure to preload (week 4 and 10) (88.8 ± 7.1 vs. 89.3 ± 7.0 
kg). There was no difference between body weights before and after either the 
whey or placebo treatments.   
 
7.5 Discussion 
This  study  has  established  that  25  g  whey  protein,  when  given  as  a  preload 
before  a  carbohydrate  meal,  slowed  gastric  emptying  and  reduced  the 
postprandial  blood  glucose  excursion  in  patients  with  diet-controlled  type  2 
diabetes,  and  importantly,  that  these  effects  were  sustained  after  four  weeks 
exposure to the preload. It had already been demonstrated in the study reported in 
Chapter 5 that a whey preload attenuated the glycaemic response to a subsequent 
high carbohydrate meal in patients with type 2 diabetes by stimulating GLP-1, 
GIP and insulin secretion and slowing gastric emptying (Ma et al. 2009c), and in 
the study reported in Chapter 6, that 25 g whey induced a similar, acute reduction 
in postprandial blood glucose after a buffet style meal. The current study has,   142 
accordingly, established the feasibility and efficacy of the preload concept with 
more sustained administration. During a four week period, the preload was well 
tolerated and compliance was excellent.   
 
The mechanisms by which whey protein lowers glycaemia include an increase in 
insulin secretion, both by stimulating GLP-1 and GIP, and by absorbed amino 
acids such as leucine, isoleucine, valine and lysine released after digestion of 
whey (Fieseler et al. 1995; Nilsson et al. 2007). The latter appear responsible for 
the  majority  of  insulin  stimulation  (Nilsson  et  al.  2007),  although  the  two 
mechanisms may potentially interact (Fieseler et al. 1995). Moreover, it has been 
demonstrated that whey protein consumption is associated with reduced hepatic 
insulin extraction and enhanced C-peptide clearance (Lan-Pidhainy and Wolever 
2009). At the time of writing this thesis, the hormone data were not available. 
However, the fact that the slowing of gastric emptying and decrease in glycaemia 
were unchanged over 4 weeks in the current study suggests that the gut hormones 
would  also  be  unchanged  and  that  the  dominant  mechanism  accounting  for 
glucose-lowing is incretin stimulation.   
 
It  has  been  increasingly  recognised  that  gastrointestinal  motor  function,  in 
particular the rate of gastric emptying, is a major determinant of the postprandial 
glucose excursion in healthy subjects and patients with type 2 diabetes. In the   143 
study  reported  in  Chapter  5,  a  whey  protein  preload  acutely  attenuated  the 
glycaemic response in patients with type 2 diabetes, in part by slowing gastric 
emptying  (Ma  et  al.  2009c).  However,  the  rate  of  gastric  emptying  can  be 
influenced by dietary modifications (Cunningham et al. 1991b; Corvilain et al. 
1995).  For  example,  short-term  supplementation  of  the  diet  with  glucose 
accelerates  gastric  emptying  of  both  glucose  and  fructose  in  healthy  subjects 
(Horowitz et al. 1996a). Similarly, dietary supplementation with fat leads to more 
rapid gastric emptying of a high fat meal (Cunningham et al. 1991a). There is 
little information about the chronic effects of protein supplementation, but in the 
current study, no adaptive changes in gastric emptying were evident after giving 
the protein preload for four weeks. This might support the use of protein, rather 
than other macronutrient preloads, for long term administration in the control of 
glycaemia.  It  is  possible  that  gastric  emptying  did  not  adapt  after  4  weeks 
because  the  test  meal  was  relatively  low  in  protein,  as  adaptation  of  gastric 
emptying appears to be macronutrient-specific (Beckoff et al. 2001).   
 
In the current study, the chronic effects of protein on glycaemic control were 
assessed  by  glycated  haemoglobin,  fructosamine  and  CGMS.  Glycated 
haemoglobin  is  regarded  as  the  gold  standard  for  monitoring  blood  glucose 
control over the preceding 12 weeks, and is widely used for this purpose in the 
clinical management of diabetic patients (Landgraf 2006). In present study, a   144 
four week treatment period was probably insufficient to detect a difference in 
glycated haemoglobin. The capacity for detecting a change was also diminished 
by the good glycaemic control at baseline (glycated haemoglobin 6.0 ± 0.3 vs. 
6.0 ± 0.2 %). Fructosamine correlates with glycated haemoglobin and can be 
altered  by  shorter-term  changes  in  glycaemia  (Youssef  et  al.  2008).  After 
treatment with whey preload for 4 weeks, there was a non-significant trend for 
fructosamine to be lower than after 4 weeks exposure to placebo. CGMS has 
been developed recently as a noninvasive measure of dynamic glucose changes 
in the interstitial fluid every 5 min for 72 h  (Pearce et al. 2008).  It has been 
shown that CGMS recordings correlate closely with capillary blood glucose in 
detecting asymptomatic hypoglycaemia and glycaemic fluctuations (Caplin et al. 
2003) and represent  a more responsive index for assessing glycaemic control 
than glycated haemoglobin and fructosamine in some patients, such as those on 
haemodialysis (Riveline et al. 2009). The analysis of the CGMS data will be of 
considerable  interest,  but  has  not  been  completed  at  the  time  of  writing  this 
thesis.   
 
Chronic  modulation  of  dietary  protein  intake  could  potentially  affect  energy 
intake, as well as glucose homeostasis (Farnsworth et al. 2003). Whey protein 
preloads are associated with secretion of satiety hormones such as GLP-1 and 
CCK (Ma et al. 2009c) (Chapter 5). However, no acute effects of a 25 g or 55 g   145 
protein preload were observed on energy intake from a buffet style meal in the 
study reported in Chapter 6. Accordingly, it is not surprising that there were no 
differences in energy intake in the 3 day diet diary analysis in the current study. 
In both studies the number of subjects was relatively small. Hence, a type 2 error 
cannot be excluded. It is also possible that the whey preload will affect patterns 
of  energy  intake,  as  opposed  to  total  energy  intake;  this  remains  to  be 
determined.   
 
In conclusion, there are sustained, beneficial effects of a small protein preload 
(25 g) on glycaemia and gastric emptying in patients with diet-controlled type 2 
diabetes.  These  observations  indicate  that  dietary  strategies,  involving  whey 
protein to modulate postprandial glycaemic excursions, are feasible in patients 
with type 2 diabetes and should be pursued. It should be recognized that this 
study involved a relatively small number of patients with well controlled diabetes. 
Longer-term studies involving larger numbers of type 2 patients, including those 
with poor glycaemic control, are needed to determine whether this approach can 
achieve sustained improvement in glycaemia.   
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Figure 7.1 Blood glucose concentrations on the four study days, at „baseline‟ and 
during weeks 4, 6, and 10, in 7 type 2 diabetic patients. On each study day, 
subjects  ingested  125  g  chocolate  flavoured  drink  (100  ml  water  with  either 
chocolate flavoured „diet‟ sauce or with 25 g whey protein isolate) 30 min before 
a radiolabeled mashed potato meal. Data are mean ± standard error. * P < 0.05, 
1
st whey day vs. 1
st placebo day; # P < 0.05, 2
nd whey day vs. 2
nd placebo day.   147 
                 
 
Figure 7.2 Gastric emptying on the four study days, at „baseline‟ and during 
weeks 4, 6, and 10, in 7 type 2 diabetic patients. On each study day, subjects 
ingested 125 g chocolate flavoured drink (100 ml water with either chocolate 
flavoured  „diet‟  sauce  or  with  25  g  whey  protein  isolate)  30  min  before  a 
radiolabeled mashed potato meal. Data are mean ± standard error. * P < 0.05, 1
st 
whey day vs. 1
st placebo day; # P < 0.05, 2
nd whey day vs. 2
nd placebo day.   148 
                         
 
Figure  7.3  Fructosamine  and  glycated  haemoglobin  at  „baseline‟  and  during 
weeks 4, 6, and 10, in 7 type 2 diabetic patients. These represent the values 
before and after 4 weeks treatment with 25 g whey or placebo preload, taken 
before each main meal.   149 
                       
 
Figure 7.4 Energy intake over 72 hours at „baseline‟ and during weeks 4, 6, and 
10, in 7 type 2 diabetic patients.   
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CHAPTER 8: EFFECTS OF ENTERICALLY COATED, 
NUTRIENT-CONTAINING PELLETS ON GLYCAEMIA AND THE 
RELEASE OF GASTROINTESTINAL PEPTIDES IN PATIENTS WITH 
TYPE 2 DIABETES 
8.1 Summary 
Dietary  and  pharmacological  strategies  to  increase  endogenous  glucagon-like 
peptide-1 (GLP-1) secretion are attracting much interest in the management of 
diabetes.  The  study  presented  in  this  chapter  evaluates  the  effects  of 
enterically-coated pellets designed to release lauric acid in the ileum („Clinical 
Testing  Material  #3‟  or  „CTM#3‟)  on  GLP-1  secretion  and  the  glycaemic 
response after both the „carrier meal‟ (breakfast), and a subsequent lunch. Ten 
patients  with  type  2  diabetes,  managed  by  diet  alone,  were  studied  on  two 
separate days. On each study day, they consumed a „carrier meal‟ (breakfast) 
containing either 10 g CTM#3 or placebo pellets. A second meal (lunch) was 
consumed at t = 240 min. Blood samples were taken to measure blood glucose, 
serum insulin, and plasma glucose-dependent insulinotropic polypeptide (GIP) 
and  GLP-1.  Blood  glucose  concentrations  were  lower,  and  plasma  GLP-1 
concentrations higher after CTM# 3 than placebo, after both breakfast and lunch 
(P < 0.05 for each). The rise in serum insulin after breakfast and lunch did not   151 
differ between CTM#3 and placebo. In conclusion, there was a glucose lowering 
effect  of  CTM#3  after  both  breakfast  and  lunch,  associated  with  prolonged 
stimulation of GLP-1 in patients with type 2 diabetes. Exposure of the distal 
small intestine to a small quantity of nutrient can have profound effects on gut 
hormone release and glycaemic control.   
 
8.2 Introduction   
Achieving  good  postprandial  glycaemic  control  appears  to  be  of  relatively 
greater    importance than targeting fasting blood glucose to optimize glycated 
haemoglobin  and  reduce  the  onset  and/or  progression  of  microvascular,  and 
probably macrovasular, complications of diabetes (Ceriello et al. 2008). Both the 
rate of gastric emptying, and the action of the incretin hormones, GLP-1 and GIP, 
are  major  determinants  of  postprandial  glucose  excursions  (Chaikomin  et  al. 
2006).  In  healthy  subjects,  GLP-1  and  GIP  account  for  up  to  70  %  of 
postprandial insulin secretion (Holst et al. 2009), while differences in the rate of 
gastric emptying are responsible for about one third of the variation in the initial 
rise in blood glucose after an oral glucose load in healthy subjects and patients 
with  type  2  diabetes  (Horowitz  et  al.  1993;  Jones  et  al.  1996).    Therefore, 
dietary and pharmacological strategies that act on the incretin axis, in particular 
focusing on GLP-1, have risen to prominence in the management of diabetes.   
Dietary  strategies  that  aim  to  stimulate  endogenous  GLP-1  release  require   152 
interaction  of  macronutrients,  or  other  GLP-1  secretagogues,  with  sensors 
located in the small intestine, that regulate both gastric emptying and hormone 
release. The degree of nutrient-mediated small intestinal „feedback‟ is dependent 
on the length of contact with stimulating nutrient  (Lin et al. 1989; Lin et al. 
1990), and the region of small intestine exposed (Pilichiewicz et al. 2006). For 
example, gastric emptying is  strongly inhibited  by  delivering  nutrients to  the 
ileum  (Lin  et  al.  1989;  Lin  et  al.  1990),  an  effect  modulated  by  release  of 
peptides including GLP-1 and polypeptide YY (PYY) from L-cells, which are 
located most densely in the ileum and colon (Baggio and Drucker 2007).   
 
One effect of the bariatric operation, Roux-en-Y gastric bypass (RYGB), is to 
accelerate  transit  of  ingested  nutrients  to  the  distal  small  intestine.  It  is 
increasingly  recognized  that  such  surgery  ameliorates  type  2  diabetes  before 
significant weight loss has occurred (le Roux et al. 2006a). The mechanism(s) 
underlying this phenomenon appear to be related to increased GLP-1 secretion 
from L-cells in the ileum or colon (Morinigo et al. 2006), such that after RYGB, 
glucose-stimulated  concentrations  of  GLP-1  are  increased  up  to  four  fold 
compared to pre-operative values (Laferrere et al. 2007).   
 
Meyer Nutriceuticals (Santa Monica, CA, USA) has designed enterically-coated 
pellets („clinical testing materials‟) to release macronutrients in the distal small   153 
intestine. Clinical testing material number 3 (CTM#3) consists of pellets of a 
diameter of 1-3 mm containing 47 % lauric acid by weight, enterically coated to 
release  lauric  acid  in  the  ileum  and  colon.  CTM#3  also  contains  4.7  % 
paracetamol, as a pharmacokinetic marker that is rapidly absorbed throughout the 
small  and  large  intestine,  and  can  be  assayed  in  peripheral  blood  to  yield 
information about the timing of lauric acid release. When given with a „carrier 
meal‟ of 415 kcal, the entry of pellets into the small intestine is regulated so that 
they start to arrive in the ileum with one hour of meal ingestion and continue to 
do so over another 2 – 3 h. Dissolution and discharge of nutrient from the pellets 
begins  in  <  30  min  and  takes  up  to  6  h  to  complete  (unpublished  in  vitro 
observations), so that the ileum is exposed continuously to lauric acid for > 3 h 
following meal ingestion. For several more hours, the colon is also exposed to 
lauric acid. The capacity of CTM#3 to release nutrient in the ileum and colon in 
this fashion has been validated in healthy volunteers (unpublished observations).   
 
In addition to inducing release of the incretin hormone GLP-1, nutrient exposure 
of the ileum could also slow the rate of gastric emptying of a subsequent meal. It 
is  increasingly  accepted  that  gastric  emptying  is  a  major  determinant  of  the 
postprandial glycaemic response, and patients with type 2 diabetes can benefit 
from slowing of gastric emptying (Chapter 5), which is the main action of some 
pharmacological therapies such as exenatide (Gilbert and Pratley 2009). Gastric   154 
emptying could be regulated by secretion of GLP-1 and PYY, as well as by 
stimulation of neural pathways. 
 
The hypothesis underlying the present study was that a small load of lauric acid, 
released in the ileum so as to provide a long length of intestinal exposure, would 
induce sufficient release of GLP-1 to reduce the glycaemic response after both 
the „carrier meal‟, given as a breakfast, and after a subsequent lunch, in patients 




Ten  patients  with  type  2  diabetes,  diagnosed  by  World  Health  Organization 
criteria and managed by diet alone (5 male; age: 62 ± 2 yr; body mass index: 
28.9  ±  0.1  kg/m
2),  were  recruited  by  newspaper  advertisement.  None  had  a 
history  of  significant  comorbidities,  was  a  smoker,  or  was  taking  medication 
known  to  influence  gastrointestinal  function.  The  mean  duration  of  known 
diabetes was 4.6 ± 0.6 yr, glycated haemoglobin was 5.9 ± 0.2 % (normal range: 
< 6.0 %), and all had plasma creatinine ≤ 0.12mmol/L. 
 
The study protocol was approved by the Research Ethics Committee of the Royal   155 
Adelaide  Hospital,  and  each  subject  provided  written  informed  consent.  All 
experiments were carried out in accordance with the Declaration of Helsinki. 
 
8.3.2 Protocol 
Each  subject  was  studied  on  two  occasions,  separated  by  at  least  3  days,  in 
double-blinded, randomized fashion. On the evening preceding each study day 
(~1900  h),  subjects  were  given  a  standardized  meal  (McCains  frozen  beef 
lasagne (McCain  Foods Proprietary  Ltd, Australia, 656  kcal),  consumed  with 
bread,  a  non-alcoholic  beverage  and  one  piece  of  fruit.  Following  the  meal, 
subjects were asked to fast from solids and liquids (14 h for solids, 12 h for 
liquids, other than water) until the following morning.   
 
Subjects  attended  the  Discipline  of  Medicine  at  approximately  0800h.  An 
intravenous cannula was inserted into an antecubital vein for blood sampling. 
The  „carrier  meal‟  („breakfast‟,  415  kcal;  71  g  carbohydrate,  12  g  fat,  4.3  g 
protein) comprising 3 pikelets (Golden, North Ryde,  NSW, Australia), coated 
with  9  g  butter  (Westin  Star,  Rowville,  VIC,  Australia),  15  g  golden  syrup 
(Smith‟s, Richlands, NSW, Australia), and 140 g pureed apple (Goulburn Valley, 
Shepparton,  VIC,  Australia),  and  containing  either  10  g  CTM#3  or  placebo 
pellets, was consumed with 100 ml water at t = 0. A second meal („lunch‟, 708 
kcal; 89 g carbohydrate, 26 g fat, 29 g protein) was consumed at t = 240 min and   156 
it contained one sandwich (60 g white bread, 50 g ham, 10 g margarine), 300 ml 
orange juice, 200 g strawberry yogurt, 20 g cheese portion and 10 g crackers. 
Subjects were seated comfortably in a chair for the duration of the study. Blood 
samples were obtained at frequent intervals for measurements of blood glucose, 
serum  insulin  and  plasma  GLP-1  and  GIP.  Blood  samples  were  placed  in 
prechilled EDTA tubes containing 400 kIU aprotinin (Trasylol, Bayer Australia 
Ltd, Pymble, NSW, Australia) per litre blood for incretin hormone assays and 
pre-chilled serum tubes with clotting activator for insulin assays, both stored on 
ice, and centrifuged at 3200 rpm and 4 ºC for 15 min. Samples were stored at -70 
C  until  analyzed.  On  one  of  the  study  days,  autonomic  nerve  function  was 
evaluated using standardized cardiovascular reflex tests (Ewing and Clarke 1982), 
after completion of the other measurements. 
 
8.3.3 Measurements 
Blood glucose concentrations 
Blood glucose concentrations were measured immediately using a glucometer 
(Medisense  Precision  QID,  Abbott  Laboratories,  Bedford,  MA,  USA).  The 
accuracy  of  the  method  has  been  validated  against  the  hexokinase  technique 
(Horowitz et al. 1991).   
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Serum insulin, plasma GLP-1 and GIP 
Serum  insulin  was  measured  by  a  solid-phase,  two-site  chemiluminescent 
immunometric assay (Ma et al. 2009b). The sensitivity was 2 mU/L, intra-assay 
coefficient of variation (CV) 3.9 % and inter-assay CV 5.0 %. Total GLP-1 was 
measured  by  radioimmunoassay  (RIA)  (GLPIT-36HK,  Linco  Research,  St. 
Charles,  MO,  USA)  (Ma  et  al.  2009c).  The  sensitivity  was  3  pmol/L,  and 
inter-assay CV 9.2 %. Plasma GIP was measured by RIA, with a sensitivity of 2 
pmol/L, and both intra- and inter-assay CVs of 15 % (Ma et al. 2009c).   
 
Cardiovascular autonomic function 
Parasympathetic  function  was  assessed  by  the  variation  in  heart  rate  (R-R 
interval) during deep breathing and the heart rate response to standing („30:15‟ 
ratio); sympathetic function was determined by the fall in systolic blood pressure 
in response to standing. Each test result was scored according to age-adjusted 
predefined criteria as: 0 = normal, 1 = borderline, and 2 = abnormal, for a total 
maximum score of 6. A score of 3 or higher was taken as evidence of autonomic 
dysfunction (Ewing and Clarke 1982).   
 
8.3.4 Statistical analysis 
Incremental areas under the blood glucose and plasma hormone concentration 
curves (iAUC) were calculated using the trapezoidal rule, ignoring any negative   158 
values (Wolever 2004). Data were analyzed in two periods, after breakfast (t = 
0-240 min) and after lunch (t = 240-480 min) using repeated measures ANOVA, 
with treatment and time as factors. In the event of significant treatment × time 
interactions,  individual  time  points  were  compared  with  means  comparisons. 
Baseline and peak values were compared using student‟s paired test. All analyses 
were performed using StatView (version 5.0, Abacus Concepts, Inc., Berkeley, 
CA, USA) and SuperANOVA (version 1.11, Abacus Concepts, Inc., Berkeley, 
CA,  USA).  Data  are  shown  as  mean  values  ±  standard  error;  P  <  0.05  was 
considered statistically significant. 
 
8.4 Results 
All  subjects  tolerated  the  study  well.  The  mean  score  for
  autonomic  nerve 
dysfunction  was  1.8  ±  0.4;  four  of  the  ten  diabetic  subjects  had  definite 
autonomic dysfunction.   
 
8.4.1 Blood glucose concentrations (Figure 1A) 
Fasting blood glucose did not differ between the two study days. After breakfast 
(t = 0 – 240 min), blood glucose concentrations increased on both days (P < 
0.0005), but were lower after CTM#3 than placebo (P < 0.05, treatment × time 
interaction). The differences were evident after t = 45 min up to t = 150 min. The   159 
peak  blood  glucose  concentration  was  also  lower  after  CTM#3  than  placebo 
(10.0 ± 0.6 vs. 10.9 ± 0.7 mmol/L; P < 0.01).   
 
Before lunch (t = 240 min), blood glucose values did not differ between the study 
days, but was lower than before breakfast at t = -2 min on the placebo day (7.9 ± 
0.5 vs. 7.0 ± 0.5 mmol/L; P < 0.05), but not with CTM#3. After lunch (t = 240 - 
480 min), blood glucose increased on both days (P < 0.005), again was lower 
after  CTM#3  than  placebo  (P  <  0.05,  treatment  ×  time  interaction)  with  a 
significant difference at t = 330 min. The peak blood glucose was also lower after 
CTM#3 (9.0 ± 0.5 mmol/L vs. 9.7 ± 0.5 mmol/L, P < 0.05). 
 
The peak blood glucose level was lower after lunch than after breakfast on both 
study days (placebo: 9.7 ± 0.5 vs 10.9 ± 0.7 mmol/ L, P < 0.05; CTM#3: 9.0 ± 
0.5 vs. 10.0 ± 0.6 mmol/L, P < 0.01). 
 
8.4.2 Serum insulin concentrations (Figure 1B) 
Fasting serum insulin concentrations did not differ between the two days. After 
breakfast, serum insulin increased on both days (P < 0.0005), with no difference 
between CTM#3 and placebo.   
 
Insulin concentrations before lunch (t = 240 min) did not differ between CTM#3   160 
and placebo, but were higher before lunch than before breakfast at t = -2 min for 
both CTM#3 and placebo (P < 0.05 and P < 0.005 respectively). After lunch (t = 
240-480 min), serum insulin increased on both days (P < 0.0005 for both), again 
with no difference between CTM#3 and placebo.   
 
The insulin response to lunch was greater than to breakfast on both days (iAUC 
14062.6 ± 4106.5 vs. 9046.8 ± 2366.4 mU.min/L after placebo, and 10922.4 ± 
2928.7 vs. 8688.3 ± 2755.1 mU.min/L after CTM#3; P < 0.05 for both).   
 
8.4.3 Insulin:glucose ratio (Figure 1C) 
The insulin:glucose ratio did not differ between CTM#3 and placebo, either after 
breakfast or after lunch.   
 
The insulin:glucose ratio after lunch was greater than after breakfast on both days 
(iAUC: 918.3 ± 241.5 vs. 1524.6 ± 477.3 mU.min/mol after placebo, and 1264.8 
± 364.2 vs. 961.4 ± 315.2 mU.min/L after CTM#3; P < 0.05 for both). 
   
8.4.4 Plasma GLP-1 concentrations (Figure 1D) 
Fasting GLP-1 concentrations did not differ between the two study days. After 
breakfast (t = 0-240 min), GLP-1 increased on both days (P < 0.05) with greater   161 
concentrations after CTM#3 than placebo (P < 0.01, treatment × time interaction), 
with significant differences at t = 90, 150, 180 and 240 min. 
 
Plasma  GLP-1  concentrations  did  not  differ  after  CTM  #3  v.  placebo  before 
lunch, at 240 min, but were higher before lunch than before breakfast (t = -2 min) 
with CTM #3 (19.3 ± 2.9 vs. 12.2 ± 2.5 mmol/L; P < 0.05), but not with placebo. 
After lunch (t = 240-480 min), GLP-1 concentrations increased on both days and 
were higher after CTM#3 than placebo (P < 0.05, treatment effect). The peak 
GLP-1 concentration was also greater after CTM#3 than placebo (39.2 ± 5.3 vs. 
29.0 ± 3.5 pmol/L; P < 0.05).   
 
On both days, iAUC GLP-1 was greater after lunch than after breakfast (1524.6 
± 477.3 vs. 918.3 ± 241.5 pmol.min/L after placebo, and 1268.4 ± 364.2 vs. 
961.4 ± 315.2 pmol.min/L after CTM#3; P < 0.05 for both).   
 
8.4.5 Plasma GIP concentrations (Figure 1E) 
Fasting plasma GIP concentrations did not differ between the two days. After 
breakfast (t = 0-240 min), there was a rise in plasma GIP on both days (P < 0.05), 
with no difference between CTM#3 and placebo.   
 
Plasma GIP concentrations before lunch (t = 240 min) did not differ, but were   162 
higher before lunch than before breakfast (t = -2 min), with both CTM#3 and 
placebo  (P  <  0.001  and  P  <  0.005  respectively).  On  both  days,  plasma  GIP 
increased after lunch (P < 0.0005), again with no difference between CTM#3 and 
placebo.   
 
8.4.6 Plasma paracetamol concentrations (Figure 1F) 
Plasma paracetamol concentrations increased progressively to a peak occurring 
at 320 ± 16.4 min, indicating sustained release from CTM#3 throughout most of 
the study. 
 
8.5 Discussion   
This study establishes that there is a glucose lowering effect of a dose of CTM#3 
given with breakfast, compared to placebo, observed after both breakfast and 
lunch,  and  associated  with  prolonged  stimulation  of  GLP-1  release.  This 
represents „proof of concept‟ that even a small nutrient load (4.7 g lauric acid, ~ 
40 kcal), when delivered over a long length of ileum and colon, can stimulate a 
relatively large amount of GLP-1. The magnitude of reduction in blood glucose 
was ~ 1 mmol/L, which although modest, is likely to be clinically significant in 
these  well-controlled  patients  who  had  modest  glycaemic  excursions  on  the 
placebo day. The glucose-lowering effect would likely be greater if blood glucose   163 
levels had been higher. The difference in blood glucose was less marked after 
lunch  than  after  breakfast,  but  the  lunch  contained  proportionally  less 
carbohydrate, and more protein and fat, which would have contributed to greater 
insulin secretion after lunch, and would in itself would have limited the rise in 
blood glucose after lunch on the placebo day (Karamanlis et al. 2007), making it 
difficult to demonstrate any additional effect of CTM#3. 
 
GLP-1 is secreted from L-cells mainly in the ileum and colon, with fewer L-cells 
found in the duodenum and jejunum (Theodorakis et al. 2006). Digestion of fat 
to yield fatty acids is required for GLP-1 secretion (Feinle et al. 2003), and the 
secretion of GLP-1 is also length-dependent, with greater release when > 60 cm 
of small intestine is exposed to glucose (Little et al. 2006a). It would, therefore, 
be expected that GLP-1 secretion in response to nutrients in the ileum would be 
greater than in the proximal small intestine (Little et al. 2006a; Hira et al. 2009b). 
In  healthy  subjects,  we  have  observed  that  CTM#3  consumed  with  breakfast 
potentiated the release of polypeptide  YY (PYY), a hormone co-located with 
GLP-1  in  the  L-cells  of  the  distal  gut  (Wen  et  al.  1995)  (unpublished 
observations).  The  current  study  confirmed  that  CTM#3  taken  with  breakfast 
stimulates  the  release  of  GLP-1  more  than  placebo,  in  patients  with  type  2 
diabetes. The fact that the timing of the peak in plasma GLP-1, which occurred 
after  lunch,  was  similar  to  the  peak  plasma  concentration  of  paracetamol,   164 
indicates that the pellets continued to release lauric acid slowly over about 6 
hours.   
 
The  incretin  hormones,  GLP-1  and  GIP,  contribute  to  postprandial  insulin 
secretion  approximately  equally  in  healthy  subjects  (Vilsboll  et  al.  2003b). 
However, in type 2 diabetic patients, while the insulinotropic effect of GLP-1 is 
preserved, that of GIP is abolished (Nauck et al. 1993b). Nevertheless, despite 
marked  stimulation  of  GLP-1  by  CTM#3  in  the  current  study,  neither  serum 
insulin nor the insulin:glucose ratio was greater than with placebo, indicating that 
other mechanisms are likely to be involved in the observed lowering of blood 
glucose concentrations.   
 
Among  the  multiple  actions  of  GLP-1  on  glucose  homeostasis,  inhibition  of 
gastric emptying (the „ileal brake‟) represents an important effect, which may 
outweigh  the  insulinotropic  action  of  GLP-1,  as  demonstrated  in  studies 
involving „physiological‟ infusions of exogenous GLP-1 (Nauck et al. 1997), or 
the  GLP-1  antagonist,  exendin(9-39)  (Deane  et  al.  2009).  Slowing  of  gastric 
emptying  also  plays  a  dominant  role  in  the  action  of  the  GLP-1  analogue, 
exenatide, to improve postprandial glycaemia (Cervera et al. 2008). It is possible 
that the blood glucose lowering effect of CTM#3 is partly explained by the action 
of  GLP-1  on  gastric  emptying.  However,  we  have  previously  observed  that   165 
emptying of CTM#3 pellets given with the carrier meal was not slower than that 
of  placebo  pellets,  when  evaluated  by  scintigraphy  in  healthy  subjects 
(unpublished data). This is consistent with that the absence of any difference in 
the initial rise in blood glucose (after breakfast or lunch) in the current study. 
Nevertheless,  we did  not  measure the  gastric emptying  of either breakfast  or 
lunch in this group of patients.   
 
GLP-1 also has the capacity to suppress glucagon secretion (Meier et al. 2003), 
and  intravenous  administration  of  GLP-1  in  physiological  concentrations  has 
been  shown  to  lower  plasma  glucagon  in  patients  with  type  2  diabetes.  The 
glucagonostatic  action  of  GLP-1  is  glucose-dependent  (Baggio  and  Drucker 
2007), but is not dependent on the stimulation of insulin (Nauck et al. 1997). 
However, we did not measure plasma glucagon levels in the present study.   
 
Extrapancreatic influences on glucose homeostasis, such as paracrine and portal 
effects of GLP-1, may be at least as important as its endocrine effects. In rodents, 
the GLP-1 receptor is present on visceral afferent neurons in the hepatic portal 
region (Vahl et al. 2007), and both GLP-1 and glucose in portal venous blood act 
synergistically to decrease peripheral blood glucose levels (Burcelin et al. 2001; 
Ionut et al. 2005). Indeed, intraportal infusion of GLP-1 can increase glucose 
disposal without any change in pancreatic hormone secretion, by increasing both   166 
hepatic and extra-hepatic glucose uptake, a response controlled by autonomic 
nerves  (Johnson  et  al.  2007).  Another  possibility  is  that  stimulation  of  vagal 
afferent  nerves  in  the small  intestinal  villi by  GLP-1, in  a paracrine  manner, 
participates  in  the  glucose  lowering  effects  of  GLP-1,  especially  since 
postprandial GLP-1 concentrations in the small intestine lymph are much greater 
than  in  peripheral  blood  (D'Alessio  et  al.  2007).  However,  this  remains 
speculative.     
 
We did not show any differences in plasma GIP between CTM#3 and placebo. 
This reinforces the idea that the amelioration of the postprandial blood glucose 
was due to GLP-1, and supports the concept that CTM #3 was releasing lauric 
acid in the ileum rather than in the proximal small intestine.   
 
The peak blood glucose value after lunch was lower than after breakfast despite a 
greater load of carbohydrate being consumed in the lunch, on both the CTM#3 
and placebo days. This „second meal effect‟ could be due to both the greater 
amount of protein and fat in the lunch than in the breakfast, and to the presence 
of residual  nutrients  in the distal  small  intestine  at  the time  when lunch  was 
consumed, reflected in higher GLP-1 and insulin levels at this time even on the 
placebo day.   
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In  conclusion,  we  showed  that  CTM#3,  consumed  with  breakfast,  decreased 
postprandial  glycaemia  and  stimulated  GLP-1  release  in  patients  with  type  2 
diabetes. The current dose of CTM#3 was chosen on the basis of previous data in 
healthy subjects, and the optimum dose needs to be clarified. A higher dose may 
not  necessarily  be more effective, because limited data from  healthy subjects 
indicate  that  higher  doses  induce  more  rapid  small  intestinal  transit  and  less 
prolonged  ileal  contact  (unpublished  observations).  Conversely,  it  remains 
unknown whether a lower dose would suffice, particularly if the dose were split 
and given before each meal. For example, a dose  of 5  g CTM#3 may be as 
effective as 10 g in lowering blood glucose, if local concentrations released from 
the 5 g dose were greater than the threshold for release of GLP-1 from ileal 
L-cells  between  0  and  240  min.  Likewise,  subsequent  GLP-1  release  from 
residual CTM#3 entering the colon at 240-360 min may then also be as effective 
for a 5 g as for a 10 g dose. Moreover, a second dose of 5 g ingested with lunch 
might boost GLP-1 after lunch, caused by the presence concurrently of the first 5 
g dose in the colon and the second 5 g dose in the ileum, thus enhancing the 
post-lunch effect. Finally, the combination of CTM#3 with a DPP-IV inhibitor 
could potentially have synergistic effects on the glycaemic and incretin hormone 
responses to a meal in patients with type 2 diabetes, and warrants evaluation in 
future studies.   168 
 
     
Figure  8.1  Concentrations  of  blood  glucose  (A),  serum  insulin  (B), 
insulin/glucose ratio (C), GLP-1 (D) and GIP (E) in response to breakfast with 
CTM#3 or placebo at t = 0 min and a standard lunch at t = 240 min in 10 
patients with type 2 diabetes, and plasma paracetamol concentrations (F) with 
CTM#3. *CTM#3 vs. placebo, P < 0.05. Data are means ± SE. There was a 
treatment effect between CTM#3 and placebo  for plasma GLP-1 (P < 0.05). 
There was no significant difference in serum insulin and plasma GIP between 
CTM#3 and placebo.     169 
CHAPTER 9: EFFECTS OF VARIATIONS IN DUODENAL GLUCOSE 
LOAD ON GLYCAEMIC, INSULIN AND INCRETIN RESPONSES IN 
TYPE 2 DIABETES 
9.1 Summary   
The postprandial incretin response has been reported to be deficient in type 2 
diabetes, but most studies have not controlled for variations in the rate of gastric 
emptying.  We  evaluated  the  blood  glucose,  serum  insulin,  and  plasma 
glucagon-like  peptide-1  (GLP-1)  and  glucose-dependent  insulinotropic 
polypeptide (GIP) responses to intraduodenal (ID) glucose in patients with type 2 
diabetes, and compared these to our previous data from 10 healthy controls. 8 
males with well-controlled type 2 diabetes, managed by diet alone, were studied 
on  four  occasions  in  single-blind,  randomized  order.  Blood  glucose,  serum 
insulin  and  plasma  hormones  were  measured  during  120  min  ID  glucose 
infusions at (i) 1 (“G1”), (ii) 2 (“G2”), and (iii) 4 (“G4”) kcal/min, or (iv) saline 
control  (“S”).  Type  2  diabetic  patients  had  higher  basal  (P  <  0.0001)  and 
incremental (P < 0.0001) blood glucose responses to G2 and G4, when compared 
with healthy controls. In both groups, the stimulation of insulin and GLP-1 by 
increasing glucose loads were not linear; responses to G1 and G2 were minimal, 
whereas  responses  to  G4  were  much  greater  (P  =  0.0001  for  each).  In  both 
healthy subjects and patients with type 2 diabetes, there was a load dependent   170 
increase in plasma GIP. In patients with well-controlled type 2 diabetes, blood 
glucose, insulin, and GLP-1 responses are critically dependent on the duodenal 




In healthy subjects, the incretin hormones, GLP-1 and GIP, account for up to 
70 % of postprandial insulin secretion (Nauck et al. 1986b; Shuster et al. 1988). 
In type 2 patients, the incretin effect is reported to be substantially attenuated, 
which  potentially  leads  to  insufficient  insulin  secretion  and  potentiates 
postprandial hyperglycaemia (Nauck et al. 1986a). The secretion of GIP appears 
relatively  normal  in  these  patients  (Krarup  1988),  whereas  its  insulinotropic 
activity is markedly diminished (Elahi et al. 1994), particularly during the „late 
phase‟ of insulin secretion (Vilsboll et al. 2002). In contrast to GIP, the insulin 
response to exogenous GLP-1 remains intact in type 2 diabetes (Nauck et al. 
1993c), but there has been some controversy as to whether endogenous GLP-1 
secretion is impaired. Some studies have reported that plasma concentrations of 
both  total  and active GLP-1 are lower in  response to  a standardized meal  in 
diabetic patients (Toft-Nielsen et al. 2001; Vilsboll et al. 2001), but others have 
failed to show a difference between healthy subjects and patients with type 2 
diabetes (Ryskjaer et al. 2006; Vollmer et al. 2008). Furthermore, postprandial   171 
GLP-1  concentrations  are  not  impaired  in  patients  with  impaired  glucose 
tolerance (Vollmer et al. 2008), women with gestational diabetes (Meier et al. 
2005), and first-degree relatives of type 2 patients (Nauck et al. 2004b), arguing 
against GLP-1 deficiency in the primary pathogenesis of diabetes.     
 
The rate of gastric emptying regulates the entry of glucose and other nutrients 
into the small intestine in the range of 1-4 kcal/min (Brener et al. 1983; Schirra et 
al.  1996;  Gentilcore  et  al.  2006c),  and  is,  therefore,  an  important  factor  in 
determining incretin hormone secretion in both healthy subjects and patients with 
diabetes. Even minor changes in the initial rate of gastric emptying of glucose 
substantially influence the glycemic and incretin responses  (O'Donovan et  al. 
2004b; Chaikomin et al. 2005). For example, incretin concentrations were greater 
when glucose was infused intraduodenally at an initially rapid, and subsequently 
slower rate, when compared to a constant infusion providing the same total load, 
in both healthy subjects and type 2 patients  (O'Donovan et al. 2004b). While 
gastric  emptying  is  known  to  be  delayed  in  30-50  %  of  patients  with 
long-standing  diabetes  (Horowitz  et  al.  1991),  it  is  noteworthy  that  all 
comparisons of the incretin effect between type 2 patients and healthy subjects 
have involved oral administration of nutrients, and potential differences in the 
rate of gastric emptying have not been considered as a confounding factor. A 
direct comparison of the incretin response to intraduodenally delivered glucose   172 
between type 2 patients and healthy subjects has not previously been undertaken.   
 
In  our  previous  study  in  healthy  subjects  (Pilichiewicz  et  al.  2007a),  a  low 
duodenal glucose load (~ 1 kcal/min) caused minimum rise in blood glucose and 
plasma  insulin,  while  GLP-1  was  only  substantially  elevated  with  a  high 
duodenal  glucose  load  (4  kcal/min).  A  better  understanding  of  the  incretin 
response to increasing duodenal glucose loads in patients with type 2 diabetes is 
fundamental  to  developing  strategies  to  regulate  the  postprandial  glucose 
excursion.   
 
The aims of this study were i) to evaluate glycaemia, insulinaemia, and incretin 
hormone  concentrations  in  response  to  duodenal  glucose  loads,  spanning  a 
physiological range, in patients with type 2 diabetes, and ii) to compare these 
with our previous data from 10 healthy controls (Pilichiewicz et al. 2007a). 
   
9.3 Methods 
9.3.1 Subjects 
8 male patients with type 2 diabetes (age 57 ± 4 yrs), as diagnosed by World 
Health  Organization  criteria  and  managed  by  diet  alone,  were  recruited  by 
newspaper  advertisement.  None  had  a  history  of  significant  comorbidities,   173 
gastrointestinal  symptoms,  or  was  taking  medication  known  to  influence 
gastrointestinal function. The mean duration of known diabetes was 5.4 ± 1.1 yr, 
glycated haemoglobin was 6.2 ± 0.3 %, and body mass index (BMI) was 26.5 ± 
1.4 kg/m
2. Data were compared to healthy subjects (age 32 ± 4 yrs; BMI 25.1 ± 
0.4 kg/m
2) (Pilichiewicz et al. 2007a).   
 
9.3.2 Protocol 
Following  an  overnight  fast  (14  h  for  solids  and  12  h  for  liquids),  subjects 
attended  the  laboratory  at  0830  h.  Each  subject  underwent  four  studies,  in 
single-blind,  randomized  fashion,  separated  by  4  -  7  days.  On  each  day,  a 
manometric  assembly  (diameter  3.5  mm;  Dentsleeve,  International  Ltd.,  Mui 
Scientific,  Ontario,  Canada)  was  inserted  through  an  anesthetised  nostril  and 
allowed  to  pass  through  the  stomach  into  the  duodenum  by  peristalsis 
(Pilichiewicz  et  al.  2007a).  The  manometric  assembly  contained  an  infusion 
channel, located ~ 14.5 cm distal to the pylorus. There were also two other saline 
perfused sideholes on either side of the pylorus, used to maintain the correct 
position of the catheter by continuous measurement of the transmucosal potential 
difference (TMPD), using established criteria (antral TMPD < -20 mV, duodenal 
TMPD > -15 mV, difference > 15 mV) (Heddle et al. 1988a; Heddle et al. 1989). 
This required the insertion of a 20G saline-filled cannula subcutaneously in the 
forearm as a reference (Pilichiewicz et al. 2007a). An intravenous cannula was   174 
placed into a forearm vein for blood sampling.     
 
When the catheter was positioned correctly, subjects received an intraduodenal 
infusion of glucose at either (i) 1 kcal/min (G1), (ii) 2 kcal/min (G2) or (iii) 4 
kcal/min (G4), or (iv) saline control, for 120 min. By varying the mixture of 
glucose and saline, the osmolarity (1,390 mosmol/L) and volume (4 ml/min) of 
all solutions were kept identical (Pilichiewicz et al. 2007a). At baseline and at 
frequent intervals throughout the infusion period, blood samples were taken for 
measurement of blood glucose, serum insulin and plasma GLP-1 and GIP. Blood 
samples  were  placed  in  both  a  prechilled  EDTA  tube  containing  400  kIU 
aprotinin (Trasylol, Bayer Australia Ltd, Pymble, Australia) per liter blood for 
GLP-1 and GIP assays and a pre-chilled serum tube with clotting activator for 
insulin assay, both stored on ice, and centrifuged at 3200 rpm and 4 ºC for 15 
min. Plasma and serum were separated and samples were stored at -70 ºC for 
subsequent analysis using established assays. At t = 120 min, the catheter was 
removed  and  subjects  were  allowed  to  leave.  On  one  of  the  study  days, 
autonomic nerve function was evaluated using standardized cardiovascular reflex 
tests (Ewing and Clarke 1982), after completion of the other measurements. 
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9.3.3 Measurements 
Blood glucose concentrations 
Blood glucose concentrations were measured immediately using a glucometer 
(Medisense Precision QID, Abbott Laboratories, Bedford, MA, USA). We have 
previously  validated  the  accuracy  of  this  method  against  the  hexokinase 
technique (Horowitz et al. 1991).   
 
Serum insulin and plasma GLP-1 and GIP assays 
Serum  insulin  was  measured  by  a  solid-phase,  two-site  chemiluminescent 
immunometric  assay  (Immulite  2000  Insulin,  Siemens  Medical  Solutions 
Diagnostics, Los Angeles, CA, USA). The sensitivity was 2 mU/L, intra-assay 
coefficient of variation (CV) 3.9 % and inter-assay CV 5.0 %. Total GLP-1 was 
measured  by  radioimmunoassay  (RIA)  (GLPIT-36HK,  Linco  Research,  St. 
Charles, MO, USA). The sensitivity was 3 pmol/L, and inter-assay CV 9.2 %. 
Plasma GIP was measured by RIA, with a sensitivity of 2 pmol/L, and both intra- 
and inter-assay CVs of 15 % (Pilichiewicz et al. 2007a).   
 
In the study with healthy controls, total GLP-1 was measured by a different RIA 
with intra-assay CVs of 17 %, inter-assay CVs of 18 % and sensitivity of 1.5 
pmol/liter (Pilichiewicz et al. 2007a). Antibody was supplied by Professor S. R. 
Bloom (Hammersmith Hospital, London, UK) (Pilichiewicz et al. 2007a), and   176 
was  no  longer  available  for  the  current  study.  Although  it  is  likely  that  the 
different assays would give similar measurements, we did not compare these data 
statistically. However, we believe that valid qualitative comparisons could be 
made.   
 
Cardiovascular autonomic function 
Parasympathetic  function  was  assessed  by  the  variation  in  heart  rate  (R-R 
interval) during deep breathing and the heart rate response to standing („30:15‟ 
ratio); sympathetic function was determined by the fall in systolic blood pressure 
in response to standing. Each test result was scored according to age-adjusted 
predefined criteria as: 0 = normal, 1 = borderline, and 2 = abnormal, for a total 
maximum score of 6. A score of 3 or higher was taken as evidence of autonomic 
dysfunction (Ewing and Clarke 1982). 
 
9.3.4 Statistical analysis 
Data were evaluated using repeated measures ANOVA, with „glucose load‟ and 
„time‟ as factors within the diabetic group, and „glucose load‟ and „group‟ as 
factors when comparing data with healthy controls. In the event of a glucose load 
×  time  interaction,  individual  time  points  were  compared  with  means 
comparisons.  Baseline  blood  glucose  and  hormone  concentrations  were 
compared  using  paired  t-tests  within  groups,  and  unpaired  t  tests  between   177 
controls  and  diabetic  patients.  All  analyses  were  performed  using  StatView 
(version 5.0, Abacus Concepts,  Inc., Berkeley, CA, USA) and SuperANOVA 
(version 1.11, Abacus Concepts, Inc., Berkeley, CA, USA). Data are shown as 
mean  values  ±  standard  error;  P  <  0.05  was  considered  significant.  The 
homeostasis  model  assessment  of  insulin  resistance  (HOMA-IR)  was  used  to 
estimate insulin sensitivity, and was calculated by the formula: fasting glucose 
(mmol/L)  ×  fasting  insulin  value  (pmol/L)/22.5  (Matthews  et  al.  1985).  The 
incremental glucose (∆G30) and insulin (∆I30) (in pmol/L) responses at t = 30 min 
were used to calculate beta cell function corrected for insulin sensitivity, using 
the formula (∆I30/∆G30)/HOMA-IR (Jensen et al. 2002).   
 
9.4 Results 
All  subjects  tolerated  the  study  well.  The  mean  score  for
  autonomic  nerve 
dysfunction  was  2.1  ±  0.8;  two
  of  the  eight  diabetic  subjects  had  definite 
autonomic dysfunction. GLP-1 concentration data were available from only 9 of 
10 control subjects.   
 
9.4.1 Blood glucose concentrations (Figure 1A) 
Fasting blood glucose did not differ among the four study days in the type 2 
patients. Blood glucose concentrations were higher from t = 30 to 120 min during   178 
all  glucose  infusions,  compared  with  saline  (P  <  0.05,  treatment  ×  time 
interaction, P = 0.0001). There was a time-dependent increase in blood glucose 
during  G1,  G2  and  G4  infusions  (P  <  0.05).  The  increase  in  blood  glucose 
between t = 30 min and 120 min was greater during G2 and G4 compared with 
G1 (P < 0.05) and was greater from t = 45 min to 90 min during G4 compared 
with G2 (P < 0.0005). The peak blood glucose concentration (t = 120 min) was 
higher during G2 infusion than that during G1 (P < 0.0005). The peak blood 
glucose concentration was higher during G4 infusion than during G2 (15.6 ± 0.9 
vs. 13.8 ± 1.0 mmol/L; P < 0.005). Blood glucose fell thereafter despite ongoing 
intraduodenal  infusion,  such  that  there  was  no  difference  in  blood  glucose 
concentrations at 120 min between G2 and G4 infusions.   
 
Compared to  healthy subjects,  type 2 diabetic patients  had higher basal  (P < 
0.0005) and incremental (P < 0.0005) blood glucose responses to G2 and G4, but 
not  G1  glucose  loads.  However,  in  the  diabetic  patients,  the  blood  glucose 
continued to rise from baseline during G1, whereas it plateaued in the controls. 
There was no significant difference between the glycemic response to G2 and G4 
in healthy subjects, in contrast to the patients with type 2 diabetes. Nevertheless, 
even in type 2 patients, the increase in blood glucose with increasing duodenal 
glucose loads was not linear. 
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9.4.2 Serum insulin concentrations (Figure 1B) 
The baseline serum insulin concentrations were not different among the four days 
in type 2 patients. There was a treatment × time interaction (P = 0.0001); the rise 
in insulin with G2 and G4 infusions (P < 0.05 for both), but not G1, was greater 
than saline, between t = 45 min to 120 min for G2 and t = 30 min to 120 min for 
G4  (P  <  0.05).  Insulin  concentrations  did  not  differ  between  saline  and  G1 
infusions.  During  G4  infusion,  insulin  concentrations  were  markedly  greater, 
compared with G1 infusion from t = 30 min (P < 0.05), and G2 infusion from t = 
45 min (P < 0.05).   
 
Fasting insulin  levels  were higher in  diabetic patients  compared with  healthy 
subjects (10.5 ± 0.2 mU/L vs. 2.7 ± 0.1 mU/L; P < 0.05), and the HOMA-IR 
score indicated that the type 2 patients were insulin resistant (G1: 21.6 ± 8.0 
pmol.mmol, G2: 21.7 ± 8.0 pmol.mmol; G4: 23.4 ± 7.2 pmol.mmol in type 2 
patients and G1: 4.9 ± 0.7 pmol.mmol, 4.4 ± 0.6 pmol.mmol and G4: 4.2 ± 0.4 
pmol.mmol  in  healthy  controls).  In  both  groups,  the  insulin  responses  to 
increasing glucose loads were not linear, with minimal insulin response to G1 
and  G2,  but  a  much  greater  response  to  G4.  Incremental  increases  to  each 
glucose  load  did  not  differ  statistically  between  patients  with  diabetes  and 
healthy subjects.   
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9.4.3 Plasma GLP-1 concentrations (Figure 1C) 
Fasting GLP-1 concentrations did not differ among the four study days in type 2 
patients.  GLP-1  increased  markedly  from  t  =  15  min  to  120  min  during  G4 
infusion (P < 0.005, treatment × time interaction), compared with G1, G2 and 
saline, during which GLP-1 concentrations did not differ.   
 
As discussed, the difference in the GLP-1 assay between type 2 patients and 
healthy  subjects  precluded  statistical  comparison  between  the  groups. 
Nevertheless,  the  GLP-1  responses  to  each  load  appeared  similar  in  the  two 
groups, and were not grossly deficient in the type 2 patients. However, in healthy 
subjects,  there  was  an  early,  transient  increase  at  t  =  15  min  (P  <  0.05)  in 
response to each glucose load, which was not observed with G1 and G2 infusions 
in the type 2 patients.       
 
9.4.4 Plasma GIP concentrations (Figure 1D) 
Fasting levels of GIP were not different among the four study days. There were 
rapid rises in GIP during all glucose infusions until t = 30 min, with a plateau 
thereafter to 120 min. There was a treatment × time interaction (P = 0.0001), 
such that plasma GIP concentrations were higher during G4 than G2 and G1 (P < 
0.0005 for both), and higher during G2 than G1 (P < 0.0005).     181 
Fasting plasma GIP was higher in type 2 patients compared with healthy subjects 
(18.2 ± 0.3 pmol/L vs. 9.2 ± 1.4 pmol/L; P < 0.05). However, in both groups, 
there was  a load-dependent increase in GIP, which was approximately linear, 
although in healthy subjects the difference between G2 and G4 did not reach 
statistical  significance.  The  incremental  increase  in  GIP  in  response  to  each 
glucose load did not differ between the two groups.   
 
9.4.5 Beta cell function (Figure 2) 
Compared with healthy controls, (∆I30/∆G30)/HOMA-IR was markedly reduced 
in response to each glucose load in type 2 diabetic patients (P < 0.005). This 
index of beta cell function increased with increasing glucose loads (P < 0.01) in 
healthy controls, but not in type 2 patients, so that the difference between groups 
become greater as the glucose load increased (P < 0.05, group × load interaction).   
 
9.5 Discussion   
Our study evaluated the effect of duodenal glucose loads delivered at 1, 2 and 4 
kcal/min  on  blood  glucose,  serum  insulin,  and  plasma  GIP  and  GLP-1 
concentrations in patients with type 2 diabetes, and compared these with our 
previous  data  from  healthy  controls.  We  demonstrated  that  the  increments  in 
blood glucose, plasma insulin and GLP-1 concentrations with increasing glucose   182 
loads were not linear. Furthermore, the incremental increases in GIP and GLP-1 
were qualitatively similar in patients with type 2 diabetes and healthy subjects, 
implying  that  the  secretion  of  incretin  hormones  is  not  grossly  impaired  in 
patients with relatively well-controlled type 2 diabetes managed with diet alone, 
compared with healthy subjects.   
 
We measured only total GLP-1 and GIP concentrations, which are of greatest 
relevance in a study focusing on secretion, rather than action, of the incretins. We 
infused glucose intraduodenally and, therefore, eliminated differences in the rate 
of gastric emptying as a source of variation in the incretin responses. Moreover, 
we  studied  rates  of  glucose  infusion  that  spanned  the  physiological  range  of 
gastric emptying (Brener et al. 1983; Schirra et al. 1996; Gentilcore et al. 2006c).   
 
In previous studies, a reduction of 20-30 % in postprandial GLP-1 concentrations 
was reported in patients with type 2 diabetes compared with healthy subjects 
(Toft-Nielsen et al. 2001; Vilsboll et al. 2001). A deficient GLP-1 response would 
provide a hypothetical explanation for the development of diabetes; however, this 
was  not  observed  in  subsequent  studies  (Ryskjaer  et  al.  2006;  Vollmer  et  al. 
2008). Moreover, the presence of apparently impaired GLP-1 release does not 
appear  to  correlate  with  early  phase  insulin  deficiency  (Vilsboll  et  al.  2001). 
None  of  these  studies  has  controlled  for  differences  in  the  rate  of  gastric   183 
emptying,  particularly  in  patients  with  long-standing  diabetes,  of  whom  it  is 
established that 30–50 % have delayed emptying (Horowitz et al. 1991). Rapid 
gastric emptying has been also reported in some „early‟ type 2 patients (Phillips 
et al. 1992), although this has not been consistently observed (Jones et al. 1996). 
Furthermore, the rate of gastric emptying can be affected by acute variations in 
the  blood  glucose  concentration.  In  both  healthy  subjects  and  patients  with 
diabetes, marked hyperglycaemia (16–20 mmol/L) leads to prolonged emptying 
times for solids and liquids, compared with euglycaemia (5–8 mmol/L) (Fraser et 
al. 1990), and even small variations in blood glucose, within the physiological 
range (~ 8 mmol/L versus 4 mmol/L), have an appreciable effect on the rate of 
gastric emptying in healthy and diabetic subjects (Schvarcz et al. 1997). A recent 
report indicated that GLP-1 and GIP responses to a mixed meal were attenuated 
by acute hyperglycaemia in healthy humans  (Vollmer et al. 2009). While the 
mechanisms of this effect were not evaluated, it seems likely that delayed gastric 
emptying would have been a major contributing factor (O'Donovan et al. 2004b). 
The effect of chronic hyperglycaemia on gastric emptying and incretin hormone 
release in patients with type 2 diabetes has not been investigated, and further 
studies evaluating the effects of chronic hyperglycaemia are, therefore, indicated.   
 
There has been much recent interest in the effects of exogenous GLP-1 and its 
analogs in patients with diabetes, whereas the mechanisms of endogenous GLP-1   184 
secretion remain relatively unclear. While the greatest density of GLP-1 secreting 
L  cells  is  found  in  the  distal  small  intestine  and  colon,  plasma  GLP-1 
concentrations  normally  rise  within  minutes  of  glucose  entry  to  the  small 
intestine (Deacon 2005). It has been suggested that a threshold load of glucose 
delivery  (~  1.8  kcal/min)  needs  to  be  exceeded  in  order  to  stimulate  GLP-1 
release (Schirra et al. 1996). However, our group has observed an early, albeit 
transient,  peak  in  GLP-1  secretion,  at  relatively  low  rates  of  glucose 
administration  (1  kcal/min)  in  healthy  volunteers  (Kuo  et  al.  2008).  One 
explanation  for  this  phenomenon  is  that  a  significant  number  of  L-cells  are 
present  in  the  duodenum  and  jejunum  (Theodorakis  et  al.  2006).  Within  the 
limitations  of  a  change  in  our  assay  for  GLP-1,  we  did  not  observe  gross 
differences  in  GLP-1  secretion  between  type  2  patients  and  healthy  subjects. 
However,  the  early  rise  in  GLP-1  that  we  have  observed  in  healthy  subjects 
appeared  to  be  absent  in  type  2  patients.  The  mechanism  underlying  this 
deficiency is not clear, nor is its functional significance.   
 
We did not show any differences in incremental GIP responses to each glucose 
load  between  type  2  patients  and  healthy  subjects,  which  is  consistent  with 
previous  reports  (Nauck  et  al.  2004a;  Vollmer  et  al.  2008).  Interestingly,  we 
observed  higher  fasting  GIP  concentrations  in  patients  with  type  2  diabetes, 
compared with healthy subjects, also in agreement with previous data showing   185 
that fasting GIP levels were markedly greater in diabetic patients and subjects 
with impaired glucose tolerance (Mazzaferri et al. 1985; Theodorakis et al. 2004). 
It  has  been  suggested  that  GIP  hypersecretion  in  the  fasting  state  might  be 
associated with hyperinsulinaemia, and might contribute to the pathogenesis of 
early type 2 diabetes (Mazzaferri et al. 1985; Theodorakis et al. 2004). It is not 
clear  whether  hyperinsulinaemia  could  also  influence  the  postprandial  GIP 
response; our diabetic subjects did have higher fasting insulin levels than healthy 
controls, but the postprandial insulin concentrations were comparable. It has been 
reported  that  glucose  absorption  via  SGLT1  is  involved  in  stimulating  GIP 
secretion  (Wachters-Hagedoorn  et  al.  2006).  Given  the  proximal  location  of 
K-cells (Schirra et al. 1996), it is not surprising that there was a dose-dependent 
increase in the plasma GIP response in both healthy subjects and patients with 
type 2 diabetes as the rate of duodenal glucose infusion increased.   
 
In  the  present  study,  fasting  blood  glucose  and  incremental  increases  with 
increasing glucose loads in patients with type 2 diabetes were greater than in 
healthy  subjects,  which  is  not  unexpected.  There  are  several  potential 
explanations  for these differential  responses.  Beta cell failure is  probably the 
major factor for higher blood glucose levels in the diabetic patients, since an 
established  index  of  beta  cell  function  ((∆I30/∆G30)/HOMA-IR)  (Jensen  et  al. 
2002)  was  markedly  lower  in  diabetic  patients  compared  to  healthy  controls   186 
across all glucose loads, with the difference being magnified as duodenal glucose 
delivery  increased.  Secondly,  given  that  the  maximal  capacity  of  glucose 
absorption is about 0.5 g per 30 cm of small intestine per minute in healthy 
humans (Duchman et al. 1997), both 2 and 4 kcal/min infusions might reach, or 
exceed the absorptive capacity of the most proximal small intestine (Pilichiewicz 
et al. 2007a). In type 2 patients, the glycemic response to intraduodenal glucose 
was not linear, but the overall blood glucose response to 4 kcal/min was greater 
than during 2 kcal/min. It is not known whether glucose absorption is increased 
in patients with type 2 diabetes, although increased absorption has been reported 
in  rodent  models  of  diabetes  (Fujita  et  al.  1998),  and  expression  of  the 
monosaccharide transporters SGLT1, GLUT5 and GLUT2 is enhanced in type 1 
and 2 diabetic humans (Dyer et al. 2002). Thirdly, the diabetic patients were 
insulin resistant on the basis of their HOMA-IR values, and this would have 
impaired glucose disposal. Fourthly, hepatic glucose release would potentially be 
greater than in healthy subjects (Rayner et al. 2001), due to mechanisms that 
include  a  failure  of  suppression  of  glucagon  secretion,  although  we  did  not 
measure plasma glucagon concentrations.   
 
We  have  demonstrated  that  the  secretion  of  incretins,  particularly  GLP-1,  is 
critically dependent on the rate of small intestinal glucose entry in both healthy 
and type 2 patients. If glucose entry is at the low end of the physiological range   187 
(about  1  kcal/min),  the  incretin  response  appears  relatively  less  important. 
Moreover, we showed that beta cell failure is less evident at low than high rates 
of duodenal glucose delivery. This might indicate that an appropriate strategy in 
the management of type 2 patients who are not on insulin is to slow the emptying 
of carbohydrate from the stomach, such as by a high fibre diet or fat „preload‟ 
(Ray et al. 1983; Gentilcore et al. 2006b).   
 
In conclusion, we have demonstrated that impaired GLP-1 is not an early defect 
in type 2 diabetes. We studied patients with a short duration of diabetes who were 
well-controlled by diet alone. Therefore, studies in patients with longstanding 
diabetes,  or  who  are  less  well  controlled,  are  indicated.  Although  defective 
release of incretin hormones in previous studies involving patients with type 2 
diabetes may not be fully accounted for by delayed gastric emptying, it is clear 
that this variable must be taken into account in future studies of the incretin 
response.   188 
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Figure  9.1  Blood  glucose  (A),  plasma  insulin  (B),  GLP-1  (C)  and  GIP  (D) 
concentrations in response to 120 min intraduodenal glucose infusion at (i) 1 
(“G1”), (ii) 2 (“G2”), and (iii) 4 (“G4”) kcal/min, or (iv) saline control (“S”) in 
10 healthy subjects and 8 type 2 patients. Data are presented as mean ± SEM. * 
vs. control: P < 0.05, # vs. G1: P < 0.05, §  vs. G2: P < 0.05.     190 
 
 
Figure 9.2 Beta cell function as measured by (∆I30/∆G30)/HOMA-IR, in response 
to intraduodenal glucose infusions delivered at (i) 1 (“G1”), (ii) 2 (“G2”), and (iii) 
4 (“G4”) kcal/min, in 10 healthy subjects and 8 type 2 patients. This index of 
beta cell function was markedly lower for each glucose load in type 2 diabetic 
patients,  compared  to  healthy  subjects  (*  P  <  0.005),  with  the  difference 
increasing as the glucose load increased (P < 0.05, group × load interaction).   
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CHAPTER 10: EFFECT OF THE ARTIFICIAL SWEETNER, 
SUCRALOSE, ON GASTRIC EMPTYING AND INCRETIN HORMONE 
RELEASE IN HEALTHY SUBJECTS   
Adapted from Ma J et al. Am J Physiol Gastrointest Liver Physiol.296:G735-739, 
2009. 
 
10.1 Summary     
The incretin hormones, glucagon-like peptide-1 (GLP-1), and glucose-dependent 
insulinotropic polypeptide (GIP), play an important role in glucose homeostasis 
in both health and diabetes. In mice, sucralose, an artificial sweetener, stimulates 
GLP-1 release via sweet  taste receptors on enteroendocrine cells.  We studied 
blood glucose, plasma levels of insulin, GLP-1 and GIP and gastric emptying (by 
a breath test) in 7 healthy humans after intragastric infusions of (i) 50 g sucrose 
in water to a total volume of 500 ml (~ 290 mosmol/L), (ii) 80 mg sucralose in 
500  ml  normal  saline  (~  300  mosmol/L,  0.4  mM  sucralose),  (iii)  800  mg 
sucralose in 500 ml normal saline (~ 300 mosmol/L, 4 mM sucralose), (iv) 500 
ml normal saline (~ 300 mosmol/L), all labelled with 150 mg 
13C-acetate. Blood 
glucose increased only in response to sucrose (P < 0.05). GLP-1, GIP and insulin 
also increased after sucrose (P = 0.0001), but not after either load of sucralose, or 
saline. Gastric emptying of sucrose was slower than that of saline (T50: 87.4 ±   192 
4.1 min vs. 74.7 ± 3.2 min, P < 0.005), whereas there were no differences in T50 
between sucralose 0.4 mM (73.7 ±  3.1 min), or 4 mM (76.7 ± 3.1 min) and saline. 
We conclude that sucralose, delivered by intragastric infusion, does not stimulate 
insulin, GLP-1 or GIP release, or slow gastric emptying in healthy humans.   
 
10.2 Introduction 
The interaction of nutrient with the small intestine plays an important role in the 
regulation of appetite, energy intake and glucose homeostasis. For example, the 
suppression of energy intake induced by small intestinal fat infusion is much 
greater than that in response to an equivalent intravenous fat load (Welch et al. 
1985).  Exposure  of  the  small  intestine  to  nutrients  is  also  associated  with 
feedback inhibition to slow the rate of gastric emptying (Heddle et al. 1988a; 
Andrews et al. 1998). Both the slowing of gastric emptying and suppression of 
appetite are mediated by the secretion of gastrointestinal  hormones, including 
GLP-1  (MacIntosh  et  al.  1999;  Schirra  et  al.  2006),  the  release  of  which  is 
strongly stimulated by carbohydrate (Lavin et al. 1998). GLP-1 is one of the two 
known  „incretin‟  hormones  that  stimulate  glucose-dependent  insulin  release 
(Deacon 2005). In healthy humans, GLP-1 and GIP account for at least 50 % of 
the postprandial insulin response (Shuster et al. 1988). GLP-1 in pharmacological 
doses also inhibits glucagon secretion, slows gastric emptying and suppresses   193 
appetite, leading to weight loss in the long term (Nauck and Meier 2005). GLP-1, 
but not GIP, has preserved insulinotropic effects in patients with type 2 diabetes 
(Nauck et al. 1993c). Therefore, the GLP-1 analogues, such as exenatide and 
liraglutide, and enzyme dipeptidyl peptidase-IV (DPP-IV) inhibitors that enhance 
circulating  concentrations  of  active  GLP-1,  such  as  sitagliptin,  have  been 
developed for therapeutic use (Ahren 2007; Drucker 2007).   
 
The detection system for sweet taste on the tongue has been established for a 
decade. Sweet tastants are detected by G-protein-coupled receptors (GPCR) of 
the  T1R  family,  of  which  T1R2  and  T1R3  receptors  heterodimerise  to  form 
broadly-tuned  sweet  taste  receptors.  T1R2+T1R3  couples  to  a  G-protein, 
gustducin, and in turn, to the transient receptor potential ion channel TRPM5 
(Ruiz-Avila et al. 2001). It has recently been established that the alpha subunit of 
gustducin, α-gustducin, is expressed in the mucosa of the murine gastrointestinal 
tract (Olsson et al. 2006; Sutherland et al. 2007b). Expression of α-gustducin is 
evident throughout the mouse small intestine, and amongst several cell types, 
appears to  co-localize  with  GLP-1-secreting  L-cells.  The sweet  taste receptor 
molecules  T1R2,  α-gustducin  and  TRPM5  have  now  been  shown  to  also  be 
expressed in the human small intestinal mucosa (Sutherland et al. 2007a). 
 
Artificial sweeteners have been used to replace carbohydrate in the management   194 
of diabetes and obesity (American Diabetes Association 2004). Sucralose is a 
noncaloric  sweetener  derived  from  sucrose,  and  is  approximately  600  times 
sweeter. While sucralose (1-5 mM) has been shown to stimulate GLP-1 from 
human L-cells in vitro, in a concentration-dependent manner (Jang et al. 2007a), 
it  is  not  known  whether  this  effect  occurs  in  vivo.  A  report  that  long-term 
(3-month) dietary supplementation with sucralose (667 mg daily) did not alter 
glycated haemoglobin in patients with type 2 diabetes (Grotz et al. 2003) argues 
against a significant effect. However, there is a lack of data about the effects of 
sucralose on gastric emptying or GLP-1 release, in either animals or humans. 
 
The aims of our study were to evaluate the effects of sucralose, at a concentration 
chosen to match the sweetness of a sucrose load (0.4 mM), and at a much higher 
concentration (4 mM), in the range shown to stimulate GLP-1 release from a 
human enterendocrine cell line in vitro, on gastric emptying and GLP-1, GIP, 




7 healthy subjects  (age  24  ±  2  years;  body mass  index 21.6  ±  1.2 kg/m
2) 
were  studied.  None  had  a  history  of  gastrointestinal  disease,  was  taking   195 
medications known to affect gastrointestinal motility or appetite, was a smoker, 
or habitually consumed more than 20 g of alcohol per day. The study protocol 
was approved by the Royal Adelaide Hospital Research Ethics Committee, and 
each subject provided written, informed consent prior to taking part. The number 
of subjects was based on power calculations derived from our previous work 
(Gentilcore et al. 2005). 
 
10.3.2 Protocol   
Each subject attended the Discipline of Medicine at the Royal Adelaide Hospital 
at approximately 0830 h after an overnight fast (14 h for solids, 12 h for liquids) 
on  four  occasions,  each  separated  by  3-7  days.  Women  were  studied  in  the 
follicular phrase of the menstrual cycle. On each study day, a catheter (external 
diameter ~ 3 mm) was introduced into the stomach via an anaesthetized nostril. 
Its  intragastric  position  was  verified  by  rapid  injection  of  10  ml  air  and 
auscultation over the upper abdomen. An intravenous cannula was inserted into a 
forearm  vein  to  allow  repeated  blood  sampling.  All  subjects  received  an 
intragastric infusion, over 3 min (t = -3 to 0 min), of either (i) 50 g sucrose 
dissolved in water to a total volume of 500 ml (~ 290 mosmol/L), (ii) 80 mg 
sucralose (Tate & Lyle Inc, Decatur, IL, USA) in 500 ml normal saline (~ 300 
mosmol/L,  0.4  mM  sucralose,  equivalent  sweetness  to  sucrose),  (iii)  800  mg 
sucralose in 500 ml normal saline (~ 300 mosmol/L, 4 mM sucralose), or (iv)   196 
500 ml normal saline (~ 300 mosmol/L), in randomized, single-blind fashion. All 
of the infusates were labeled with 150 mg 
13C-acetate, and breath samples were 
collected immediately before and every 5 min after intragastric infusion in the 
first hour, and every 15 min for a further 3 h (Chew et al. 2003). Blood was 
sampled immediately before the infusion (t = -3 min), and at t = 0, 5, 15, 30, 60, 
90, 120, 150, 180 and 240 min for measurement of blood glucose, and plasma 
GLP-1, GIP and insulin. After 240 min, the nasogastric catheter and intravenous 
cannula were removed, the subject was offered lunch and then allowed to leave 




13CO2  enrichment  in the breath  samples  was  measured by mass spectroscopy 
(ABCA 20–20 mass spectrometer, Europa Scientific, Crewe, United Kingdom) to 
determine the percentage 
13CO2 recovery per hour and the cumulative percentage 
13CO2 recovery over 4 h (Chew et al. 2003). The gastric half-emptying time (T50) 
and  gastric  emptying  coefficient  (GEC)  were  calculated  as  measures  of  the 
gastric emptying rate (Maes et al. 1994) . Breath tests using the 13C acetate label 
have been validated against scintigraphy for the measurement of liquid gastric 
emptying (Braden et al. 1995; Chew et al. 2003). 
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Blood glucose, plasma GLP-1, GIP and insulin concentrations   
Blood  glucose  concentrations  were  determined  immediately  using  a  portable 
glucometer (Medisense Precision QID, Abbott Laboratories, Bedford, MA, USA). 
The  remainder  of  each  blood  sample  was  placed  in  a  prechilled  EDTA  tube 
containing 400 kIU aprotinin (Trasylol, Bayer Australia Ltd, Pymble Australia) 
per litre blood, and then centrifuged at 3200 rpm for 15 min (4  ºC). Plasma was 
separated and samples were stored at -70  ºC for subsequent analysis (MacIntosh 
et  al.  1999). Total  plasma GLP-1 was  measured by  radioimmunoassay  (RIA) 
(GLPIT-36HK, Linco Research, St. Charles, MO, USA). The sensitivity was 3 
pmol/L, and the inter-assay coefficient of variation (CV) was 9.2 %. Total plasma 
GIP was measured by RIA (41). The sensitivity was 2 pmol/L, and both the intra- 
and inter-assay CVs were 15 %. Plasma insulin was measured by solid-phase, 
two-site  chemiluminescent  immunometric  assay  (Immulite  2000  Insulin, 
Siemens  Medical  Solutions  Diagnostics,  Los  Angeles,  CA,  USA).  Sensitivity 
was 2 mU/L, intraassay CV was 3.9 % and interassay CV was 5.0 %. 
 
10.3.4 Statistical analysis 
Blood glucose and plasma hormone concentrations were analyzed by repeated 
measures analysis of variance (SuperANOVA, Abacus Concepts, Berkeley, CA, 
USA) with time and treatment as factors. T50 and GEC were also analyzed by 
ANOVA.  Post  hoc  means  comparisons  were  performed  in  the  event  of  a   198 
significant treatment  ×  time interaction. Statistical significance was accepted at 
P < 0.05, and data are presented as mean values  ±  standard error.   
 
10.4 Results   
The  study  was  well  tolerated  by  all  subjects.  Fasting  blood  glucose 
concentrations and plasma GLP-1, GIP and insulin concentrations did not differ 
between the four study days.   
 
10.4.1 Gastric emptying 
There was a significant treatment effect for T50 between the 4 study days (P < 
0.005). T50 was longer for sucrose than saline (87.4  ±  4.1 min vs. 74.7  ±  3.2 
min; P < 0.005), whereas there were no differences in T50 between sucralose at 
0.4 mM (73.7  ±  3.1 min) or sucralose at 4 mM (76.7  ±  3.1 min) and saline. 
Accordingly, GEC was less for sucrose when compared to saline (4.3  ±  0 vs. 
4.7  ±  0.1; P < 0.0005), whereas it was not different between sucralose 0.4 mM 
(4.8  ±  0.1) or 4 mM (4.6  ±  0.1) and saline. 
 
10.4.2 Blood glucose concentrations (Figure 1A) 
There  was  a rise in blood  glucose after sucrose  administration  (P = 0.0001),   199 
which was evident from t = 5 min and decreased progressively after about 30 min, 
falling below baseline levels at 90 min. There was a significant treatment  × 
time interaction (P = 0.0001), with the blood glucose concentration being greater 
after sucrose (P < 0.05) between 5 min and 60 min and lower between 90 min 
and 120 min (P < 0.05) compared with saline infusion. There were no significant 
differences in blood glucose between either load of sucralose and saline.   
 
10.4.3 Plasma insulin concentrations (Figure 1B) 
Plasma insulin rose promptly after sucrose administration (P = 0.0001), with a 
maximum response at 15 min, then fell to basal levels by t = 240 min. Insulin 
concentrations were markedly greater after sucrose infusion between 5 min and 
120 min compared to those after saline infusion (P < 0.05). Neither sucralose 
load stimulated an insulin response.   
 
10.4.4 Plasma GLP-1 concentrations (Figure 1C) 
There was a marked increase in plasma GLP-1 after sucrose administration (P = 
0.0001), which was maximal  at  15 min followed by  a subsequent  decline to 
baseline levels by t = 60 min. The GLP-1 level was greater after sucrose between 
5 and 15 min, and less at t = 90 min, compared to saline (P < 0.05). There was no 
difference between sucralose at 0.4 mM or 4 mM and saline.     200 
10.4.5 Plasma GIP concentrations (Figure 1D) 
There was a prompt rise in plasma GIP after sucrose infusion (P = 0.0001). After 
a peak between 5-15 min, GIP declined progressively to baseline values by 240 
min.  Plasma  GIP  was  greater  between  5  min  and  150  min  after  sucrose, 
compared  to  saline  infusion  (P  <  0.05).  There  was  no  difference  between 
sucralose at 0.4 mM or 4 mM and saline.   
 
10.5 Discussion 
This study is the first to evaluate the incretin, insulin and glycaemic responses to 
sucralose  administration, and to determine whether this artificial  sweetener is 
capable of generating feedback in the small intestine that slows gastric emptying, 
in healthy humans. In contrast to administration of sucrose, sucralose given by 
intragastric infusion had no effect on GLP-1, GIP, or insulin secretion, or gastric 
emptying, both at a concentration chosen to match the sweetness of the sucrose 
load (0.4 mM), and at a much higher concentration (4 mM), in the range shown 
to stimulate GLP-1 release from a human enterendocrine cell line in vitro (Jang 
et al. 2007a). This is consistent with reports that sucralose failed to influence 
plasma  glucose  or  serum  C-peptide  in  patients  with  type  1  and  2  diabetes 
(Mezitis  et  al.  1996),  and  that  the  noncaloric  sweetener,  stevioside,  failed  to 
stimulate GLP-1 or GIP in patients with type 2 diabetes (Gregersen et al. 2004).   201 
Similarly, there was no effect of sucralose on fasting blood glucose or glycated 
haemoglobin levels over three months in patients with type 2 diabetes (Grotz et 
al. 2003).   
 
We  administered  sucralose  by  intragastric  infusion  in  this  study,  rather  than 
infusing directly into the small intestine. However, since sucralose is stable in 
acidic  solution  (less  than  1  %  hydrolysis  at  pH  3  after  1  year  (Grice  and 
Goldsmith 2000)), it is unlikely that the properties of sucralose would have been 
altered by exposure to gastric acid, prior to emptying into the small intestine. We 
do  not  believe  that  giving  the  test  solution  orally,  rather  than  by  intragastric 
infusion, would have altered the outcome, since there is no evidence for an effect 
of the cephalic phase of digestion on incretin hormone release (Ahren and Holst 
2001).  We  selected  a  higher  concentration  of  sucralose  that  was  towards  the 
upper  end  of  the  effective  range  in  vitro  (Jang  et  al.  2007a),  and  a  lower 
concentration that approximated that used in the food industry, and observed no 
effect of sucralose at either concentration. It should be recognized that while we 
cannot be absolutely certain that these concentrations were too high or too low to 
stimulate  a  response  (Jang  et  al.  2007a),  it  would  not  have  been  feasible  to 
undertake additional study days in the same volunteers, particularly given the 
volume  of  blood  sampled.  We  also  did  not  measure  the  concentration  of 
sucralose within the small intestinal lumen, but given that the emptying of both   202 
sucralose  solutions  from  the  stomach  was  rapid,  we  would  not  anticipate  a 
substantial difference from the concentrations administered intragastrically.     
 
The presence of carbohydrate in the small intestine is a well established stimulus 
for  GLP-1  and  GIP  secretion,  leading  to  glucose-dependent  insulin  secretion 
from the β-cells, and feedback that regulates gastric emptying (Lin et al. 1989). 
Direct exposure of carbohydrate to the mucosa of the small intestine appears to 
be an essential requirement for GLP-1 and GIP secretion (Deacon 2005), and the 
magnitude of the former is dependent on the rate of delivery of glucose into the 
small intestine (Pilichiewicz et al. 2007a). Elements of the sweet taste receptor 
present in the tongue have recently been identified in both rodent (Olsson et al. 
2006;  Sutherland  et  al.  2007b)  and  human  (Sutherland  et  al.  2007a)  small 
intestine. The T1R2+3 heterodimer should, by analogy to the tongue, respond to 
various sweet-tasting molecules as diverse as sucrose, saccharin, acesulfame-K 
and sucralose (Nelson et al. 2001; Zhao et al. 2003). Furthermore, it has been 
demonstrated in two mouse enteroendocrine cell lines, GLUTag and STC-1, that 
sweet taste receptors are co-localized with GLP-1 and GIP (Kieffer et al. 1995; 
Reimann and Gribble 2002), and that sucralose stimulates secretion of GLP-1 
and GIP from GLUTag cells (Margolskee et al. 2007). Mice that lack α-gustducin 
show markedly defective GLP-1 secretion in response to glucose  (Jang et al. 
2007a). Furthermore, the human L-cell line, NCI-H716, expresses α-gustducin   203 
and several other taste signaling elements (Jang et al. 2007a), and GLP-1 release 
from  NCI-H716  cells  is  stimulated  by  glucose,  sucrose  and  sucralose,  and 
blocked by the sweet receptor antagonist, lactisole, or siRNA for α-gustducin 
(Jang et al. 2007a). However, until this study, there has been no information 
available regarding effect of artificial sweeteners on GLP-1 release in humans in 
vivo.  Moreover,  even  in  mice,  only  a  minority  (8  %)  of  L-cells  coexpress 
α-gustducin (Sutherland et al. 2007b); the potential stimulus for GLP-1 release 
from the remainder is unclear.  It should also be noted that major differences 
between  species  are  evident  with  regards  to  incretin  hormone  release.  For 
example, fructose stimulates the release of GLP-1 in rats (Ritzel et al. 1997) and 
humans (Rayner et al. 2000b), but not in dogs (Shima et al. 1990).   
 
Although  sucrose,  sucralose  and  other  sweet  tastants  all  bind  to  the  T1R2+3 
heterodimer, they do not  act  in  identical  fashion, at  least  on the tongue.  For 
example, sucrose binds with a different affinity from sucralose (Nie et al. 2005), 
while absence of T1R3  receptors  in  knockout  mice completely  abolishes  any 
taste preference for sucralose, but merely diminishes the preference for sucrose 
(Damak et al. 2003). Moreover, functional brain imaging in humans indicates 
differences in central activation between sucrose and identically sweet sucralose 
solutions (Frank et al. 2008).   
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Absorption of monosaccharide may be necessary for GLP-1 or GIP release; this 
seems to be true for GIP at least (Wachters-Hagedoorn et al. 2006), since rapidly 
and  slowly  digestible  carbohydrates  differ  considerably  in  their  ability  to 
stimulate GIP secretion (Wachters-Hagedoorn et al. 2006), while phloridzin, an 
inhibitor of the SGLT1 glucose transporter, suppresses GIP release (Fushiki et al. 
1992). Absorption of monosaccharide via SGLT1 has also been suggested as a 
trigger for GLP-1 secretion from L-cells (Gribble et al. 2003).   
 
We  have  not  examined  whether  sucralose  has  any  effect  on  carbohydrate 
absorption  in  humans.  Supplementation  of  the  diet  with  sucralose  increases 
SGLT1 mRNA and glucose absorption in wild type mice, but not in T1R3 or 
α-gustducin  knockout  mice  (Margolskee  et  al.  2007).  Furthermore,  sucralose, 
acesulfame  potassium  and  saccharin  stimulate  glucose  absorption  in  rats  by 
enhancing apical insertion of GLUT2 (Mace et al. 2007). This raises the question 
as to whether the combination of an artificial sweeter with carbohydrate could 
have a synergistic effect on incretin release, even if sucralose has no effect alone, 
and  might  account  for  the  observation  that  chronic  exposure  of  mice  to 
oligofructose (a non-digestible sugar) enhances GLP-1 secretion in response to a 
high fat diet (Cani et al. 2006).   
 
It should also be recognized that GPCR other than T1R2 have recently been   205 
linked to incretin hormone release. For example, GPR40 and GPR119 are both 
GPCR that may stimulate incretin release in response to fatty acids, and agonists 
of these receptors could be therapeutically useful in diabetes (Chu et al. 2008). 
Furthermore,  sweet  taste  sensors  other  than  T1R2,  such  as  SGLT3 
(Diez-Sampedro et al. 2003), could be important in the detecting carbohydrate in 
the small intestine.   
 
In conclusion, we have not been able to  demonstrate that sucralose given by 
intragastric  infusion  stimulates  GLP-1  or  GIP  release  in  humans,  or  elicits  a 
feedback  response  to  slow  gastric  emptying.  This  implies  that  artificial 
sweeteners  may  have  no  therapeutic  benefit  in  the  dietary  management  of 
diabetes, other than as a substitute for carbohydrate.   206 
        
   
Figure 10.1: Concentrations of blood glucose (A), plasma insulin (B), plasma 
GLP-1 (C) and plasma GIP (D) in response to intragastric infusion of 500 ml 
solutions  containing  either  (i)  50  g  sucrose,  (ii)  normal  saline,  (iii)  80  mg 
sucralose (0.4 mM), or  (iv) 800 mg sucralose (4 mM) in  7  healthy  subjects. 
*sucrose  vs.  saline,  P  <  0.05.  Data  are  mean  values  ±  SEM.  There  were  no 
significant differences in blood glucose, plasma insulin, plasma GLP-1 and GIP 
between either load of sucralose and saline.     207 
CHAPTER 11: EFFECT OF THE ARTIFICIAL SWEETENER, 
SUCRALOSE, ON SMALL INTESTINAL GLUCOSE ABSORPTION IN 
HEALTHY HUMANS 
11.1 Summary   
It has been reported that the artificial sweetener, sucralose, stimulates glucose 
absorption in rodents by enhancing apical availability of the glucose transporter 
GLUT2.  We  evaluated  whether  exposure  of  the  proximal  small  intestine  to 
sucralose  affects  glucose  absorption,  and/or  the  glycaemic  response  to  an 
intraduodenal (ID) glucose infusion, in healthy humans. 10 healthy subjects were 
studied  on  two  separate  occasions  in  single-blind,  randomized  order.  Each 
subject received an ID infusion of sucralose (4 mM in 0.9 % saline), or control 
(0.9 % saline) at 4 mL/min for 150 min (t = -30 to 120 min). After 30 min (t = 0), 
glucose (25 %) and its non-metabolized analogue, 3-O-methylglucose (3-OMG; 
2.5 %), were co-infused intraduodenally (T = 0 to 120 min; 1 kcal/min). Blood 
was  sampled  at  frequent  intervals.  Blood  glucose  and  serum  3-OMG 
concentrations increased during ID glucose/3-OMG infusion (P < 0.001 for both). 
However, there were no differences in either blood glucose or serum 3-OMG 
concentrations between sucralose and control infusions. In conclusion, sucralose 
does  not  appear  to  modify  the  rate  of  glucose  absorption,  nor  the  glycaemic   208 
response to ID glucose, when given acutely in healthy humans.     
 
11.2 Introduction   
The mechanisms by which the gut senses nutrients are unclear, and the „receptor‟ 
for  detecting  luminal  carbohydrate  has,  until  recently,  been  elusive.  Recent 
studies  indicate  the  presence  of  G-protein  coupled  taste  receptors,  T1R2  and 
T1R3, and their taste signal transduction partners, the G-protein gustducin and 
the transient receptor potential ion channel TRPM5, in the mucosa of the mouse 
and human gastrointestinal tract (Sutherland et al. 2007b; Young et al. 2009). 
These  receptors,  analogous  to  sweet  taste  receptors  on  the  tongue,  broadly 
respond  to  sugars  and  artificial  sweeteners,  and  amongst  several  cell  types, 
appear  to  co-localize  with  glucagon-like  peptide-1  (GLP-1)-secreting  L-cells 
(Jang et al. 2007b) .   
 
It  has  been  reported  that  the  artificial  sweetener,  sucralose,  stimulates  the 
secretion of both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) 
from the mouse enteroendocrine cell line GLUTag (Margolskee et al. 2007), and 
stimulates GLP-1 secretion from the human L-cell line NCI-H716 (Jang et al. 
2007b), a response that is blocked by the sweet receptor antagonist, lactisole, and 
siRNA for  -gustducin  (Jang et al. 2007b). However, it was demonstrated in 
Chapter 10 that sucralose, in two different loads, had no effect on GLP-1, GIP, or   209 
insulin secretion, and did not elicit any feedback response on gastric emptying in 
healthy humans (Ma et al. 2009a). While this implies that artificial sweeteners 
may have no therapeutic benefit in the dietary management of diabetes, other 
than as a substitute for carbohydrate, it remains possible that sucralose affects 
small intestinal carbohydrate absorption, as a result of its interaction with the 
sweet taste receptor. 
 
Glucose is absorbed from the small intestine through both the sodium-dependent 
glucose transporter 1 (SGLT1), and the facilitative transporter GLUT2 (Kellett et 
al.  2008). Supplementation  of the diet with  sucralose increases expression of 
SGLT1 in the enterocytes of wild type mice, but not in mice deficient in T1R3 or 
-gustducin  (Margolskee  et  al.  2007).  The  presence  of  sucralose  enhances 
insertion of GLUT2 into the apical region of the enterocyte, and thus stimulates 
glucose absorption in the rat (Mace et al. 2007; Mace et al. 2009). For example, 
sucralose administration doubled the level of GLUT2 protein detected in apical 
membrane vesicles in response to low luminal glucose concentrations (20 mM) 
(Mace et al. 2007), and the maximum rate of glucose absorption was reached 
after 20 min of exposure to sucralose in vivo (Mace et al. 2009). This raises the 
question  as  to  whether  the  combination  of  an  artificial  sweetener  with 
carbohydrate could have a synergistic effect on glucose absorption in humans. 
The  notion  that  consuming  artificial  sweeteners  together  with  carbohydrates   210 
could  enhance  glucose  absorption,  and  therefore  elevate  postprandial  blood 
glucose concentrations, is of fundamental clinical importance. 
 
The aim of the current study was to evaluate whether exposure of the proximal 
small intestine to sucralose affects the subsequent response to glucose, in terms 




10 healthy subjects (8 male, 2 female; age 27 ± 2 yr; body mass index 23.4 ± 0.8 
kg/m2)  were  studied  twice  in  a  randomized,  single-blind,  cross-over  design. 
None  of  them  had  a  history  of  gastrointestinal  disease,  upper  or  lower 
gastrointestinal symptoms, or significant previous surgery. Each subject provided 
written informed consent prior to participating, and the study was approved by 
the Royal Adelaide Hospital Research Ethics Committee.   
 
11.3.2 Protocol 
The  study  followed  a  randomized,  single-blind,  cross-over  design.  All 
participants attended the Discipline of Medicine at the Royal Adelaide Hospital 
at approximately 0830 h after an overnight fast (14 h for solids, 12 h for liquids)   211 
on  two  occasions,  separated  by  at  least  3  days.  Women  were  studied  in  the 
follicular  phase  of  the  menstrual  cycle,  to  avoid  potential  influences  of  the 
menstrual cycle on upper gastrointestinal function (Brennan et al. 2009).   
 
On each study day, a multilumen silicone catheter (external diameter 4 mm) was 
introduced into the stomach through an anaesthetised nostril, and allowed to pass 
into the duodenum by peristalsis. This catheter incorporated a sidehole to deliver 
infusions into the proximal duodenum; its position was monitored continuously 
during  the  study  by  measurement  of  the  transmucosal  potential  difference 
(TMPD), from two other saline-perfused side holes on either side of the pylorus, 
using established criteria (antral TMPD < -20 mV, duodenal TMPD > -15 mV, 
difference > 15 mV) (Heddle et al. 1988a). This required the insertion of a 20G 
saline-filled  cannula  subcutaneously  in  the  forearm  as  a  reference.  When  the 
catheter  was  positioned  correctly,  an  intravenous  cannula  was  inserted  into  a 
forearm vein for subsequent blood sampling. 
 
After baseline blood samples were taken (t = -30), an intraduodenal infusion of 
sucralose (960 mg made up to 600 mL with 0.9 % saline (sucralose concentration 
4 mM, total osmolality ~ 300 mosmol/L), or 600 mL 0.9 % saline alone as a 
control (~ 300 mosmol/L)), commenced and continued at a rate of 4 mL/min for 
150 min (t = -30 to 120 min). At t = 0 min, an intraduodenal glucose solution (30   212 
g glucose together with 3 g 3-O-methylglucose (3-OMG, Sigma-Aldrich, MO, 
USA), made up to a total volume of 120 mL with water, ~ 1390 mM glucose), 
also commenced via the same channel in the catheter and continued at a rate of 1 
mL/min (= 1 kcal/min) for 120 min (t = 0 to 120 min).   
 
Venous  blood  samples  (~  20  mL)  were  taken  immediately  before  the 
intraduodenal infusion commenced, and at t = -15, 0, 5, 10, 20, 30, 40, 60, 90, 
and 120 min. Blood glucose concentrations were measured immediately using a 
glucometer (Medisense Precision QID, Abbott Laboratories, Bedford, MA, USA). 
The remainder of each blood sample was placed in a serum tube, and centrifuged 
at 3200 rpm for 15 min. Serum was separated and samples stored at -70  ºC for 
subsequent analysis of 3-OMG concentrations by liquid chromatography/mass 
spectrometry. 3-OMG is an analogue of glucose that is absorbed from the gut in 
the same way as glucose but not metabolised; therefore serum concentrations 
represent an index of glucose absorption (Fordtran et al. 1962).   
 
11.3.3 Statistical analysis 
Repeated  measures  analysis  of  variance  (SuperANOVA,  Abacus  Concepts, 
Berkeley, CA, USA) was used to analyze the blood glucose and serum 3-OMG 
concentrations with both treatment and time as factors. Statistical significance 




All subjects tolerated the study well. 
 
11.4.1 Blood glucose concentrations (Figure 1A) 
There  was  no  difference  in  baseline  glucose  concentrations  between  the  two 
study days. Blood glucose concentrations also did not differ over t = -30 min to 0 
min, during infusions of sucralose or saline. There was a rise in blood glucose 
concentration following commencement of the ID glucose infusion, which was 
evident from t = 20 min (P < 0.001) on both days. There was no difference in 
blood glucose concentrations in subjects receiving sucralose or saline infusions. 
 
11.4.2 Serum 3-OMG concentrations (Figure 1B) 
Serum 3-OMG concentrations increased from 20 min following commencement 
of  the  ID  glucose  infusion  (P  <  0.001)  on  both  study  days.  There  was  no 
difference  in  serum  3-OMG  concentrations  in  subjects  receiving  sucralose  or 
saline infusions. 
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11.5 Discussion   
This study indicates that intraduodenal administration of sucralose has no effect 
on the rate of glucose absorption from the lumen of the small intestine, and does 
not elevate postprandial blood glucose concentrations, in healthy humans. 
 
Sucralose is used as a non-caloric sweetener in the food industry and is widely 
consumed by individuals with obesity and diabetes. The recent identification of 
elements of the sweet taste receptor in the rodent and human small intestine, that 
are  linked  to  peptide  hormone  release  and  modulation  of  glucose  transport, 
suggests  that  artificial  sweeteners  could  potentially  be  metabolically  active. 
However, in vivo studies in mice  (Fujita et al. 2009) and humans (Ma et al. 
2009a) have failed to support any effect of sucralose on insulin, GLP-1 or GIP 
release. Recently, it was reported in rats that sucralose acted synergistically with 
glucose to activate the T1R2+T1R3 heterodimer and increase the rate of small 
intestinal  glucose  absorption  by  inserting  GLUT2  into  the  apical  membrane 
(Mace et al. 2007). Hence, consuming artificial sweeteners in conjunction with 
carbohydrate  raises  concerns  about  increasing  the  postprandial  glycaemic 
response, particularly as there is already over-expression of SGLT1 and GLUT2 
in the small intestine in animal models of diabetes (Burant et al. 1994; Dyer et al. 
1997) and in diabetic humans (Dyer et al. 2002). Our study is the first to examine 
the  potential  interaction  of  intraluminal  sucralose  with  glucose  in  relation  to   215 
small intestinal glucose absorption and blood glucose concentrations in healthy 
humans,  and  the  negative  outcome  is  consistent  with  studies  that showed  no 
effect  of  sucralose  supplementation  on  glycaemic  control  in  patients  with 
diabetes (Mezitis et al. 1996; Grotz et al. 2003).   
 
In the present study, we infused sucralose and glucose directly into duodenum, 
rather than administering them orally, in order to regulate precisely the exposure 
of the small intestine to these substances. In studies where sucralose stimulated 
the  T1R2+T1R3  receptor,  resulting  in  apical  insertion  of  GLUT2,  the 
concentration  of  sucralose  was  1  mM  (Mace  et  al.  2007).  Therefore,  4  mM 
sucralose should have been a sufficient concentration to achieve a response. We 
used a high glucose concentration (1390 mM), which would itself be expected to 
induce apical GLUT2 insertion maximally (Mace et al. 2007), but this process 
would  have  taken  about  20  min  (Mace  et  al.  2009),  so  if  prior  exposure  to 
sucralose did indeed modulate apical GLUT2, a difference in glucose absorption 
should have been evident early in the ID glucose infusion. 
 
Species differences are likely to account for the lack of effect of sucralose in 
humans. It has been reported that there is much lower duodenal expression of 
GLUT2 in humans than in rats and mice, while expression of SGLT1 is much 
greater in  humans  (Kim et  al.  2007). Therefore, SGLT1 is  likely to  play the   216 
dominant role in glucose absorption in the human small intestine. Mutation of 
SGLT1  in  humans  results  in  glucose-galactose  malabsorption,  whereas 
absorption of these sugars is not disrupted by mutations of GLUT2 (Wright et al. 
2003).  Moreover,  if  apical  GLUT2  insertion  occurred  in  humans,  one  might 
expect this to ameliorate the effects of SGLT1 mutation and allow glucose to be 
tolerated in this disorder, but this appears not be the case  (Dyer et al. 2002). 
Supplementation of a low-sugar chow with sucralose for two weeks in mice has 
been reported to increase SGLT1 protein and mRNA expression (Margolskee et 
al. 2007). Therefore, it is still possible that prolonged exposure to sucralose could 
increase small intestinal glucose absorption in humans, although this would need 
to be evaluated in a separate study.   
 
In conclusion, this study has demonstrated that intraduodenal administration of 
sucralose  does  not  acutely  enhance  the  absorption  of  glucose  from  the  small 
intestine, or increase blood glucose concentrations, in healthy humans.   217 
     
 
Figure 11.1: Concentrations of blood glucose (A) or serum 3-OMG (B) in 10 
healthy subjects  in  response to  an  ID  infusion  of  sucralose (4 mM  in  0.9 % 
saline), or control (0.9 % saline) at 4 mL/min for 150 min (t = -30 to 120 min) 
with  co-infusion  of  glucose  (25  %)  and  3-O-methylglucose  (3-OMG;  2.5  %) 
between t = 0 and 120 min (1 kcal/min). Data are presented as mean values ± 
SEM. There are no significant differences in blood glucose or serum 3-OMG 
concentrations between saline or sucralose days.   
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CHAPTER 12: EFFECTS OF CEFACLOR ON GASTRIC EMPTYING 
AND CHOLECYSTOKININ RELEASE IN HEALTHY HUMANS   
Adapted from Ma J et al, Regul Pept. 159(1-3): 156-9, 2010. 
 
12.1 Summary   
In rodents, cephalosporin antibiotics can mimic peptones and stimulate release of 
cholecystokinin  (CCK),  a  hormone  that  slows  gastric  emptying.  The  rate  of 
gastric  emptying  is  a  major  determinant  of  postprandial  blood  glucose  and 
insulin concentrations. The effect of orally administered cefaclor on plasma CCK 
and  gastric  emptying,  as  well  as  postprandial  glycaemic  and  insulinaemic 
responses, was therefore evaluated in healthy humans. 8 healthy subjects were 
studied  on  two  days  each  in  double-blind,  randomized  order.  On  each  day, 
subjects consumed 1000 mg cefaclor or placebo 30 min before a mashed potato 
meal labeled with 
13C octanoic acid. Blood and breath samples were collected for 
4 hours after the meal. Blood glucose, serum insulin and plasma CCK increased 
in response to the carbohydrate meal on both study days, and cefaclor had no 
effect on these responses. Similarly, the gastric half-emptying time (measured by 
breath test) did not differ (placebo: 137.5 ± 6.0 min vs. cefaclor: 143.1 ± 8.0 min). 
Cefaclor, when given before a meal in the form of a capsule, does not stimulate 
CCK release or slow gastric emptying in healthy humans.   219 
12.2 Introduction 
Gastric emptying is regulated by the integrated activity of the proximal stomach, 
antrum,  pylorus  and  duodenum.  Exposure  of  the  small  intestine  to  nutrient 
induces feedback that slows gastric emptying by relaxing the fundus, suppressing 
antral pressures and augmenting pyloric contractions (Heddle et al. 1988a). This 
feedback inhibition is mediated by the secretion of gastrointestinal hormones, of 
which the best characterized is CCK (Schwizer et al. 1997). The CCK-1 receptor 
antagonist,  loxiglumide,  abolishes  the  inhibitory  action  of  lipid  on  gastric 
emptying (Schwizer et al. 1997).   
 
CCK is secreted from the I-cells of the proximal small intestine in response to 
nutrients (Liddle 1997). Protein, particularly protein hydrolysates (peptones), and 
fat,  are  strong  stimuli  for  CCK  release,  whereas  carbohydrate  is  less  potent 
(Liddle 1997). In the intestinal cell line STC-1, peptones trigger CCK secretion 
and  gene  transcription  directly  (Cordier-Bussat  et  al.  1997).  Various 
cephalosporin antibiotics, which have a tripeptide structure, and therefore mimic 
the molecular structure of peptones, have similar effects (Nemoz-Gaillard et al. 
1998). In rats, intragastric administration of the cephalosporin antibiotic, cefaclor, 
between  15  and  500  mg/kg,  results  in  a  dose-dependent  slowing  of  gastric 
emptying (Bozkurt et al. 2000), an effect mediated via a capsaicin-sensitive vagal 
afferent pathway involving CCK-1 receptors (Bozkurt et al. 2000; Darcel et al.   220 
2005). Similarly, duodenal perfusion with cefaclor (500 mg/kg) stimulates the 
discharge of CCK-responsive vagal afferents in this species, an effect probably 
mediated  via  the  peptone  transporter  PepT1  (Darcel  et  al.  2005).  In  mice, 
intraperitoneal  administration  of  various  cephalosporins  accelerates  gastric 
emptying over the range 2-200 mg/kg, and slows gastric emptying when given at 
higher doses (> 1000 mg/kg) (Kuo et al. 1998). Given the persuasive evidence 
that cephalosporins have the capacity to affect gastric emptying in rodents, it is 
surprising that little information is available in humans, although there is one 
report  that  intravenous  cefazolin  had  no  impact  on  gastric  emptying  in  the 
critically  ill  (Chapman  et  al.  2003).  However,  parenteral  administration  of 
cephalosporins would not  be expected to influence a luminal peptide sensing 
mechanism. 
 
Control of postprandial glycaemia is increasingly recognized as fundamental to 
the management of diabetes. Gastric emptying accounts for about one third of the 
variance  in  postprandial  blood  glucose  after  an  oral  glucose  load  in  healthy 
subjects (Horowitz et al. 1993) and in patients with type 2 diabetes (Jones et al. 
1996), and minor variations in the initial rate of carbohydrate entry into the small 
intestine can have major effects on glycaemic and insulin responses (O'Donovan 
et al. 2004b). Accordingly, dietary or pharmacological interventions which affect 
gastric emptying influence the glycaemic response to carbohydrate meals. For   221 
example, accelerating nutrient entry from the stomach to the small intestine with 
erythromycin  increases  the postprandial  glycaemic response, whereas  slowing 
gastric  emptying  with  morphine  attenuates  postprandial  blood  glucose 
concentrations in type 2 patients (Gonlachanvit et al. 2003).   
   
The  aim  of  the  current  study  was  to  evaluate  the  acute  effects  of  orally 
administered cefaclor (about 15 mg/kg, a dose shown to be effective in rats and 
at the upper end of the clinical dosing range in humans) on CCK release, gastric 
emptying,  and  postprandial  glycaemic  and  insulinaemic  responses  in  healthy 




8 healthy subjects (4 male, 4 female; age: 28.3 ±  3.0 yr; BMI: 22.4 ±  0.7 kg/m
2) 
were studied twice in a randomized, double-blind, cross-over design. None was 
taking  medication  known  to  influence  gastrointestinal  function.  The  study 
protocol  was  approved  by  the  Royal  Adelaide  Hospital  Research  Ethics 
Committee, and each subject provided written informed consent prior to taking 
part.   
   222 
12.3.2 Protocol 
All  participants  attended  the  laboratory  at  approximately  0830  h  after  an 
overnight fast (14 h for solids, 12 h for liquids) on two occasions, each separated 
by at least 3 days. Women were studied in the follicular phrase of the menstrual 
cycle. On each day, an intravenous cannula was inserted into an antecubital vein 
for  blood  sampling  and  at  t  =  -30  min,  subjects  consumed  2  capsules  each 
containing 500 mg cefaclor (Link Pharmaceuticals Ltd., UK; encapsulated by the 
Pharmacy Department, Royal Adelaide Hospital) or identical placebo (containing 
starch), with 50 ml water, 30 minutes before a mashed potato meal (given at t = 0 
min)  in  a  double-blind  and  randomized  design.  The  meal  consisted  of  65  g 
powdered potato (Deb, Epping, NSW, Australia) and 20 g glucose, reconstituted 
with 250 ml water and 1 egg yolk containing 100 L 
13C octanoic acid. Subjects 
consumed the meal within 5 minutes. Breath samples were collected immediately 
before, and every 5 minutes after, meal ingestion for the first hour, and every 15 
min  for  a  further  3  hours.  Venous  blood  samples  (~  18  ml)  were  taken 
immediately before administration of the capsules (ie. t = -30 min), and then at t 
=  -15,  0,  15,  30,  60,  90,  120,  150,  180  and  240  min.  Blood  glucose 
concentrations  were  measured  immediately  using  a  glucometer  (Medisense 
Precision QID, Abbott Laboratories, Bedford, MA, USA). The remainder of each 
blood sample was placed in both a prechilled-EDTA tube containing 400 kIU 
aprotinin (Trasylol, Bayer Australia Ltd, Pymble Australia) per litre blood for   223 
CCK assay and an ice-chilled serum tube with clotting activator for insulin assay, 
both stored on ice, and centrifuged at 3200 rpm for 15 min. Plasma and serum 




Breath samples were measured for isotope enrichment by an isotope ratio mass 
spectrometer (ABCA 2020, Europa Scientific, Crewe, England) with an on-line 
gas  chromatographic  purification  system.  The  half-emptying  time  (T50)  and 
gastric emptying coefficient (GEC) were calculated using the formulae described 
by  Ghoos  et  al  (Ghoos et  al. 1993).  This  method  has  been  validated  against 
scintigraphy for the measurement of gastric emptying (Chew et al. 2003).   
 
Serum insulin and plasma CCK concentrations 
Serum  insulin  was  measured  by  a  solid-phase,  two-site  chemiluminescent 
immunometric  assay  (Immulite  2000  Insulin,  Siemens  Medical  Solutions 
Diagnostics, Los Angeles, CA, USA). The sensitivity was 2 mU/L, intraassay 
coefficient of variation (CV) was 3.9 % and interassay CV was 5.0 %. Plasma 
CCK-8 was measured by radioimmunoassay using an adaption of the method of 
Santangelo  et  al  (Santangelo  et  al.  1998),  (antibody  C2581,  Lot  105H4852, 
Sigma Chemical, St. Louis, MO, USA) with less than 2 % cross-reactivity for   224 
gastrin. Intra-assay CV was 6.2 %, inter-assay CV was 14.2 % and sensitivity 
was 1 pmol/L.   
 
12.3.4 Statistical analysis 
Paired  t-tests  (Statview,  SAS  Institute  Inc.,  Cary,  NC,  USA)  were  used  to 
compare T50 and GEC, and baseline blood glucose, serum insulin and plasma 
CCK  values,  while  repeated  measures  analysis  of  variance  (SuperANOVA, 
Abacus  Concepts,  Berkeley,  CA,  USA)  was  used  to  compare  blood  glucose, 
serum insulin, and plasma CCK concentrations with time and treatment as factors. 
P ≤ 0.05 was taken to indicate statistical significance, and data are presented as 
mean values ± standard error. 
 
12.4 Results   
All subjects tolerated the study well.   
 
12.4.1 Blood glucose, serum insulin and plasma CCK concentrations (Figure 
1A-C) 
Baseline blood glucose, serum insulin and plasma CCK concentrations did not 
differ between the two study days. There was a rise in blood glucose and serum   225 
insulin after the meal on both study days (P ≤ 0.001), with no difference between 
cefaclor and placebo. Between t = -30 to 0 min (ie. prior to the meal), there was 
no increase from baseline CCK after either cefaclor or placebo. After the meal, 
plasma CCK increased on both days (P ≤ 0.001), without any difference between 
them.   
 
12.4.2 Gastric emptying   
There was no significant difference in T50 between the 2 study days (cefaclor: 
143.1 ±  8.0 min vs. placebo: 137.5 ± 6.0 min; P = 0.33). Similarly, the GEC did 
not differ between cefaclor (3.0 ±  0.1) and placebo (2.9 ±  0.1). 
 
12.5 Discussion 
In this study, it was not possible to demonstrate that oral cefaclor, at a dose of 
1000  mg,  stimulates  any  CCK  release  or  slows  gastric  emptying,  and, 
accordingly, it had no effect on blood glucose or insulin responses to a high 
carbohydrate meal in healthy subjects.   
 
In humans and rats, protein and fat are potent stimuli for CCK release. Free fatty 
acids have recently been shown to stimulate CCK release via G-protein-coupled 
fatty acid receptors such as the GPR120 receptor, which mediates Ca 
2+ influx in   226 
STC-1 cells in response to long chain fatty acids (Tanaka et al. 2008). While the 
gut mechanisms responsible for CCK secretion in response to protein are yet to 
be fully elucidated, it has been suggested that di- and tri-peptides, which are 
more  potent  stimuli  for  CCK  release  than  polypeptides  or  monomeric  amino 
acids (Cuber et al. 1990), are transported by the oligopeptide transporter PepT1, 
a process linked to CCK release in the murine enteroendocrine cell line STC-1 
(Matsumura  et  al.  2005).  More  recently,  another  G  protein-coupled  receptor, 
GPR93, has been identified in rat enterocytes as a molecular sensor which is 
activated by peptones, and accompanied by an increase in CCK transcription 
(Choi et al. 2007b). Cefaclor, as a peptidomimetic, has the capacity to stimulate 
CCK secretion from STC-1 cells in vitro (Nemoz-Gaillard et al. 1998), and from 
rat small intestine in vivo (Darcel et al. 2005), an effect attributed to Pep T1 
transport-induced activation of signal transduction pathways (Matsumura et al. 
2005).  However,  cefaclor  itself  does  not  activate  GPR93,  but  does  act 
synergistically  with  protein  hydrolysate  to  potentiate  CCK  release  via  this 
mechanism (Choi et al. 2007a), in a rat enterocyte line (hBRIE 380i) that does 
not express PepT1 (Choi et al. 2007a).     
 
The  reason  that  cefaclor  failed  to  stimulate  CCK  release  in  humans  remains 
uncertain.  However,  the  dose  given  (about  15  mg/kg)  is  comparable  to  that 
shown to be effective in rats (3 ml of a 3 mM solution) (Bozkurt et al. 2000) and   227 
was four times thse standard therapeutic dose. Accordingly, any substantial dose 
increase would have caused ethical concerns. Cefaclor was administrated 30 min 
before the meal, in the expectation that the presence of cefaclor in the small 
intestine would both induce the release of CCK, and slow gastric emptying in 
advance  of  meal  ingestion,  an  approach  we  have  used  previously  with  other 
substances  that  stimulate  gut  peptide  secretion  (Ma  et  al.  2009c).  It  was 
anticipated that this time interval would coincide with maximal exposure of the 
small  intestine  to  cefaclor,  given  that  the  peak  plasma  concentration  occurs 
between 30 min and 60 min after an oral dose of 1000 mg (Lode et al. 1979). 
Using  the  mean  values  and  standard  deviations  derived  from  the  results,  the 
current study had a 90 % power to detect a 15 % change in half emptying time, 
and a 90 % power to detect a 75 % increase from fasting in plasma CCK at 30 
minutes after study drug administration, at the alpha 0.05 level. Accordingly, this 
study  appears  to  exclude  a  clinically  significant  effect  of  cefaclor  on  either 
gastric  emptying  or  CCK  secretion.  Although  the  study  design  did  not 
incorporate  a  positive  control,  our  group  has  previously  demonstrated  clear 
effects of small protein loads on gastric emptying using breath tests (Karamanlis 
et al. 2007) and scintigraphy (Ma et al. 2009c), and on gut peptide secretion, in a 
similar number of subjects. 
 
Rather  than  an  issue  of  dose,  it  may  be  more  likely  that  species  differences   228 
between  rodents  and  humans  account  for  the  discrepant  observations  on  the 
stimuli that induce CCK release; in humans the presence of nutrient might be a 
necessary condition for the secretion of CCK (Liddle 2000).   
 
The current observations are important because they highlight the caution needed 
in  extending  in  vitro  or  rodent  data  to  humans.  Furthermore,  they  appear  to 
exclude an acute effect of cephalosporin antibiotics in the clinical dose range on 
CCK release, gastric emptying or blood glucose metabolism.   
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Figure 12.1: Concentrations of blood glucose (A), serum insulin (B) and plasma 
CCK (C) in 8 healthy subjects in response to oral cefaclor (1000 mg) or placebo 
administered  30  minutes  prior  to  a  potato  meal.  On  one  study  day,  subjects 
consumed 2 capsules each containing 500 mg cefaclor (total dose 1000 mg) with 
50 ml water, 30 minutes before a mashed potato meal consisting of 65 g powered 
potato  and  20  g  glucose,  reconstituted  with  250  ml  water  and  1  egg  yolk 
containing 100 L 
13C octanoic acid. On the other study day, subjects consumed 
1000 mg placebo prior to the mashed potato meal. Data are presented as mean 
values ± SEM. There were no significant differences in blood glucose, serum 
insulin or plasma CCK levels between placebo and cefaclor days.     230 
CHAPTER 13: CONCLUSION 
The  studies  reported  in  this  thesis  provide  support  for  the  fundamental 
importance  of  gastrointestinal  function  in  the  regulation  of  glycaemia  and 
appetite in healthy individuals and patients with type 2 diabetes.   
 
Gut  functions  involved  in  glycaemic  regulation  include  gastric  emptying  and 
incretin  hormone  release,  which  are  modified  by  the  interaction  between 
nutrients and the small intestine. Among the macro-nutrients, fat is most potent 
inhibitor  of  gastric  emptying.  A  previous  study  had  established  that  giving  a 
small  amount  of  fat  (oil)  30  min  before  a  carbohydrate  meal,  delayed  the 
postprandial increase in blood glucose, plasma insulin and GIP, and stimulated 
the release of GLP-1, in patients with diet-controlled type 2 diabetes (Gentilcore 
et al. 2006b). When compared to giving the oil as a „preload‟, ingestion of oil 
with the meal had modest effects on gastric emptying, glycaemia and incretin 
hormone responses. The putative underlying mechanism is that when oil was 
given before the meal, both digested and non-digested fat would be present in the 
small  intestine  to  slow  gastric  emptying  and  stimulate  incretin  hormones,  in 
advance of meal consumption. In this fat preload study, there was only a trend for 
reduction  of  peak  blood  glucose  levels,  and  measurements  had  not  been 
continued  for  sufficiently  long  to  determine  whether  the  overall  glycaemic   231 
response was less.   
 
Protein is a stronger stimulus for insulin release, and has a lower energy density, 
than fat. In the study presented in Chapter 5, ingestion of a whey protein preload 
(55 g) 30 min before, or with, a high carbohydrate meal, markedly slowed gastric 
emptying, and was associated with stimulation of GLP-1, as with the fat preload 
in  patients  with  diet-controlled  type  2  diabetes.  In  contrast  to  the  fat  study, 
protein stimulated GIP and insulin secretion - the latter substantially. Glycaemic 
responses after protein were markedly decreased (peak blood glucose by about 3 
mmol/L), which is comparable to pharmacological therapy. However, it should 
be  noted  that  this  dose  of  whey  protein,  which  was  chosen  on  the  basis  of 
previous data that  indicated it would be sufficient  to  stimulate gut  hormones 
(Bowen et al. 2006c), does impose a caloric load of 220 kcal. Therefore, it would 
be important to confirm whether the observed effects would be maintained with a 
smaller load of protein, in order to minimize the additional energy load. It would 
also be interesting to determine whether the protein preload included suppressed 
appetite and energy intake, and whether the acute effects were maintained with 
continued use over the long term.   
 
The  next  study,  therefore,  aimed  to  determine  whether  a  whey  preload  at  a 
smaller dose (25 g) remained effective in lowering postprandial glycaemia, and   232 
also  whether whey  suppressed  appetite and energy intake at  a  subsequent  ad 
libitum  meal  in  patients  with  type  2  diabetes  (Chapter  6).  There  was  a 
dose-dependent increase in fullness and an increase in plasma CCK and GIP after 
both protein preloads (25 g and 55 g) as well as a reduction in postprandial blood 
glucose concentrations in patients with diet-controlled type 2 diabetes; GLP-1 
and insulin data were not available at the time of writing. Despite the increase in 
fullness, there were no significant differences in energy intake between either 
protein preload  and placebo. However, the number of subjects  was  relatively 
small, and the ability of the preload to suppress energy intake might be critically 
dependent on the timing of the subsequent meal.   
 
The study reported in Chapter 7 represents the first evaluation of the chronic 
effects of a protein preload on gastric emptying and glycaemic control in type 2 
diabetes. Patients with diet-controlled type 2 diabetes were exposed to 4 week 
periods  of  either  a  whey  or  placebo  preload  before  each  main  meal,  in  a 
randomized crossover design. The dose of whey (25 g) was the lower of the 
doses shown to  be effective in  reducing  glycaemia acutely  (Chapter 6). This 
study showed that the effects on gastric emptying and postprandial glycaemia 
were sustained over 4 weeks.   
 
The site, and length of exposure, of the small intestine to nutrient is likely to be   233 
important in determining the release of gut peptides, including GLP-1. In the 
study reported in Chapter 8, the capacity of an enteric coated pellet formulation 
of  lauric  acid  (CTM#3)  to  release  GLP-1  and  improve  the  postprandial 
glycaemic response in type 2 diabetes was evaluated. CTM#3 was designed to 
release a small amount of fatty acid over a long length of terminal ileum. A 
glucose-lowering effect of CTM#3 was observed after both breakfast (containing 
the pellets) and lunch, associated with prolonged stimulation of GLP-1 release. 
Neither  serum  insulin,  nor  the  insulin  to  glucose  ratio,  were  increased 
significantly by CTM#3, suggesting that paracrine and portal effects of GLP-1 
may be at least as important as its endocrine effects. Other potential actions of 
GLP-1 that may be relevant include the suppression of glucagon and possibly, 
slowing of gastric emptying.   
 
In healthy subjects, the incretin hormones account up to 70 % of the postprandial 
insulin  response.  In  patients  with  type  2  diabetes,  the  incretin  response  is 
reported to be attenuated. The secretion of GIP in type 2 diabetes appears to be 
normal, whereas the insulinotropic effect of GIP is reduced, while the insulin 
response to  GLP-1  appears intact,  but  its  postprandial secretion is  said to  be 
impaired. However, no studies had previously taken into account the potential 
confounding influence of different rates of gastric emptying in determining the 
incretin response. In the study reported in Chapter 9, the effects of intraduodenal   234 
infusion of glucose at 1, 2, and 4 kcal/min, which spans the physiological range 
of  gastric  emptying,  on  blood  glucose,  serum  insulin  and  plasma  incretin 
hormones were evaluated, and were compared with data from healthy subjects. 
In both groups, incremental increases in serum insulin and plasma GLP-1 with 
increasing glucose loads were not linear, and were much greater in response to 4 
kcal/min than 1 or 2 kcal/min, while GIP increased more directly in proportion to 
the glucose load. However, with intraduodenal glucose delivery at a known rate, 
the incremental increases in GLP-1 and GIP were qualitatively similar in patients 
with type 2 diabetes and healthy subjects, implying that the incretin responses to 
glucose are not grossly impaired in well-controlled type 2 diabetes. Furthermore, 
the results suggested that if glucose entry to the small intestine is at the low end 
of the physiological range (about 1 kcal/min), the incretin response is relatively 
less  important,  adding  to  the  rationale  for  interventions  that  slow  gastric 
emptying  in  the  treatment  of  type  2  diabetes.  Finally,  it  was  observed  that 
defective  insulin  secretion  was  evident  even  in  these  well  controlled  type  2 
patients, but was less marked in response to lower than higher rates of duodenal 
glucose delivery.   
 
Direct  exposure  of the  small  intestine  to  nutrients,  including  carbohydrate, is 
important to regulate gastric emptying and gut hormone release. It has recently 
been established that elements of the sweet taste receptor, identified in the tongue,   235 
are  also  found  in  the  small  intestine.  Among  several  cell  types,  sweet  taste 
receptors appear to colocalize with GLP-1-secreting L-cells, and sucralose was 
recently reported to stimulate GLP-1 release in vitro. In the study reported in 
Chapter  10,  the  effects  of  sucralose  at  a  concentration  chosen  to  match  the 
sweetness of a sucrose load (0.4 mM), and at a much higher concentration (4 
mM), in the range shown to stimulate GLP-1 release in vitro, were examined. In 
contrast to sucrose, neither load of sucralose, given by intragastric infusion, had 
any effect on GLP-1, GIP or insulin secretion. It has been reported in rats that 
sucralose also acts synergistically with glucose, by stimulating the sweet taste 
receptor and, thereby, inducing the insertion of GLUT2 into the apical membrane 
to  enhance  the  rate  of  glucose  absorption  (Mace  et  al.  2007).  In  the  study 
reported in Chapter 11, the potential interaction of intraluminal sucralose with 
glucose,  in  relation  to  small  intestinal  glucose  absorption  and  blood  glucose 
concentrations, was examined in healthy humans. Sucralose did not increase the 
rate of absorption of the glucose analogue, 3-OMG, nor the glycaemic response 
to  intraduodenal  glucose,  when  given  acutely.  The  outcome  of  the  studies  in 
Chapters 10 and 11 indicates that artificial sweeteners have no therapeutic role in 
the management of diabetes, other than as a substitute for carbohydrate.   
 
Protein,  particularly  protein  hydrolysates  (peptones),  is  a  known  stimulus  for 
CCK  release  (Liddle  1997).  In  rats,  intragastric  administration  of  the   236 
cephalosporin  antibiotic,  cefaclor,  which  shares  a  tripeptide  structure  with 
peptone,  results  in  a  dose-dependent  slowing  of  gastric  emptying  by  a 
CCK-dependent mechanism (Bozkurt et al. 2000). In Chapter 12, it was reported 
that oral cefaclor, at a dose of 1000 mg in healthy humans, had no effect on CCK 
release, gastric emptying, or postprandial glycaemic and insulinaemic responses 
to a carbohydrate meal. The reason that cefaclor failed to stimulate CCK release 
in  humans  remains  unclear,  but  as  for  sucralose,  species  differences  between 
rodents and humans may well account for the discrepant observations.   
 
In summary, the studies presented in this thesis indicate that a small preload of 
protein,  given  in  advance  of  a  meal,  can  stimulate  gut  hormone  release  and 
insulin secretion, slow gastric emptying, and dramatically improve the glycaemic 
response to a meal. Furthermore, a relatively small protein load is well tolerated 
over several weeks, and without apparent adaptation to its effects on glycaemia. 
Similar effects appear to be achievable by administrating small macronutrient 
loads in enteric coated formulations, so as to target release over a long length of 
terminal  ileum.  The fact  that GLP-1  secretion  appears intact,  at  least  in  well 
controlled  type  2  diabetes,  provides  a  rationale  for  strategies  to  stimulate 
endogenous  GLP-1  release.  Unfortunately,  neither  of  the  non-nutrient  stimuli 
tested in these studies (sucralose and cefaclor) had any effects on GLP-1 or CCK 
secretion in humans. Nevertheless, dietary strategies to stimulate small intestinal   237 
feedback appear extremely promising and should be developed further for the 
management of patients with type 2 diabetes.     238 
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